WO2023064717A2

WO2023064717A2 - Antibodies for sars-cov-2 and uses thereof

Info

Publication number: WO2023064717A2
Application number: PCT/US2022/077810
Authority: WO
Inventors: Christopher J. Emig; Rosanna CHAU; Payam Shahi; Kim-Xuan NGUYEN; YuShuan Lai; Robin Emig; John BEABER; Steven Henry; Marco MENA
Original assignee: Augmenta Bioworks, Inc.
Priority date: 2021-10-08
Filing date: 2022-10-07
Publication date: 2023-04-20
Also published as: WO2023064717A3

Abstract

The disclosure relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The disclosure also relates to anti-SARS-CoV-2 antibodies that have been obtained from subjects who became immune to this coronavirus, and to methods of using these anti-SARS-CoV-2 antibodies. Methods for neutralizing SARS-CoV-2 are disclosed, as well treatments for SARS-COV-2 using the anti-SARS-CoV-2 antibodies.

Description

ANTIBODIES FOR SARS-COV-2 AND USES THEREOF

REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM

[1] The official copy of the Sequence Listing is submitted concurrently with the specification as an xml file, made with WIPO Sequence Version 2.1.0, via EFS-Web, with a file name of “\ABW0026.xml”, a creation date of October 6, 2022, and a size of 921 kilobytes. The Sequence Listing filed via EFS-Web is part of the specification and is incorporated in its entirety by reference herein.

BACKGROUND OF THE DISCLOSURE

[2] There is considerable interest in being able to discover antibodies to specific antigens. Such antibodies are useful as research tools and for diagnostic and therapeutic applications. However, the identification of such useful antibodies is difficult and once identified, these antibodies often require considerable redesign before they are suitable for therapeutic applications in humans.

[3] Many methods for identifying antibodies involve display of antibody libraries derived by amplification of nucleic acids from B cells or other tissues. These approaches have limitations that limit the useful antibodies obtained from the library. For example, most antibody libraries do not pair the heavy and light chains obtained from memory B-cells or plasma cells that have mounted an effective immune response against an immunological challenge. In addition, most human antibody libraries known contain only the antibody sequence diversity that can be experimentally captured or cloned from a biological source (e.g., B cells). Accordingly, such libraries may overrepresent some sequences, while completely lacking or under-representing other sequences especially paired light and heavy chains that form useful antibodies, particularly those from a successful immune response.

[4] It is an object of this invention to provide libraries of immune binding proteins that are enriched for useful immune binding proteins. It is also an obj ect of the invention to provide methods for making such libraries that are enriched for useful multimers of immune binding proteins. It is a further object of the invention to provide methods for amplifying nucleic acids from B-cells and plasma cells so that the pairing of light and heavy chains is maintained. It is an object of the invention to obtain libraries of antibodies relevant to disease therapies by obtaining paired light and heavy chain antibodies from individuals whom have mounted antibody responses against a variety of immunologic challenges related to, for example, infectious diseases (an infectious agent), cancer, auto-immune disease, neurodegenerative disease, and allergies.

[5] SARS-CoV-2 is the causative agent, the virus that causes, COVID-19. It is novel coronavirus that first infected humans starting in December 2019. At the time of the filing of this application SARS-CoV-2 had infected at least 1,279,546 person in the United States, and had killed at least 76,527 persons. There is a present unmet medical need for therapies to treat SARS-CoV-2 infections and reduce the morbidity and mortality of this disease in the United States and around the world.

SUMMARY OF THE INVENTION

[6] The disclosure relates to antibodies obtained from subjects who acquired immunity to coronavirus, SARS-CoV-2. Over a thousand human antibodies have been obtained from these subjects in a screening to identify antibody clones that bound to targets from SARS-CoV-2. The targets or mixture of targets used to identify the anti-SARS-CoV-2 antibodies were SARS-CoV-2 Spike 1 Protein (SI), SARS-CoV-2 Spike 2 Protein (S2), SARS-CoV-2 Receptor Binding Domain, SARS-CoV-2 Spike 1 Protein OR SARS-CoV-2 Spike 2 Protein (S1+S2), SARS-CoV-2 Spike 1 Protein OR SARS-CoV-2 S2 Protein OR SARS-CoV-2 Membrane Protein OR SARS-CoV-2 Envelope Protein (S1+S2+E+M). The nucleic acid and amino acid sequences of the variable region heavy chains and light chains for these anti-SARS-CoV-2 antibodies are disclosed herein. The antibodies can be monoclonal, and can be fully human antibodies, chimeric antibodies, or CDR- grafted antibodies. The antibodies can be full length or and antibody fragment. Antibody fragments include any of the well-known formats or types, including for example, antigen-binding fragments (Fab), single chain variable fragments (scFv) and “third generation” (3G).

[7] Specific antibodies disclosed herein include, for example, anti-SARS-CoV-2 (SC2) antibody 3417 (SC2 Ab 3417 or 3417), SC2 antibody 3387 (3387), SC2 antibody 3705 (3705), SC2 antibody 3388 (3388), SC2 antibody 3396 (3396), SC2 antibody 3908 (3908), SC2 antibody 3916 (3916), SC2 antibody 3929 (3929), SC2 antibody 3940 (3940), SC2 antibody 4021 (4021). Several antibodies, including SC2 antibody 3387 (3387) and SC2 antibody 3705 (3705) have shown affinity for various variants of SARS-CoV-2 now present in the population. Several antibodies including SC2 antibody 3387 (3387), SC2 antibody 3705 (3705), SC antibody 3396, and SC2 antibody 3417 (3417) have also shown neutralizing activity against SARS-CoV-2.

[8] The anti-SARS-CoV-2 antibodies can be full length antibodies such as, for example, an IgG (e.g., IgGl, IgG2, IgG3, or IgG4), an IgM, an IgA, an IgD, or an IgE. The anti-SARS-CoV-2 antibody can be an antibody fragment such as, for example, a Fab, F(ab’)2, single chain antibody (scFv), Fv, or other antibody fragments made from recombinant nucleic acids encoding fragments of the antibody chains. The antibody fragments can also be made by digestion of an anti-SARS- CoV-2 antibody to generate a smaller fragment. The anti-SARS-CoV-2 antibody can be obtained from a B-cell, a plasma cell, a B memory cell, a pre-B-cell or a progenitor B-cell.

[9] Compositions and formulations described here can comprise one or more of the anti-SARS- CoV-2 antibodies for administration to a subject. The compositions with the anti-SARS-CoV-2 antibodies can also include other drugs or agents for treatment of the subject. For example, the anti-SARS-CoV-2 antibody compositions can include analgesics, other antiviral drugs, other antiviral antibodies, and/or agents that reduce symptoms caused by infection with SARS-CoV-2.

[10] Methods described herein use the anti-SARS-CoV-2 antibodies to neutralize (e.g., in vitro or in vivo or both) the SARS-CoV-2 virus and inhibit the virus from infecting cells. The methods can be used to treat subjects with active infections from SARS-CoV-2 and thereby reduce the symptoms in a subject, time of infection of the subject, or transmission of virus to others by the infected subject. The methods can also be used prophylactically to reduce, inhibit, or prevent infection of a subject by the SARS-CoV-2 virus.

BRIEF DESCRIPTION OF THE FIGURES

[11] FIG. 1 (3) shows a work flow chart for obtaining clones expressing a desired antigen binding protein using a single cell selecting device.

[12] FIG. 2 shows a bar graph of virus neutralization by the anti-SARS-CoV2 antibodies.

[13] FIG. 3 shows a line graph of virus neutralization by the anti-SARS-CoV2 antibodies.

[14] FIG. 4 shows a line graph of neutralization of the delta variant by SARS-CoV-2 antibody (SC2 antibody 3387).

[15] FIG. 5 shows a line graph of neutralization activity of Wuhan-1 by anti-SARS-CoV-2 antibodies.

[16] FIG. 5 shows bar graphs of viral titer in Hamsters inoculated with SARS-CoV-2 after prophylactic treatment with an anti-SARS-CoV-2 antibody.

DETAILED DESCRIPTION OF THE INVENTION

[17] Before the various embodiments are described, it is to be understood that the teachings of this disclosure are not limited to the particular embodiments described, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present teachings will be limited only by the appended claims.

[18] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present teachings, some exemplary methods and materials are now described.

[19] It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims can be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements or use of a “negative” limitation. Numerical limitations given with respect to concentrations or levels of a substance are intended to be approximate, unless the context clearly dictates otherwise. Thus, where a concentration is indicated to be (for example) 10 micrograms (“pg”), it is intended that the concentration be understood to be at least approximately or about 10 pg.

[20] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which can be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present teachings. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Definitions

[21] As used herein, an “antibody” refers to a protein functionally defined as a binding protein and structurally defined as comprising an amino acid sequence that is recognized as being derived from the framework region of an immunoglobulin encoding gene of an animal producing antibodies. An antibody can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

[22] A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

[23] Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab')2 dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see, Fundamental Immunology, W. E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that fragments can be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized using recombinant DNA methodologies. Preferred antibodies include VH-VL dimers, including single chain antibodies (antibodies that exist as a single polypeptide chain), such as single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light region are joined together (directly or through a peptide linker) to form a continuous polypeptide. The single chain Fv antibody is a covalently linked VH-VL heterodimer which may be expressed from a nucleic acid including VH- and VL- encoding sequences either joined directly or joined by a peptide-encoding linker (e.g., Huston, et al. Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988). While the VH and VL are connected to each as a single polypeptide chain, the VH and VL domains associate non-covalently. Alternatively, the antibody can be another fragment. Other fragments can also be generated, including using recombinant techniques. For example, Fab molecules can be displayed on phage if one of the chains (heavy or light) is fused to g3 capsid protein and the complementary chain exported to the periplasm as a soluble molecule. The two chains can be encoded on the same or on different replicons; the two antibody chains in each Fab molecule assemble post-translationally and the dimer is incorporated into the phage particle via linkage of one of the chains to g3p (see, e.g., U.S. Pat. No: 5,733,743). The scFv antibodies and a number of other structures converting the naturally aggregated, but chemically separated light and heavy polypeptide chains from an antibody V region into a molecule that folds into a three-dimensional structure substantially similar to the structure of an antigen-binding site are known to those of skill in the art (see e.g., U.S. Pat. Nos. 5,091,513, 5,132,405, and 4,956,778). In some embodiments, the scFv is a diabody as described in Holliger et al., Proc. Nat’ 1 Acad. Sci. vol. 90, pp. 6444-6448 (1993), which is incorporated by reference in its entirety for all purposes. In some embodiments, antibodies include all those that have been displayed on phage or generated by recombinant technology using vectors where the chains are secreted as soluble proteins, e.g., scFv, Fv, Fab, pr (Fab')2 or generated by recombinant technology using vectors where the chains are secreted as soluble proteins. Antibodies can also include diantibodies and miniantibodies.

[24] Antibodies of the invention also include heavy chain dimers, such as antibodies from camelids. Since the VH region of a heavy chain dimer IgG in a camelid does not have to make hydrophobic interactions with a light chain, the region in the heavy chain that normally contacts a light chain is changed to hydrophilic amino acid residues in a camelid. VH domains of heavy-chain dimer IgGs are called VHH domains.

[25] In camelids, the diversity of antibody repertoire is determined by the complementary determining regions (CDR) 1, 2, and 3 in the VH or VHH regions. The CDR3 in the camel VHH region is characterized by its relatively long length averaging 16 amino acids (Muyldermans et al., 1994, Protein Engineering 7(9): 1129). This is in contrast to CDR3 regions of antibodies of many other species. For example, the CDR3 of mouse VH has an average of 9 amino acids.

[26] Libraries of camelid-derived antibody variable regions, which maintain the in vivo diversity of the variable regions of a camelid, can be made by, for example, the methods disclosed in U.S. Patent Application Ser. No. 20050037421, published Feb. 17, 2005.

[27] As used herein, “HA,” “NB,” and “NA” respectively mean hemagglutinin, NB protein and neuraminidase. HA, NB and NA are antigenic glycoproteins located on the surface of influenza viruses. These glycoproteins are responsible for the binding the virus to the cell that is to be infected and processes that result in infection with the virus.

[28] As used herein, the term “naturally occurring” means that the components are encoded by a single gene that was not altered by recombinant means and that pre-exists in an organism, e.g., in an antibody library that was created from naive cells or cells that were exposed to an antigen.

[29] As used herein, the term “antigen” refers to substances that are capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, such as, with specific antibodies or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulates, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (epitopes) combines with the antibody or a specific receptor on a lymphocyte. More broadly, the term "antigen" may be used to refer to any substance to which an antibody binds, or for which antibodies are desired, regardless of whether the substance is immunogenic. For such antigens, antibodies may be identified by recombinant methods, independently of any immune response.

[30] As used herein, the term “epitope” refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Epitopes include that portion of an antigen or other macromolecule capable of forming a binding interaction that interacts with the variable region binding pocket of an antibody. [31] As used herein, the term “binding specificity” of an antibody refers to the identity of the antigen to which the antibody binds, preferably to the identity of the epitope to which the antibody binds.

[32] As used herein, the term “chimeric polynucleotide” means that the polynucleotide comprises regions which are wild-type and regions which are mutated. It may also mean that the polynucleotide comprises wild-type regions from one polynucleotide and wild-type regions from another related polynucleotide.

[33] As used herein, the term “chimeric polynucleotide” means that the polynucleotide comprises regions which are wild-type and regions which are mutated. It may also mean that the polynucleotide comprises wild-type regions from one polynucleotide and wild-type regions from another related polynucleotide.

[34] As used herein, the term “complementarity-determining region” or “CDR” refer to the art- recognized term as exemplified by the Kabat and Chothia. CDRs are also generally known as hypervariable regions or hypervariable loops (Chothia and Lesk (1987) J Mol. Biol. 196: 901; Chothia et al. (1989) Nature 342: 877; E. A. Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md.) (1987); and Tramontane et al. (1990) J Mol. Biol. 215: 175). “Framework region” or “FR” refers to the region of the V domain that flank the CDRs. The positions of the CDRs and framework regions can be determined using various well known definitions in the art, e.g., Kabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Johnson et al., supra; Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)). Definitions of antigen combining sites are also described in the following: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc, M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan l;29(l):207-9 (2001); MacCallum et al, Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262 (5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin, et al, Methods Enzymol., 203, 121-153, (1991); Pedersen et al, Immunomethods, 1, 126, (1992); and Rees et al, In Sternberg M. J. E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996).

[35] The term “conservative substitution” refers to substitution of an amino acid in a polypeptide with a functionally, structurally or chemically similar natural or unnatural amino acid. In certain embodiments, the following groups each contain natural amino acids that are conservative substitutions for one another:

1) Glycine (Gly/G), Alanine (Ala/ A);

2) Isoleucine (Ile/I), Leucine (Leu/L), Methionine (Met/M), Valine (Val/V);

3) Phenylalanine (Phe/F), Tyrosine (Tyr/Y), Tryptophan (Trp/W);

4) Serine (Ser/S), Threonine (Thr/T), Cysteine (Cys/C);

5) Asparagine (Asn/N), Glutamine (Gln/Q);

6) Aspartic acid (Asp/D), Glutamic acid (Glu/E); and

7) Arginine (Arg/R), Lysine (Lys/K), Histidine (His/H).

[36] As used herein, the term “hapten” is a small molecule that, when attached to a larger carrier such as a protein, can elicit an immune response in an organism, e.g., such as the production of antibodies that bind specifically to it (in either the free or combined state). A “hapten” is able to bind to a preformed antibody, but may fail to stimulate antibody generation on its own. In the context of this invention, the term “hapten” includes modified amino acids, either naturally occurring or non-naturally occurring. Thus, for example, the term “hapten” includes naturally occurring modified amino acids such as phosphotyrosine, phosphothreonine, phosphoserine, or sulphated residues such as sulphated tyrosine (sulphotyrosine), sulphated serine (sulphoserine), or sulphated threonine (sulphothreonine); and also include non-naturally occurring modified amino acids such as p-nitro-phenylalanine.

[37] As used herein, the term “heterologous” when used with reference to portions of a polynucleotide indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid. Similarly, a “heterologous” polypeptide or protein refers to two or more subsequences that are not found in the same relationship to each other in nature.

[38] As used herein, the term “host cell” refers to a prokaryotic or eukaryotic cell into which the vectors of the invention may be introduced, expressed and/or propagated. A microbial host cell is a cell of a prokaryotic or eukaryotic micro-organism, including bacteria, yeasts, microscopic fungi and microscopic phases in the life-cycle of fungi and slime molds. Typical prokaryotic host cells include various strains of E. coli. Typical eukaryotic host cells are yeast or filamentous fungi, or mammalian cells, such as Chinese hamster ovary cells, murine NIH 3T3 fibroblasts, human embryonic kidney 193 cells, or rodent myeloma or hybridoma cells.

[39] As used herein, the term “immunological response” to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Usually, an “immunological response” includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.

[40] As used herein, the term “isolated” refers to a nucleic acid or polypeptide separated not only from other nucleic acids or polypeptides that are present in the natural source of the nucleic acid or polypeptide, but also from polypeptides, and preferably refers to a nucleic acid or polypeptide found in the presence of (if anything) only a solvent, buffer, ion, or other component normally present in a solution of the same. The terms “isolated” and “purified” do not encompass nucleic acids or polypeptides present in their natural source.

[41] As used herein, the term “mammal” refers to warm-blooded vertebrate animals all of which possess hair and suckle their young.

[42] As used herein, “percentage of sequence identity” and “percentage homology” are used interchangeably herein to refer to comparisons among polynucleotides or polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, where the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence for optimal alignment of the two sequences. The percentage may be calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Alternatively, the percentage may be calculated by determining the number of positions at which either the identical nucleic acid base or amino acid residue occurs in both sequences or a nucleic acid base or amino acid residue is aligned with a gap to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Those of skill in the art appreciate that there are many established algorithms available to align two sequences. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv Appl Math. 2:482, 1981; by the homology alignment algorithm of Needleman and Wunsch, J Mol Biol. 48:443, 1970; by the search for similarity method of Pearson and Lipman, Proc Natl Acad Sci. USA 85:2444, 1988; by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Software Package), or by visual inspection (see generally, Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement). Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., J. Mol. Biol. 215:403-410, 1990; and Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1977; respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website. BLAST for nucleotide sequences can use the BLASTN program with default parameters, e.g., a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. BLAST for amino acid sequences can use the BLASTP program with default parameters, e.g., a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc Natl Acad Sci. USA 89: 10915, 1989). Exemplary determination of sequence alignment and % sequence identity can also employ the BESTFIT or GAP programs in the GCG Wisconsin Software package (Accelrys, Madison WI), using default parameters provided.

[43] The term “pharmaceutically acceptable” refers to a substance (e.g., an active ingredient or an excipient) that is suitable for use in contact with the tissues and organs of a subject without excessive irritation, allergic response, immunogenicity and toxicity, is commensurate with a reasonable benefit/risk ratio, and is effective for its intended use. A “pharmaceutically acceptable” excipient or carrier of a pharmaceutical composition is also compatible with the other ingredients of the composition.

[44] As used herein, the terms “protein”, “peptide”, “polypeptide” and “polypeptide fragment” are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer can be linear or branched, it may comprise modified amino acids or amino acid analogs, and it may be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component. [45] As used herein, the term “protracting moiety” means a molecule that can be attached to a polypeptide (e.g., an antibody light and/or heavy chain) to increase its molecular weight so that the polypeptide’s residence time in the blood (and/or serum) is increased. For example, the protracting moiety can increase the serum/blood half-life of the polypeptide. The increased half-life or residence time can be the result of, for example, reduced glomerular filtration by the kidney, and/or reduced uptake by the liver, and/or reduced binding and removal by immune binding proteins, etc. A protracting moiety can be, for example, another polypeptide, a polymer (e.g., synthetic polymer, natural polymer, etc.), etc.

[46] As used herein, the term “purified” means that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99.8% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).

[47] As used herein, the terms “RBD”, “SI”, “S2”, “EP”, and “MP” mean, respectively, SARS- CoV-2 receptor binding domain (RBD), SARS-CoV-2 Spike 1 protein (SI), SARS-CoV-2 Spike 2 protein (S2), SARS-CoV-2 Envelope Proteins (EP), and SARS-CoV-2 Membrane Protein (MP).

[48] As used herein, the term “recombinant nucleic acid” refers to a nucleic acid in a form not normally found in nature. That is, a recombinant nucleic acid is flanked by a nucleotide sequence not naturally flanking the nucleic acid or has a sequence not normally found in nature. Recombinant nucleic acids can be originally formed in vitro by the manipulation of nucleic acid by restriction endonucleases, or alternatively using such techniques as polymerase chain reaction. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

[49] As used herein, the term “recombinant polypeptide” refers to a polypeptide expressed from a recombinant nucleic acid, or a polypeptide that is chemically synthesized in vitro.

[50] As used herein, the term “recombinant variant” refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added, or deleted without abolishing activities of interest, such as enzymatic or binding activities, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology.

[51] Preferably, amino acid “substitutions” are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[52] As used herein, the term “SARS-CoV-2” means the Severe acute respiratory syndrome coronavirus 2 that cause the illness COVID-19. SARS-CoV-2 includes the strains and sub-strains of coronavirus that are arising during this outbreak of SARS-CoV-2.

[53] The term “stringent hybridization conditions” refers to hybridizing in 50% formamide at 5XSSC at a temperature of 42 °C and washing the filters in 0.2XSSC at 60 °C. (1XSSC is 0.15M NaCl, 0.015M sodium citrate.) Stringent hybridization conditions also encompasses low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 °C; hybridization with a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or 50% formamide, 5XSSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5XDenhardt' s solution, sonicated salmon sperm DNA (50 pg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42 °C in 0.2XSSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C, followed by a high- stringency wash consisting of 0.1XSSC containing EDTA at 55 °C.

[54] The term “substantially homologous” or “substantially identical” in the context of two polypeptides or polynucleotides refers to two or more sequences or subsequences that have at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid or nucleic acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. The terms “substantially homologous” or “substantially identical” can mean at least about 70% amino acid or nucleic acid residue identity. The term “substantially homologous” or “substantially identical” can mean at least about 85% amino acid or nucleic acid residue identity. The substantial homology or identity can exist over a region of the sequences that is at least about 20, 30, 40, 50, 100, 150 or 200 residues in length. The sequences can be substantially homologous or identical over the entire length of either or both comparison biopolymers.

[55] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv. Appl. Math., 2:482 (1981); by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol., 48:443 (1970); by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85:2444 (1988); by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wisconsin); or by visual inspection.

[56] One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, J. Mol. Evol., 35:351-360 (1987). The method used is similar to the method described by Higgins and Sharp, CABIOS, 5: 151-153 (1989). The program can align up to about 300 sequences, each having a maximum length of about 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. Another algorithm that is useful for generating multiple alignments of sequences is Clustal W (see, e.g., Thompson et al., Nucleic Acids Research, 22:4673-4680 [1994]).

[57] Another example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol., 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction is halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults, e.g., a wordlength (W) of 11, an expectation (E) of 10, M = 5, N = -4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults, e.g., a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. LISA, 89: 10915 [1989]).

[58] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90:5873-5787 [1993]). One measure of similarity provided by the BLAST algorithm is the smallest sum probability [P(N)], which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In certain embodiments, a polynucleotide is considered similar to a reference sequence if the smallest sum probability in a comparison of the test polynucleotide to the reference polynucleotide is less than about 0.1, 0.01 or 0.001.

[59] A polypeptide can be substantially homologous or identical to a second polypeptide if the two polypeptides differ only by conservative amino acid substitutions. Two nucleic acid sequences can be substantially homologous or identical if the two polynucleotides hybridize to each other under stringent conditions, or under highly stringent conditions, as described herein.

[60] The term “therapeutically effective amount” refers to an amount of a compound that, when administered to a subject, is sufficient to prevent, reduce the risk of developing, delay the onset of, slow the progression or cause regression of the medical condition being treated, or to alleviate to some extent the medical condition or one or more symptoms or complications of that condition. The term “therapeutically effective amount” also refers to an amount of a compound that is sufficient to elicit the biological or medical response of a cell, tissue, organ, system, animal or human which is sought by a researcher, veterinarian, medical doctor or clinician.

[61] The singular terms “a”, “an”, and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Numerical limitations given with respect to concentrations or levels of a substance, such as an antigen, are intended to be approximate. Thus, where a concentration is indicated to be at least (for example) 200 pg, it is intended that the concentration be understood to be at least approximately “about” or “about” 200 pg.

Anti-SARS-CoV-2 Antibodies

[62] Antibodies are immune binding proteins that are structurally defined as comprising an amino acid sequence recognized as being derived from the framework region of an immunoglobulin. An antibody can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The immunoglobulin genes can include, for example, the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Antibody light chains can be classified as either kappa or lambda. Antibody heavy chains can be classified as gamma, mu, alpha, delta, or epsilon, which in turn can define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

[63] Antibodies can exist as intact immunoglobulins or as a number of well-known fragments. Pepsin digests an antibody below the disulfide linkages in the hinge region and can produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab')2 dimer into Fab' monomers. The Fab' monomer can be an Fab with part of the hinge region (see, Fundamental Immunology, W. E. Paul, ed., Raven Press, N.Y. (1993), which is incorporated by reference in its entirety for all purposes). Antibody fragments can also be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Antibodies can include VH-VL dimers, including single chain antibodies (antibodies that exist as a single polypeptide chain), diabodies, or single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light region are joined together (directly or through a peptide linker) to form a continuous polypeptide, (e.g., Huston, et al. Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988, which is incorporated by reference in its entirety for all purposes). Antibodies can also include other fragments, including, for example, Fab molecules displayed on phage if one of the chains (heavy or light) is fused to g3 capsid protein and the complementary chain exported to the periplasm as a soluble molecule, (e.g., U.S. Pat. No: 5,733,743, which is incorporated by reference in its entirety for all purposes). The antibody can be an scFv antibody or a number of other structures converting the naturally aggregated, but chemically separated light and heavy polypeptide chains from an antibody V region into a molecule that folds into a three dimensional structure substantially similar to the structure of an antigen-binding site are known to those of skill in the art (e.g., U.S. Pat. Nos. 5,091,513, 5,132,405, and 4,956,778, which are all incorporated by reference in their entirety for all purposes). The scFv can be a diabody as described in Holliger et al., Proc. Nat’l Acad. Sci. vol. 90, pp. 6444-6448 (1993), which is incorporated by reference in its entirety for all purposes. Antibodies include all those that have been displayed on phage or generated by recombinant technology using vectors where the chains are secreted as soluble proteins, e.g., scFv, Fv, Fab, pr (Fab'X Antibodies can also include miniantibodies. The antibody can be obtained from a B-cell, a plasma cell, a B memory cell, a pre-B-cell or a progenitor B-cell.

[64] The antibodies can be monoclonal, and can be fully human antibodies, chimeric antibodies, or CDR-grafted antibodies. The antibodies can be full length or and antibody fragment. Antibody fragments include any of the well-known formats or types, including for example, antigen-binding fragments (Fab), single chain variable fragments (scFv) and “third generation” (3G). Nelson, MAbs 2010, 2:77-83, doi: 10.4161/mabs.2.1.10786, which is incorporated by reference in its entirety for all purposes. F(ab')2, Fab, Fab' and Fv are examples of antigen-binding fragments that can be generated from the variable region of IgG and IgM.

[65] Anti-SARS-CoV-2 antibody 3417 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQVQLQESGPGLLKPSQTLSLTCTVSGVSIRNSNYFWNWIR RPAGKGLEWIGRMHSGGTTNYNPSLKSRVTVSSDAARNQFSLELTSVTAADTAVYYCAR DDPLNRFAAFQIWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGCTGAAGCCCTCGCAGACCCTGT CCCTCACCTGCACTGTCTCTGGTGTCTCCATCAGAAATAGTAATTACTTCTGGAATTG GATCCGGCGGCCCGCCGGGAAGGGACTGGAGTGGATTGGGCGTATGCATAGTGGTG GGACCACCAATTACAATCCCTCCCTCAAGAGTCGGGTCACCGTGTCAAGTGACGCGG CCAGGAACCAGTTCTCCCTGGAGTTGACCTCTGTGACCGCCGCAGACACGGCCGTGT ATTACTGTGCGAGAGATGACCCCCTTAACCGGTTCGCTGCTTTTCAAATCTGGGGCCG AGGGACACTGGTCACCGTCTCTTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTG

GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAG GACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGG TGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACA

AGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACT CACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCT

TCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCG TGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG

GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACG

TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGA GGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAG

CGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCA CGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGA CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO:

2)

Anti-SARS-CoV-2 antibody 3417 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNKYISWYQQLP GTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSVFYVF GTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ

ID NO: 3)

This light chain amino acid sequence can be encoded in a nucleic acid sequence of:

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCA CCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAAATATATATCCTGGTACCA GCAGCTCCCAGGAACAGCCCCCAAACTCCTCATTTATGACAATAATAAGCGACCCTC AGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATC ACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATAGCAG CCTGAGTGTTTTTTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTGGGTCAGCCC AAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACA AGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCT GGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAA CAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTG GAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGA AGACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 4)

[66] Anti-SARS-CoV-2 antibody 3387 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQVQLVQSGAEVMQVGASVKVSCKASGYTFTSYGISWVR QAPGQGLEWMGWINTYNGNTNYAQKLQGRVTMTTDTSTTTAYMELRSLRSDDTAVYY CARVAVGYCSGGSCYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KD YFPEP VT VSWNSGALTSGVHTFP AVLQS SGL YSLS S VVTVPS S SLGTQT YICNVNHKPS NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK (SEQ ID NO: 5)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGATGCAAGTGGGGGCCTCAGTGA AGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCG ACAGGCCCCCGGACAAGGGCTTGAGTGGATGGGATGGATCAACACTTACAATGGTA ACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCC ACGACCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTAT TACTGTGCGAGAGTCGCTGTAGGATATTGCAGTGGTGGTAGCTGCTACTACTTTGACT ACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGG TCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCC TGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCT CAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAA CGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTT GTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGT

CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA

GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTG

GTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT

ACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA

ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA

AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC

CATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCT

TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC

TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC

TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC

ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT GA (SEQ ID NO: 6).

Anti-SARS-CoV-2 antibody 3387 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSPEIVMTQSPATLSVSPGERATLSCRASQSVSNNLAWYQQK

PGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNDWPPSWTF GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 7)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CACCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAA

GAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAACAACTTAGCCTGGTACC

AGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCA

CTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGAACAGAGTTCACTCTCACCA

TCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATGACTG

GCCTCCGTCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACGGTGGC

TGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC

TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAG

GTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG

CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACG AGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA CAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQ ID NO: 8) [67] Anti-SARS-CoV-2 antibody 3705 is a single chain antibody with the amino acid sequence of:

MKYLLPTAAAGLLLLAAQPAMALEIVMTQSPATLSVSPGERATLSCRASQSVSNNLAWY QQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNDWPPS WTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVQSGAEVMQVGASVKVSCKASGYTFT SYGISWVRQAPGQGLEWMGWINTYNGNTNYAQKLQGRVTMTTDTSTTTAYMELRSLR SDDT AVYYC ARVAVGYC SGGSC YYFDYWGQGTL VTVS SGGGGSGGQHHHHHHGAEQ

KLISEEDLGSGKPIPNPLLGLDSTS (SEQ ID NO: 9)

This amino acid sequence can be encoded in a nucleic acid sequence of:

ATGAAATACCTATTGCCTACGGCGGCCGCTGGATTGTTATTACTCGCGGCCCAGCCG

GCCATGGCATTAGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCA GGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAACAACTTAGCC

TGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACC AGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGAACAGAGTTCACT

CTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATA ATGACTGGCCTCCGTCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAGGAG GAGGAGGCTCTGGGGGCGGCGGTTCTGGAGGAGGTGGAAGTcaggtgcagctggttcagtctggcg ccgaagtgatgcaagtgggggcatcagtgaaggtgtcctgtaaggcttccggttatacctttaccagctatggaatctcgtgggtgcggcagg cccctggacaagggcttgagtggatgggatggattaatacttacaatgggaacacaaactatgcacagaaactccagggcagagtaaccat gactactgacacatccacgaccacagcctacatggagctgaggagcttacgatctgatgacacggccgtttattactgtgcgcgcgtcgctgt aggctattgcagtggtggcagctgctactacttcgattactggggccagggaacattggtcaccgtcagttcaGGAGGCGGTGGT

TCAGGTGGACAACACCATCACCACCATCATGGCGCAGAACAAAAACTCATCTCAGAA GAGGATCTGGGTAGTGGCAAGCCGATCCCGAATCCTCTGCTGGGATTAGACTCCACA TCTTAA (SEQ ID NO: 10)

[68] Anti-SARS-CoV-2 antibody 3388 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVR QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

AREGNIVATISLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK KVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VSNI<ALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLD SDGSFFL YSKLTVDKSRWQQGNVF SC S VMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of:

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGA GACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCG CCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAA

TAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAA GAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAGAGAAGGGAATATAGTGGCTACGATTTCTCTGGACTACTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCA

CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC TACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTG CACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGA CCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC

CCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCAC ACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCC

CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGG TGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGA GATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAA

GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 12) Anti-SARS-CoV-2 antibody 3388 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQ LPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 13)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCA CCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGT ACCAGCAGCTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGC

CCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGC

CATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAG CAGCCTGAGTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAA GGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAG GCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGG

AAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACA

AAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGA AGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAG ACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 14)

[69] Anti-SARS-CoV-2 antibody 3396 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSGVQLVESGGGLVQPGRSLRVSCAASGFTFADYAMHWVR QAPGKGLEWVSGISWNSGNIAYADSVKGRFTISRDNAKNSLYLQMDSLRPDDTALYYCV KASTLYYYFYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD

KKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV I<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VSNI<ALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 15)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGGGAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGA GAGTCTCCTGTGCAGCCTCTGGATTCACCTTTGCTGATTACGCCATGCACTGGGTCCG GCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGAATCAGTTGGAATAGTGGTA

ACATAGCCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCA AGAACTCCCTGTATCTTCAAATGGACAGTCTGAGACCTGATGACACGGCCCTGTATT ATTGTGTAAAGGCCTCAACCCTCTACTACTATTTCTACATGGATGTCTGGGGCAAAGG GACCACGGTCACCGTTTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCA CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC TACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTG CACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGA

CCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC CCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCAC ACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCC CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGG TGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG

TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGA

GATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAA GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 16) Anti-SARS-CoV-2 antibody 3396 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSALTQPPSASGSPGQSVTISCTGTSSDVGGYDYVSWYQQ HPGKAPKFMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCCSYAGSNNY VFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPV KAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 17)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCAC CATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATGACTATGTCTCCTGGTAC CAACAGCACCCAGGCAAAGCCCCCAAATTCATGATTTATGAGGTCAGTAAGCGGCCC

TCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCG TCTCTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCTGCTCATATGCAGGCA GCAACAATTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGGTCAGCCCAAGG CTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGC CACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAA GGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAA GCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAG TCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGAC AGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 18)

[70] Anti-SARS-CoV-2 antibody 3908 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSEVQLVESRGGLVQPGGSLRLSCAATGFTLSSFDMHWVRQ ATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR GTWLRDYNFWSGYNYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK (SEQ ID NO: 19)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGGAGGTGCAGCTGGTGGAGTCTAGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGA GACTCTCCTGTGCAGCCACTGGATTCACCCTCAGTAGCTTCGACATGCACTGGGTCCG CCAAGCTACAGGAAAAGGTCTGGAGTGGGTCTCAGCTATTGGTACTGCTGGTGACAC ATACTATCCAGGCTCCGTGAAGGGCCGATTCACCATCTCCAGAGAAAATGCCAAGAA CTCCTTGTATCTTCAAATGAACAGCCTGAGAGCCGGGGACACGGCTGTGTATTACTGT GCAAGAGGGACCTGGCTCCGAGATTACAATTTTTGGAGTGGTTATAATTACTACTTTG ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCAT CGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTC CCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAAT CTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGAC CGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCC TGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC

AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGC

TGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCG

AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG

CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA

GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA

CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGC

AAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTG

ATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT

AAATGA (SEQ ID NO: 20)

Anti-SARS-CoV-2 antibody 3908 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSALTQPPSASGSPGQSVTISCTGTSSDVGGYIYVSWYQQ

HPGKAPKLIIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYADSNNYV

FGSGTRVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK

AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 21)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCAC

CATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATATCTATGTCTCCTGGTAC

CAACAACACCCAGGCAAAGCCCCCAAACTCATCATTTATGAGGTCAGTAAGCGGCCC

TCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCG

TCTCTGGGCTCCAGGCTGAAGATGAGGCTGATTATTATTGCAGCTCATATGCAGACA

GCAACAATTATGTCTTCGGAAGTGGGACCAGGGTCACCGTCCTAGGTCAGCCCAAGG

CTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGC

CACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAA

GGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAA

GCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAG

TCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGAC

AGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 22)

[71] Anti-SARS-CoV-2 antibody 3916 can have a variable region comprised of a heavy chain with the amino acid sequence of: MYRMQLLSCIALSLALVTNSQVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIR QPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQ RGQRITMVRLKRDWFDPWGQGTL VTVS S ASTKGPS VFPL APS SKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K (SEQ ID NO: 23)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGT CCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCG CCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCA CCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGA ACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTG TGCGAGGCAAAGGGGGCAACGTATTACTATGGTTCGGCTAAAACGGGACTGGTTCGA

CCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATC GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGG CTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCC CTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGC AACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATC TTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACC GTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCT GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCT GAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGA GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGC CCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAG GCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA AGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA AATGA (SEQ ID NO: 24)

Anti-SARS-CoV-2 antibody 3916 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLP GTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 25)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT CGCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCA CCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATACTGTAAACTGGTACC AGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGTAATAATCAGCGGCCCT CAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCAT CAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAG CCTGAATGGTCCTGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAA GGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAG GCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGG AAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACA AAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGA AGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAG ACAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 26)

[72] Anti-SARS-CoV-2 antibody 3929 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQVQLVQSGAEVMTVGASVKVSCKASGYTFTSYGISWVR QAPGQGLEWMGWINTYNGNTNYAQKLQGRVTMTTDTSTTTAYMELRSLRSDDTAVYY CARVAVGYCSGGSCYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KD YFPEP VT VSWNSGALTSGVHTFP AVLQS SGL YSLS S VVTVPS S SLGTQT YICNVNHKPS NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK (SEQ ID NO: 27) This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGATGACAGTGGGGGCCTCAGTGA

AGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCG

ACAGGCCCCCGGACAAGGGCTTGAGTGGATGGGATGGATCAACACTTACAATGGTA

ACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCC

ACGACCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTAT

TACTGTGCGAGAGTCGCTGTAGGATATTGCAGTGGTGGTAGCTGCTACTACTTTGACT

ACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGG

TCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT

GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCC

TGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCT

CAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAA

CGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTT

GTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGT

CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA

GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTG

GTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT

ACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA

ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA

AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC

CATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCT

TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC

TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC

TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC

ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT

GA (SEQ ID NO: 28)

Anti-SARS-CoV-2 antibody 3929 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSVLTQPPSASGTPGQRVTISCSGSSSNMGSNFVYWYQHL

PGTAPKLLIQRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGVV

FGGGTALTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK

AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 29) This light chain amino acid sequence can be encoded in a nucleic acid sequence of:

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCA

CCATCTCTTGTTCTGGAAGCAGTTCCAATATGGGAAGTAATTTTGTATACTGGTACCA

GCACCTCCCAGGAACGGCCCCCAAACTCCTCATCCAAAGAAATAATCAGCGGCCCTC

AGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATC

AGTGGGCTCCGGTCCGAGGATGAGGCTGATTACTACTGTGCAGCATGGGATGACAGC

CTGAATGGTGTGGTCTTCGGCGGAGGGACCGCGCTGACCGTCCTAGGTCAGCCCAAG

GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGG

CCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGA

AGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAA

AGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAA

GTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGA

CAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 30)

[73] Anti-SARS-CoV-2 antibody 3940 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQ

MPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR

GDCSSTSCYLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV

TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK

VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF

NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ

ID NO: 31)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTG

AAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTG

CGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCT

GATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCC

ATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTAT

TACTGTGCGAGGGGCGATTGTAGTAGTACCAGCTGCTACCTTGACTACTGGGGCCAG

GGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGG CACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGG

ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCG

TGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT

GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA

GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTC

ACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTT

CCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGT

GGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG

GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACG

TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC

AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGA

GGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAG

CGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCA

CGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGA CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO:

32)

Anti-SARS-CoV-2 antibody 3940 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSHSEQNRQRAGRERAERRVNISGAGSSTKKGTGNDVPWY QQPPDTAPKLMIYEVSNRPSGVPDRFSGSKSGTTASLTISGLQAEDEADYYCGLYPSSTVV FGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 33)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCACTCTGAGCAGAATCGGCAGCGCGCCGGGAGGGAAAGAGCGGAGCGAAGGGTG

AACATCTCCGGCGCTGGGAGCAGCACAAAAAAAGGAACAGGTAACGATGTCCCCTG

GTACCAGCAGCCCCCAGACACAGCCCCCAAACTCATGATTTATGAGGTCAGTAATCG GCCCTCAGGGGTCCCTGATCGCTTCTCGGGGTCCAAGTCTGGCACCACGGCCTCCCTG ACCATCTCGGGGCTGCAGGCTGAGGACGAGGCCGATTATTACTGCGGCTTGTATCCA

AGTAGTACTGTGGTTTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAAG GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGG CCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGA AGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAA AGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAA GTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGA CAGTGGCCCCTACAGAATGTTCATAG (SEQ ID NO: 34)

[74] Anti-SARS-CoV-2 antibody 4021 can have a variable region comprised of a heavy chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSEVQLVESGGGLVQAGGSLRLSCAASGFSFSSTYMSWVRQ APERGLEWVSNIYTDGAAHYTDSVKGRFTISRDNSKNTLYLQMESLRPEDTAVYYCTKV ITGYSSGWRPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK

KVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VSNI<ALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLD SDGSFFL YSKLTVDKSRWQQGNVF SC S VMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 35)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGGAGGTGCAACTGGTGGAGTCTGGGGGAGGCTTGGTCCAGGCTGGGGGGTCCCTGA GACTCTCCTGTGCAGCCTCTGGATTCAGCTTCAGTAGCACCTATATGAGTTGGGTCCG CCAGGCTCCAGAGAGGGGGCTGGAGTGGGTTTCAAATATTTATACCGATGGTGCGGC ACACTACACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAA CACGCTGTACCTTCAAATGGAAAGCCTGCGACCTGAGGACACGGCTGTGTATTACTG

TACGAAAGTTATCACCGGGTACAGCAGTGGCTGGCGCCCATTTGACTACTGGGGCCA GGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTG GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAG GACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGG

TGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACA AGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACT CACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCG TGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG

GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACG TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG

TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC

AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGA

GGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAG

CGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCA

CGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGA

CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT

GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 36)

Anti-SARS-CoV-2 antibody 4021 can have a variable region comprised of a light chain with the amino acid sequence of:

MYRMQLLSCIALSLALVTNSQSALTQPASVSGSPGLSITISCTGTSGDVGSYKSVSWYQQ

HPGKAPKLIIYDVNKRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSTNTLFG

GGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA

GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 37)

ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATT

CGCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACTGTCGATCAC

CATCTCCTGCACTGGAACCAGCGGCGACGTTGGTAGTTATAAGTCTGTCTCCTGGTAC

CAACAACACCCAGGCAAAGCCCCCAAACTCATCATTTATGATGTCAATAAGCGGCCC

TCAGGGGTGTCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCA

TCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATACACAAGCA

CCAACACTTTATTCGGCGGAGGGACCAAGGTGACCGTCCTGGGTCAGCCCAAGGCTG

CCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCAC

ACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGC

AGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCA

ACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCC

ACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG

GCCCCTACAGAATGTTCATAG (SEQ ID NO: 38)

[75] SC2 antibody 3417 binds to Sino CoV2 SI (spike protein 1), NAC CoV2 SI, Sino CoV2

S2 (spike protein 2) (Ka = 63 nM - Carterra LSA), Sino CoV2 SI + S2, and Sino CoV2 RBD (Receptor Binding Domain) (Ka = 7.2 nM - Carterra LSA; Ka < 1 pM ForteBio). SC2 antibody 3387 binds to SI and RBD. SC2 antibody 3388 binds to NAC CoV2 SI, Sino CoV2 S2 (K_d = 10 nM - Carterra LSA), Sino CoV2 RBD (K_d < 1 pM - ForteBio), ProteinTech CoV2 Membrane Protein, ProteinTech CoV2 Nucleocapsid, and NAC Cov2 Mosaic. SC2 antibody 3388 also cross reacts with SARS1 SI and SARS1 RBD. SC2 antibody 3396 binds to Sino CoV2 S2 (Ka = 122nM - ForteBio), Sino CoV2 RBD (K_d = 22nM - ForteBio), and NAC CoV2 Mosaic (K_d = 21 nM - ForteBio). SC2 antibody 3908 binds to Sino CoV2 SI, NAC CoV2 SI, Sino CoV2 S2 (K_d = 74 nM - ForteBio), Sino CoV2 RBD, NAC CoV2 Mosaic, and ProteinTech CoV2 Nucleocapsid. SC2 antibody 3908 also cross reacts with Coll SARS1 S1+S2 and Coll SARS1 RBD. SC2 antibody 3916 binds to NAC CoV2 SI, Sino CoV2 S2, Sino CoV2 S1+S2, Sino CoV2 RBD, NAC CoV2 Mosaic, ProteinTech Membrane Protein and ProteinTech Nucleocapsid. SC2 antibody 3916 also cross reacts with Coll SARS1 S1+S2 and Coll SARS1 RBD. SC2 antibody 3929 binds to Sino CoV2 RBD. SC2 antibody 3940 binds to Sino SARS1 SI (K_d = 15 nM - Carterra LSA), HKU1 S1+S2 (K_d = 17 nM - Carterra LSA), Sino CoV2 SI, NAC CoV2 SI, and Sino CoV2 RBD. SC2 antibody 3388 binds to NAC CoV2 SI, Sino CoV2 S2 (K_d = 10 nM - Carterra LSA), Sino CoV2 RBD (K_d < 1 pM - ForteBio), NAC COV2 Mosaic, ProteinTech Membrane Protein, and ProteinTech Nucleocapsid. SC2 antibody 3388 also cross reacts with Sino SARS1 SI and Coll SARS1 RBD. SC2 antibody 3705 NAC CoV2 SI (K_d = 57 nM), Sino CoV2 SI, Sino CoV2 S1+S2, and Sino CoV2 RBD (K_d = 1.3 nM).

[76] The anti-SARS-CoV-2 antibodies 3417 (SEQ ID NO: 1 and 3), 3387 (SEQ ID NO: 5 and 7), 3388 (SEQ ID NO: 11 and 13), 3396 (SEQ ID NO: 15 and 17), 3908 (SEQ ID NO: 19 and 21), 3916 (SEQ ID NO: 23 and 25), 3929 (SEQ ID NO: 27 and 29), 3940 (SEQ ID NO: 31 and 33), 4021 (SEQ ID NO: 35 and 37), and 3705 (SEQ ID NO: 9) also include variable regions having amino acid sequences that have 99%, 95%, 90%, 80% or 70% sequence identity with one of the heavy chains from variable region SEQ ID NO: 1, 5, 11, 15, 19, 23, 27, 31 or 35, and a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one light chains from variable region SEQ ID NO: 3, 7, 13, 17, 21, 25, 29, 33, or 37.

[77] CDRs from anti-SARS-CoV-2 antibodies 3417 (SEQ ID NO: 1 and 3), 3387 (SEQ ID NO: 5 and 7), 3388 (SEQ ID NO: 11 and 13), 3396 (SEQ ID NO: 15 and 17), 3908 (SEQ ID NO: 19 and 21), 3916 (SEQ ID NO: 23 and 25), 3929 (SEQ ID NO: 27 and 29), 3940 (SEQ ID NO: 31 and 33), 4021 (SEQ ID NO: 35 and 37), and 3705 (SEQ ID NO: 9) can be use to make CDR grafted antibodies known in the art.

[78] The CDRs of SC2 antibody 3417 are:

GGTGTCTCCATCAGAAATAGTAATTACTTC heavy chain CDR1 (SEQ ID NO: 39) ATGCATAGTGGTGGGACCACC heavy chain CDR2 (SEQ ID NO: 40) GCGAGAGATGACCCCCTTAACCGGTTCGCTGCTTTTCAAATC heavy chain CDR3 (SEQ ID NO: 41)

AGCTCCAACATTGGGAATAAATAT light chain CDR1 (SEQ ID NO: 42)

GACAATAAT light chain CDR2 (SEQ ID NO: 43)

GGAACATGGGATAGCAGCCTGAGTGTTTTTTATGTC light chain CDR3 (SEQ ID NO: 44)

The CDRs of SC2 antibody 3387 are:

GGTTACACCTTTACCAGCTATGGT heavy chain CDR1 (SEQ ID NO: 45)

ATCAACACTTACAATGGTAACACA heavy chain CDR2 (SEQ ID NO: 46)

GCGAGAGTCGCTGTAGGATATTGCAGTGGTGGTAGCTGCTACTACTTTGACTAC heavy chain CDR3 (SEQ ID NO: 47)

CAGAGTGTTAGCAACAAC light chain CDR1 (SEQ ID NO: 48)

GGTGCATCC light chain CDR2 (SEQ ID NO: 49)

CAGCAGTATAATGACTGGCCTCCGTCTTGGACG light chain CDR3 (SEQ ID NO: 50)

The CDRs of SC2 antibody 3388 are:

GGATTCACCTTCAGTAGCTATGCT heavy chain CDR1 (SEQ ID NO: 51)

ATATCATATGATGGAAGTAATAAA heavy chain CDR2 (SEQ ID NO: 52)

GCGAGAGAAGGGAATATAGTGGCTACGATTTCTCTGGACTAC heavy chain CDR3 (SEQ ID NO: 53)

AGCTCCAACATCGGGGCAGGTTATGAT light chain CDR1 (SEQ ID NO: 54)

GGTAACAGC light chain CDR2 (SEQ ID NO: 55)

CAGTCCTATGACAGCAGCCTGAGTGTGGTA light chain CDR3 (SEQ ID NO: 56)

The CDRs of SC2 antibody 3396 are:

GGATTCACCTTTGCTGATTACGCC heavy chain CDR1 (SEQ ID NO: 57)

ATCAGTTGGAATAGTGGTAACATA heavy chain CDR2 (SEQ ID NO: 58)

GTAAAGGCCTCAACCCTCTACTACTATTTCTACATGGATGTC heavy chain CDR3 (SEQ ID NO: 59)

AGCAGTGACGTTGGTGGTTATGACTAT light chain CDR1 (SEQ ID NO: 60)

GAGGTCAGT light chain CDR2 (SEQ ID NO: 61)

TGCTCATATGCAGGCAGCAACAATTATGTC light chain CDR3 (SEQ ID NO: 62)

The CDRs of SC2 antibody 3908 are:

GGATTCACCCTCAGTAGCTTCGAC heavy chain CDR1 (SEQ ID NO: 63)

ATTGGTACTGCTGGTGACACA heavy chain CDR2 (SEQ ID NO: 64)

GCAAGAGGGACCTGGCTCCGAGATTACAATTTTTGGAGTGGTTATAATTACTACTTTG

ACT AC heavy chain CDR3 (SEQ ID NO: 65) AGCAGTGACGTTGGTGGTTATATCTAT light chain CDR1 (SEQ ID NO: 66)

GAGGTCAGT light chain CDR2 (SEQ ID NO: 67)

AGCTCATATGCAGACAGCAACAATTATGTC light chain CDR3 (SEQ ID NO: 68)

The CDRs of SC2 antibody 3916 are:

GGTGGGTCCTTCAGTGGTTACTAC heavy chain CDR1 (SEQ ID NO: 69)

ATCAATCATAGTGGAAGCACC heavy chain CDR2 (SEQ ID NO: 70)

GCGAGGCAAAGGGGGCAACGTATTACTATGGTTCGGCTAAAACGGGACTGGTTCGAC

CCC heavy chain CDR3 (SEQ ID NO: 71)

AGCTCCAACATCGGAAGTAATACT light chain CDR1 (SEQ ID NO: 72)

AGTAATAAT light chain CDR2 (SEA ID NO: 73)

GCAGCATGGGATGACAGCCTGAATGGTCCTGTA light chain CDR3 (SEQ ID NO: 74)

The CDRs of SC2 antibody 3929 are:

GGTTACACCTTTACCAGCTATGGT heavy chain CDR1 (SEQ ID NO: 75)

ATCAACACTTACAATGGTAACACA heavy chain CDR2 (SEQ ID NO: 76)

GCGAGAGTCGCTGTAGGATATTGCAGTGGTGGTAGCTGCTACTACTTTGACTAC heavy chain CDR3 (SEQ ID NO: 77)

AGTTCCAATATGGGAAGTAATTTT light chain CDR1 (SEQ ID NO: 78)

AGAAATAAT light chain CDR2 (SEQ ID NO: 79)

GCAGCATGGGATGACAGCCTGAATGGTGTGGTC light chain CDR3 (SEQ ID NO: 80)

The CDRs of SC2 antibody 3940 are:

GGATACAGCTTTACCAGCTACTGG heavy chain CDR1 (SEQ ID NO: 81)

ATCTATCCTGGTGACTCTGATACC heavy chain CDR2 (SEQ ID NO: 82)

GCGAGGGGCGATTGTAGTAGTACCAGCTGCTACCTTGACTAC heavy chain CDR3 (SEQ

ID NO: 83)

AGCACAAAAAAAGGAACAGGTAACGAT light chain CDR1 (SEQ ID NO: 84)

GAGGTCAGT light chain CDR2 (SEQ ID NO: 85)

GGCTTGTATCCAAGTAGTACTGTGGTT light chain CDR3 (SEQ ID NO: 86)

The CDRs of SC2 antibody 4021 are:

GGATTCAGCTTCAGTAGCACCTAT heavy chain CDR1 (SEQ ID NO: 87)

ATTTATACCGATGGTGCGGCA heavy chain CDR2 (SEQ ID NO: 88)

ACGAAAGTTATCACCGGGTACAGCAGTGGCTGGCGCCCATTTGACTAC heavy chain

CDR3 (SEQ ID NO: 89)

AGCGGCGACGTTGGTAGTTATAAGTCT light chain CDR1 (SEQ ID NO: 90)

GATGTCAAT light chain CDR2 (SEQ ID NO: 91) AGCTCATACACAAGCACCAACACTTTA light chain CDR3 (SEQ ID NO: 92)

The CDRs of SC2 antibody 3705 are:

GGTTATACCTTTACCAGCTATGGA heavy chain CDR1 (SEQ ID NO: 93) ATTAATACTTACAATGGGAACACA heavy chain CDR2 (SEQ ID NO: 94) GCGCGCGTCGCTGTAGGCTATTGCAGTGGTGGCAGCTGCTACTACTTCGATTAC heavy chain CDR3 (SEQ ID NO: 95)

CAGAGTGTTAGCAACAAC light chain CDR1 (SEQ ID NO: 96) GGTGCATCC light chain CDR2 (SEQ ID NO: 97) CAGCAGTATAATGACTGGCCTCCGTCTTGGACG light chain CDR3 (SEQ ID NO: 98)

[79] An anti-SARS-CoV-2 antibody can also include a variable region made from a nucleic acid encoding a heavy chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the nucleic acids encoding a heavy chain (SEQ ID NO: 2, 6, 12, 16, 20, 24, 28, 32, or 36), and a nucleic acid encoding a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the nucleic acids encoding a light chain (SEQ ID NO: 4, 8, 14, 18, 22, 26, 30, 34, or 38). An anti- SARS-CoV-2 antibody can also include a variable region made from a nucleic acid encoding a heavy chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the heavy chains (SEQ ID NO: 2, 6, 12, 16, 20, 24, 28, 32 or 36), and a nucleic acid encoding a light chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the light chains (SEQ ID NO: 4, 8, 14, 18, 22, 26, 30, 34, or 38).

[80] An anti-SARS-CoV-2 antibody can be made with a variable region selected from variable regions encoded by antibodies 1-402. (See Table 1) The heavy chains are encoded by the odd numbered SEQ ID Nos. and the light chains are encoded by the even numbered SEQ ID NOs of each variable region pair. The identifier for each anti-SARS-CoV-2 variable region is in second column labeled Ab, so anti-SARS-CoV-2 variable region (1) is encoded by SEQ ID Nos: 159 (heavy chain) and 160 (light chain), anti-SARS-CoV-2 variable region (2) is encoded by SEQ ID Nos: 161 (heavy chain) and 162 (light chain), anti-SARS-CoV-2 variable region (3) is encoded by SEQ ID Nos: 163 (heavy chain) and 164 (light chain), etc.

[81] Anti-SARS-CoV-2 antibody 3910 can have a variable region comprised of a heavy chain with the amino acid sequence of:

QVQLQESGSGLVKPSQTLSLTCAVSGVSMSTGDYSWSWIRRPPGKGLEWIGYIFLGGRTY SNPSLKSRVTMSIDRSKNQFSLKLTSVTAADTAVYYCARDRSGSGTLDYWGQGTLIAVSS (SEQ ID NO: 99)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: CAAGTGCAGCTGCAGGAGTCCGGCTCCGGACTGGTGAAGCCTTCACAGACCCTGTCC CTCACCTGCGCTGTCTCTGGTGTCTCCATGAGCACTGGTGATTACTCCTGGAGCTGGA TCCGGCGGCCACCAGGGAAGGGCCTGGAGTGGATTGGTTACATCTTCCTAGGTGGGA

GAACCTACTCCAACCCGTCCCTCAAGAGTCGAGTCACAATGTCAATAGACAGGTCCA

AGAACCAGTTCTCCCTGAAGCTGACCTCTGTGACCGCCGCGGACACGGCCGTATATT

ACTGTGCCAGAGATCGCTCTGGTTCGGGGACCCTTGACTACTGGGGCCAGGGAACCC

TGATCGCCGTCTCCTCA (SEQ ID NO: 100)

Anti-SARS-CoV-2 antibody 3910 can have a variable region comprised of a light chain with the amino acid sequence of:

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGV SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLFGGGTKLTVL (SEQ ID NO: 101) This light chain amino acid sequence can be encoded in a nucleic acid sequence of:

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCA

TCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCA

ACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTCAGTAATCGGCCCTC

AGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATC

TCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGC

AGCACTCTATTCGGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: 102)

The CDRs of SC2 antibody 3910 are:

GGTGTCTCCATGAGCACTGGTGATTACTCC heavy chain CDR1 (SEQ ID NO: 103)

ATCTTCCTAGGTGGGAGAACC heavy chain CDR2 (SEQ ID NO: 104)

GCCAGAGATCGCTCTGGTTCGGGGACCCTTGACTAC heavy chain CDR3 (SEQ ID NO: 105)

AGCAGTGACGTTGGTGGTTATAACTAT light chain CDR1 (SEQ ID NO: 106)

GAGGTCAGT light chain CDR2 (SEQ ID NO: 107)

AGCTCATATACAAGCAGCAGCACTCTA light chain CDR3 (SEQ ID NO: 108)

[82] Anti-SARS-CoV-2 antibody 3915 can have a variable region comprised of a heavy chain with the amino acid sequence of:

EEQLLESGGDLVWPGGSLRLSCAASGLTFSSYSTNWVRQAPGRGLEWVASISSTSWSRY

YADSVKGRFTISRDNAKNSLYLQMNSLGVEDTAVYYCTADQRARNTGVIDYWGRGTLV TVSS (SEQ ID NO: 109)

GAGGAGCAGCTGTTGGAGTCTGGGGGAGACCTGGTCTGGCCTGGGGGGTCCCTGAGA

CTCTCCTGTGCAGCCTCTGGACTCACCTTCAGTAGCTATAGCACGAACTGGGTCCGCC AGGCTCCAGGGAGGGGGCTGGAGTGGGTCGCGTCCATTAGTAGTACTAGTTGGTCCA GATATTACGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGA ACTCGCTGTATCTGCAAATGAACAGCCTGGGAGTCGAGGATACGGCTGTGTATTACT GTACGGCAGATCAGAGAGCTCGAAACACGGGGGTCATTGACTATTGGGGCCGGGGA

ACCCTGGTCACCGTCTCCTCA (SEQ ID NO: 110)

Anti-SARS-CoV-2 antibody 3915 can have a variable region comprised of a light chain with the amino acid sequence of:

QSALTQPASVSGSPGQSITISCTGTSSDIGGYDYVSWYRQDPGKAPRLMIYEVSNRPSGVS NRFSGAKSGNTASLTISGLQAEDEADYYCSSYSSTSTSVVFGGGTKLTVL (SEQ ID NO: H l)

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCA TCTCCTGCACTGGAACCAGCAGTGACATTGGTGGTTATGACTATGTCTCGTGGTACCG ACAGGACCCAGGCAAGGCCCCCAGACTCATGATTTATGAGGTCAGTAACCGGCCCTC

AGGGGTTTCTAATCGCTTCTCTGGCGCCAAGTCTGGCAACACGGCCTCCCTGACCATC TCTGGCCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATTCAAGCACC AGCACCTCTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: 112)

The CDRs of SC2 antibody 3915 are:

GGACTCACCTTCAGTAGCTATAGC heavy chain CDR1 (SEQ ID NO: 113)

ATTAGTAGTACTAGTTGGTCCAGA heavy chain CDR2 (SEQ ID NO: 114)

ACGGCAGATCAGAGAGCTCGAAACACGGGGGTCATTGACTAT heavy chain CDR3 (SEQ ID NO: 115)

AGCAGTGACATTGGTGGTTATGACTAT light chain CDR1 (SEQ ID NO: 116)

GAGGTCAGT light chain CDR2 (SEQ ID NO: 117)

AGCTCATATTCAAGCACCAGCACCTCTGTGGTG light chain CDR3 (SEQ ID NO: 118) [83] Anti-SARS-CoV-2 antibody 3945 can have a variable region comprised of a heavy chain with the amino acid sequence of:

QLQLQESGSGLVKPSQTLSLTCAVSGGSVSSGGYSWSWIRQPPGKGLEWIGYIYDSGITSY

NPSLKSRLTISIDRSKNQFSLGLSSVTAADTAVYYCARVRRNTSGSFSTGHFDYWGQGTL VTVSS (SEQ ID NO: 119)

CAGCTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCC CTCACCTGCGCTGTCTCTGGTGGCTCCGTCAGCAGTGGTGGTTATTCCTGGAGCTGGA TCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATGATAGTGGGA TCACCTCCTACAACCCGTCCCTCAAGAGCCGACTCACCATATCAATAGACAGGTCCA AGAACCAGTTCTCCCTGGGGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATT ACTGTGCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTA CTGGGGCCAGGGAACCCTAGTCACCGTCTCCTCA (SEQ ID NO: 120)

Anti-SARS-CoV-2 antibody 3945 can have a variable region comprised of a light chain with the amino acid sequence of:

QSALTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQHHPGKAPKLMIYDVSDRPSGV SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTNTSTLYVFGTGTKVTVL (SEQ ID NO: 121)

CAGTCTGCCCTGACTCAGCCTGCCTCCGTATCTGGGTCTCCTGGACAGTCGATCACCA TCTCCTGCACTGGAACCAGCAGTGACGTTGGTGCTTATAACTATGTCTCTTGGTACCA ACACCACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTGATCGGCCCTC

AGGAGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATC TCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAACACC AGCACTCTTTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO: 122)

The CDRs of SC2 antibody 3945 are:

GGTGGCTCCGTCAGCAGTGGTGGTTATTCC heavy chain CDR1 (SEQ ID NO: 123)

ATCTATGATAGTGGGATCACC heavy chain CDR2 (SEQ ID NO: 124)

GCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTAC heavy chain CDR3 (SEQ ID NO: 125)

AGCAGTGACGTTGGTGCTTATAACTAT light chain CDR1 (SEQ ID NO: 126)

GATGTCAGT light chain CDR2 (SEQ ID NO: 127)

AGCTCATATACAAACACCAGCACTCTTTATGTC light chain CDR3 (SEQ ID NO: 128) [84] Anti-SARS-CoV-2 antibody 3947 can have a variable region comprised of a heavy chain with the amino acid sequence of:

QLQLQESGSGLVKPSQTLSLTCAVSGGSVSSGGYSWSWIRQPPGKGLEWIGYIYDSGITSY

NPSLKSRLTISIDRSKNQFSLGLSSVTAADTAVYYCARVRRNTSGSFSTGHFDYWGQGTL

VTVSS (SEQ ID NO: 129)

This heavy chain amino acid sequence can be encoded in a nucleic acid sequence of: CAGCTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCC CTCACCTGCGCTGTCTCTGGTGGCTCCGTCAGCAGTGGTGGTTATTCCTGGAGCTGGA

TCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATGATAGTGGGA TCACCTCCTACAACCCGTCCCTCAAGAGCCGACTCACCATATCAATAGACAGGTCCA AGAACCAGTTCTCCCTGGGGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATT ACTGTGCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTA

CTGGGGCCAGGGAACCCTAGTCACCGTCTCCTCA (SEQ ID NO: 130)

Anti-SARS-CoV-2 antibody 3947 can have a variable region comprised of a light chain with the amino acid sequence of:

QSVLTQPPSVSASPGQTVTISCSGSTSNIGGNYVSWYQHLPGTAPKLLIYDSNKRPSGIPDR

FSGSKSGTSATLGITGLQTEDEADYYCGTWDYRLSGAVFGGGTKLTVL (SEQ ID NO: 131) This light chain amino acid sequence can be encoded in a nucleic acid sequence of:

CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGTCCCCAGGACAAACGGTCACC

ATCTCCTGCTCTGGAAGCACCTCCAACATTGGTGGTAATTATGTCTCCTGGTACCAGC

ACCTCCCAGGAACAGCCCCCAAACTCCTCATTTATGACAGTAATAAGCGACCCTCAG

GGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCAC

CGGACTCCAGACTGAGGATGAGGCCGATTATTACTGTGGAACATGGGATTACAGACT

GAGTGGTGCGGTCTTCGGAGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: 132)

The CDRs of SC2 antibody 3947 are:

GGTGGCTCCGTCAGCAGTGGTGGTTATTCC heavy chain CDR1 (SEQ ID NO: 133)

ATCTATGATAGTGGGATCACC heavy chain CDR2 (SEQ ID NO: 134)

GCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTAC heavy chain CDR3 (SEQ ID NO: 135)

ACCTCCAACATTGGTGGTAATTAT light chain CDR1 (SEQ ID NO: 136)

GGAACATGGGATTACAGACTGAGTGGTGCGGTCGACAGTAAT light chain CDR2 (SEQ ID NO: 137) light chain CDR3 (SEQ ID NO: 138)

[85] Anti-SARS-CoV-2 antibody 3969 can have a variable region comprised of a heavy chain with the amino acid sequence of:

Q VQLVESGGGVVQPGRSLRLSC AASGFTF S S YGMHWVRQ APGKGLEW VAVIS YDGSNK

YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGVGDYAVWGQGTLVTVS

S (SEQ ID NO: 139)

CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAG

ACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGC

CAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAAT

AAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAG

AACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTAC TGTGCGAAAGGAGTGGGTGACTACGCGGTCTGGGGCCAGGGAACCCTGGTCACCGTC TCCTCA (SEQ ID NO: 140)

Anti-SARS-CoV-2 antibody 3969 can have a variable region comprised of a light chain with the amino acid sequence of:

QSALTQPASVSGSPGQSITISCTGTNSDIGGYDYVSWYQQHPGKAPKLMIFDVNNRPSGV SNRFSGSKSGNTASLTISELQSADEADYFCSSFSTRNSLVVFGGGTKLTVL (SEQ ID NO: 141)

CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCA TCTCCTGCACTGGAACCAACAGTGACATTGGTGGTTATGATTATGTCTCCTGGTACCA ACAACACCCAGGCAAAGCCCCCAAACTCATGATTTTTGACGTCAATAATCGGCCCTC AGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATC TCTGAGCTCCAGTCTGCGGACGAGGCTGATTATTTCTGCAGCTCTTTTTCAACCAGAA ACTCTCTCGTGGTGTTCGGCGGAGGGACCAAACTGACCGTCCTA (SEQ ID NO: 142) The CDRs of SC2 antibody 3969 are:

GGATTCACCTTCAGTAGCTATGGC heavy chain CDR1 (SEQ ID NO: 143)

ATATCATATGATGGAAGTAATAAA heavy chain CDR2 (SEQ ID NO: 144)

GCGAAAGGAGTGGGTGACTACGCGGTC heavy chain CDR3 (SEQ ID NO: 145)

AACAGTGACATTGGTGGTTATGATTAT light chain CDR1 (SEQ ID NO: 146)

GACGTCAAT light chain CDR2 (SEQ ID NO: 147)

AGCTCTTTTTCAACCAGAAACTCTCTCGTGGTG light chain CDR3 (SEQ ID NO: 148) [86] Anti-SARS-CoV-2 antibody 4083 can have a variable region comprised of a heavy chain with the amino acid sequence of:

QLQLQESGSGLVKPSQTLSLTCAVSGGSVSSGGYSWSWIRQPPGKGLEWIGYIYDSGITSY NPSLKSRLTISIDRSKNQFSLGLSSVTAADTAVYYCARVRRNTSGSFSTGHFDYWGQGTL VTVSS (SEQ ID NO: 149)

CAGCTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCC

CTCACCTGCGCTGTCTCTGGTGGCTCCGTCAGCAGTGGTGGTTATTCCTGGAGCTGGA TCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATGATAGTGGGA TCACCTCCTACAACCCGTCCCTCAAGAGCCGACTCACCATATCAATAGACAGGTCCA AGAACCAGTTCTCCCTGGGGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATT ACTGTGCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTA CTGGGGCCAGGGAACCCTAGTCACCGTCTCCTCA (SEQ ID NO: 150) Anti-SARS-CoV-2 antibody 4083 can have a variable region comprised of a light chain with the amino acid sequence of:

QSVLTQPPSVSAVPGQKVTISCSGNNSNIGNNLVSWYQQLPGTAPKLLIYNNNRRPSGIPD RFSGSKSGTSATLGITGLQTGDEAAYYCAARDSSLSAVVFGGGTKLTVL (SEQ ID NO: 151)

This light chain amino acid sequence can be encoded in a nucleic acid sequence of: CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGTCCCAGGACAGAAGGTCACC ATCTCCTGCTCTGGAAACAACTCCAATATTGGAAATAATCTTGTATCCTGGTACCAGC AGCTCCCAGGAACAGCCCCCAAACTCCTCATTTATAACAATAATAGGCGACCATCAG GGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCAC CGGACTCCAGACTGGGGACGAGGCCGCTTATTATTGCGCAGCAAGGGATAGCAGCCT GAGTGCTGTGGTGTTCGGCGGAGGGACCAAACTGACCGTCCTA (SEQ ID NO: 152) The CDRs of SC2 antibody 4083 are:

GGTGGCTCCGTCAGCAGTGGTGGTTATTCC heavy chain CDR1 (SEQ ID NO: 153) ATCTATGATAGTGGGATCACC heavy chain CDR2 (SEQ ID NO: 154) GCCAGAGTTCGGCGGAATACTAGTGGTTCTTTCTCGACCGGCCACTTTGACTAC heavy chain CDR3 (SEQ ID NO: 155)

AACTCCAATATTGGAAATAATCTT light chain CDR1 (SEQ ID NO: 156) AACAATAAT light chain CDR2 (SEQ ID NO: 157) GCAGCAAGGGATAGCAGCCTGAGTGCTGTGGTG light chain CDR3 (SEQ ID NO: 158)

[87] SC2 antibody 3910 binds to Sino CoV2 SI (spike protein 1), NAC CoV2 SI, and Sino CoV2 RBD (Receptor Binding Domain). SC2 antibody 3915 binds to Sino CoV2 SI (spike protein 1), NAC CoV2 SI, Sino CoV2 RBD (Receptor Binding Domain), and NAC CoV2 Mosaic. SC2 antibody 3945 binds to HKU1 S1+S2 (K_d = 11 nM Carterra LSA). SC2 antibody 3947 binds to Sino CoV2 S2 (K_d = 25 nM Carterra LSA) and HKU1 SI + S2 (K_d = 532 nM Carterra LSA). SC2 antibody 3969 binds to Sino SARS1 SI (K_d = 28 nM Carterra LSA), HKU1 SI + S2 (K_d = 12 nM Carterra LSA), and Sino Cov2 RBD (K_d = 105 nM Carterra LSA). SC2 antibody 4083 binds to Sino Cov2 S2 (K_d = 41 nM Carterra LSA).

[88] The anti-SARS-CoV-2 antibodies 3910 (SEQ ID NO: 99 and 101), 3915 (SEQ ID NO: 109 and 111), 3945 (SEQ ID NO: 119 and 121), 3947 (SEQ ID NO: 129 and 131), 3969 (SEQ ID NO: 139 and 141), and 4083 (SEQ ID NO: 149 and 151) also include variable regions having amino acid sequences that have 99%, 95%, 90%, 80% or 70% sequence identity with one of the heavy chains from variable region SEQ ID NO: 99, 109, 119, 129, 139, or 149, and a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one light chains from variable region SEQ ID NO: 101, 11, 121, 131, 141, or 151.

[89] CDRs from anti-SARS-CoV-2 antibodies 3910 (SEQ ID NO: 99 and 101), 3915 (SEQ ID NO: 109 and 111), 3945 (SEQ ID NO: 119 and 121), 3947 (SEQ ID NO: 129 and 131), 3969 (SEQ ID NO: 139 and 141), and 4083 (SEQ ID NO: 149 and 151) can be used to make CDR grafted antibodies known in the art.

[90] An anti-SARS-CoV-2 antibody can also include a variable region made from a nucleic acid encoding a heavy chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the nucleic acids encoding a heavy chain (SEQ ID NO: 2, 6, 12, 16, 20, 24, 28, 32, 36, 100, 110, 120, 130, 140, or 150), and a nucleic acid encoding a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the nucleic acids encoding a light chain (SEQ ID NO: 4, 8, 14, 18, 22, 26, 30, 34, 38, 102, 112, 122, 132, 142, or 152). An anti-SARS-CoV-2 antibody can also include a variable region made from a nucleic acid encoding a heavy chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the heavy chains (SEQ ID NO: 2, 6, 12, 16, 20, 24, 28, 32, 36, 100, 110, 120, 130, 140, or 150), and a nucleic acid encoding a light chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the light chains (SEQ ID NO: 4, 8, 14, 18, 22, 26, 30, 34, 38, 102, 112, 122, 132, 142, or 152).

[91] An anti-SARS-CoV-2 antibody can also include a variable region (e.g., starting from anti- SARS-CoV-2 variable regions (1) to (402)) made from a nucleic acid encoding a heavy chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the heavy chain from variable regions 1-402 (odd numbered SEQ ID Nos), and a nucleic acid encoding a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one of the light chain from variable region 1-402 (even numbered SEQ ID NOs). An anti-SARS-CoV-2 antibody can also include a variable region made from a nucleic acid encoding a heavy chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the heavy chains from variable regions 903-1706 (odd numbered SEQ ID Nos), and a nucleic acid encoding a light chain that hybridizes under stringent hybridization conditions with one of the nucleic acids encoding one of the light chains from variable regions 903- (even numbered SEQ ID NOs).

[92] The CDRs for the light and heavy chains of the anti-SARS-CoV-2 variable regions 1-402 are known to a person of skill in the art. These CDRs and optionally FR amino acids from the corresponding light or heavy chain can be used to make CDR grafted antibodies as described below.

[93] The anti-SARS-CoV-2 antibodies disclosed herein can bind to SARS-CoV-2 Spike Trimer, SARS-CoV-2 Receptor Binding Domain (RBD), SARS-CoV-2 Membrane Protein (E), and/or SARS-CoV-2 Nucleocapsid. Antigen specificity for the anti-SARS-CoV-2 variable regions are shown in Table 2. For example, antibodies that bind to SARS-CoV-2 RBD include, for example, anti-SARS-CoV-2 antibodies comprising the anti-SARS-CoV-2 variable region 2-6, 8-22, 24, 29- 34, 35-39, 41-42, 162, 165, 167, 172-173, 177-178, 180, 183-184, 186-187, 192-195, 288, 296, 298-299, 303-304, 313-316, 321-323, 326-328, 332, 334, 337-338, 344-345, 347, 350, 355-356, 358-360, 368-370, 378-380. For example, antibodies that bind to SARS-CoV-2 Spike trimer include, for example, anti-SARS-CoV-2 antibodies comprising the anti-SARS-CoV-2 variable region 1-4, 7, 14-16, 19-20, 31, 37, 162, 171, 186. For example, antibodies that bind to SARS- CoV-2 Membrane Protein include, for example, anti-SARS-CoV-2 antibodies comprising the anti- SARS-CoV-2 variable region 202-209, 218-219, 222-223, 227, 229-231, 242-245, 261, 280. For example, antibodies that bind to SARS-CoV-2 Nucleocapsid include, for example, anti-SARS- CoV-2 antibodies comprising the anti-SARS-CoV-2 variable region 202-209, 214-215, 218-219, 221-223, 227, 229-231, 236, 242-243, 245, 261, 271, 280.

[94] Any of the anti-SARS-CoV-2 antibodies described above can be made from a nucleic acid encoding a full-length antibody that lacks any introns, and so, is non-natural. The non-natural nucleic acids can include the combination of a variable region (e.g., anti-SARS-CoV-2 antibody variable regions 1-451) operably linked to a constant region (e.g., IgGl, IgG2, IgG3, or IgG4) that is non-natural for that variable region. Any of the above nucleic acids can be used to recombinantly make the anti-SARS-CoV-2 antibodies described herein. The anti-SARS-CoV-2 antibodies also include amino acid sequences that are non-natural including the combination of a variable region (e.g., anti-SARS-CoV-2 antibody variable regions 1-451) operably linked to a constant region (e.g., IgGl, IgG2, IgG3, or IgG4) that is non-natural for that variable region.

[95] An anti-SARS-CoV-2 antibody can bind to SARS-CoV-2 with an affinity (Kd) of less than one picomolar. An anti-SARS-CoV-2 antibody can bind with an affinity of at least 1 pM, or at least 10 pM, or at least 100 pM.

[96] The anti-SARS-CoV-2 antibodies disclosed herein can also be used to make chimeric antigen receptors for arming T-cells treat infections from SARS-CoV-2. For example, the antibodies can be formatted into a single chain structure recombinantly combined with appropriate transmembrane and signaling components to make a chimeric antigen receptor.

[97] The anti-SARS-CoV-2 antibodies disclosed herein can have neutralizing activity against SARS-CoV-2 in an in vitro cell infection model. For example, the antibodies SC2 antibody 3417, SC2 antibody 3387, SC2 antibody 3396, and SC2 antibody 3705 neutralized SARS-CoV-2 and blocked the virus from infecting cells. In addition, the SC2 antibody 3387 was able to bind to spike proteins with the mutations D614G and E484K (Sweden-1 variant of European variant B-l), or D614G,V445I,H655Y,and E583D (England/Bristol variant of European variant B-l), or G485S (related to Australia-1 variant), or N501Y (South African variant Bl.l), or S494P, or V483K, or R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P. The ability to bind all of these variants shows the broad specificity of these anti-SARS-CoV-2 antibodies.

[98] The anti-SARS-CoV-2 antibodies described herein (e.g., SC2 antibody 3387 or SC2 antibody 3705) can be used in methods to neutralize SARS-CoV-2 and/or for treating CO VID-19 infection so as to reduce at least one symptom associated with COV ID- 19. Compositions comprising at least one isolated recombinant monoclonal antibody that binds specifically to SARS- CoV-2 virus and thereby neutralizes the virus are used in these methods. The anti-SARS-CoV-2 antibody can be administered prophylactically and/or can be administered to patients with COVID- 19 infections.

Nucleic Acids

[99] The disclosure also relates to nucleic acids that encode, at least in part, the individual peptides, polypeptides, and proteins described herein. The nucleic acids may be natural, synthetic or a combination thereof. The nucleic acids may be RNA, mRNA, DNA or cDNA.

[100] Nucleic acids also include expression vectors, such as plasmids, or viral vectors, or linear vectors, or vectors that integrate into chromosomal DNA. Expression vectors can contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of cells. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria. In eukaryotic host cells, e.g., mammalian cells, the expression vector can be integrated into the host cell chromosome and then replicate with the host chromosome. Similarly, vectors can be integrated into the chromosome of prokaryotic cells.

[101] Expression vectors also generally contain a selection gene, also termed a selectable marker. Selectable markers are well-known in the art for prokaryotic and eukaryotic cells, including host cells of the invention. Generally, the selection gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. In some embodiments, an exemplary selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Other selectable markers for use in bacterial or eukaryotic (including mammalian) systems are well-known in the art.

[102] An example of a promoter that is capable of expressing a transgene encoding an immune binding protein in a mammalian host cell is the EFla promoter. The native EFla promoter drives expression of the alpha subunit of the elongation factor- 1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. The EFla promoter has been extensively used in mammalian expression plasmids and has been shown to be effective in driving expression from transgenes cloned into a lentiviral vector. See, e.g., Milone et al., Mol. Ther. 17(8): 1453-1464 (2009), which is incorporated by reference in its entirety for all purposes. Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. Other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus promoter (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, phosphoglycerate kinase (PGK) promoter, MND promoter (a synthetic promoter that contains the U3 region of a modified MoMuLV LTR with myeloproliferative sarcoma virus enhancer, see, e.g., Li et al., J. Neurosci. Methods vol. 189, pp. 56-64 (2010) which is incorporated by reference in its entirety for all purposes), an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the elongation factor- la promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the invention is not limited to the use of constitutive promoters.

[103] Inducible promoters are also contemplated herein. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, a tetracycline promoter, a c-fos promoter, the T-REx system of ThermoFisher which places expression from the human cytomegalovirus immediate-early promoter under the control of tetracycline operator(s), and RheoSwitch promoters of Intrexon. Karzenowski, D. et al., BioTechiques 39: 191-196 (2005); Dai, X. et al., Protein Expr. Purif 42:236-245 (2005); Palli, S. R. et al., Eur. J. Biochem. 270: 1308-1515 (2003); Dhadialla, T. S. et al., Annual Rev. Entomol. 43:545-569 (1998); Kumar, M. B, et al., J. Biol. Chem. 279:27211- 27218 (2004); Verhaegent, M. et al., Annal. Chem. 74:4378-4385 (2002); Katalam, A. K., et al., Molecular Therapy 13 : S 103 (2006); and Karzenowski, D. et al., Molecular Therapy 13 : S 194 (2006), U.S. Patent Nos. 8,895,306, 8,822,754, 8,748,125, 8,536,354, all of which are incorporated by reference in their entirety for all purposes.

[104] Expression vectors typically have promoter elements, e.g., enhancers, to regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.

[105] Control regions suitable for a bacterial host cell can be used in the expression vector. Suitable control regions for directing transcription of the nucleic acid constructs include, for example, the control regions obtained from the E. coli lac operon, Streptomyces coelicolor agarase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylB genes, and the prokaryotic beta-lactamase gene, the tac promoter, or the T7 promoter.

[106] In some embodiments, control regions for filamentous fungal host cells, include control regions obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alphaamylase, Aspergillus niger ox Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for Aspergillus niger neutral alpha-amylase and Aspergillus oryzae triose phosphate isomerase), and mutant, truncated, and hybrid control regions thereof. Exemplary yeast cell control regions can be from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GALI), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3- phosphate dehydrogenase (ADH2/GAP), and Saccharomyces cerevisiae 3 -phosphoglycerate kinase. [107] Exemplary control regions for insect cells include, among others, those based on polyhedron, PCNA, OplE2, OplEl, Drosophila metallothionein, and Drosophila actin 5C. In some embodiments, insect cell promoters can be used with Baculoviral vectors.

[108] Exemplary control regions for plant cells include, among others, those based on cauliflower mosaic virus (CaMV) 35S, polyubiquitin gene (PvUbil and PvUbi2), rice (Oryza saliva) actin 1 (OsActl) and actin 2 (OsAct2) control regions, the maize ubiquitin 1 (ZmUbil) control region, and multiple rice ubiquitin (RUBQ1, RUBQ2, rubi3) control regions.

[109] The expression vector can contain one or more selectable markers, which permit selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus Ucheniformis. or markers, which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol (Example 1) or tetracycline resistance. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), as well as equivalents thereof. Embodiments for use in an Aspergillus cell include the amdS and pyrG genes of Aspergillus nidulans ox Aspergillus oryzae and the bar gene of Streptomyces hygroscopicus.

[HO] It may be desirable to modify the polypeptides described herein. One of skill will recognize many ways of generating alterations in a given nucleic acid construct to generate variant polypeptides Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (e.g., in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques (see, e.g., Gillam and Smith, Gene 8:81-97, 1979; Roberts et al., Nature 328:731-734, 1987, which is incorporated by reference in its entirety for all purposes). The recombinant nucleic acids encoding the polypeptides herein can be modified to provide preferred codons which enhance translation of the nucleic acid in a selected organism.

[Hl] The polynucleotides described herein also include polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides described herein. Polynucleotides according to the invention can have at least about 80%, more typically at least about 90%, and even more typically at least about 95%, sequence identity to a polynucleotide of the invention. The invention also provides the complement of the polynucleotides including a nucleotide sequence that has at least about 80%, more typically at least about 90%, and even more typically at least about 95%, sequence identity to a polynucleotide encoding a polypeptide recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions which can routinely isolate polynucleotides of the desired sequence identities.

[112] Nucleic acids which encode protein analogs or variants in accordance with those described herein (z.e., wherein one or more amino acids are designed to differ from the wild type polypeptide) may be produced using site directed mutagenesis or PCR amplification in which the primer(s) have the desired point mutations. For a detailed description of suitable mutagenesis techniques, see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and/or Current Protocols in Molecular Biology, Ausubel et al., eds, Green Publishers Inc. and Wiley and Sons, N.Y (1994), each of which is incorporated by reference in its entirety for all purposes. Chemical synthesis using methods well known in the art, such as that described by Engels et al., Angew Chem Inti Ed. 28:716-34, 1989 (which is incorporated by reference in its entirety for all purposes), may also be used to prepare such nucleic acids.

[113] Amino acid “substitutions” for creating variants can be preferably the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, z.e., conservative amino acid replacements. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[114] The nucleic acids described herein can be linked to another nucleic acid so as to be expressed under control of a suitable promoter. The nucleic acid can be also linked to, in order to attain efficient transcription of the nucleic acid, other regulatory elements that cooperate with a promoter or a transcription initiation site, for example, a nucleic acid comprising an enhancer sequence, a polyA site, or a terminator sequence. In addition, a gene that can be a marker for confirming expression of the nucleic acid (e.g. a drug resistance gene, a gene encoding a reporter enzyme, or a gene encoding a fluorescent protein) may be incorporated. [115] When the nucleic acid described herein is introduced into a cell ex vivo, the nucleic acid of may be combined with a substance that promotes transference of a nucleic acid into a cell, for example, a reagent for introducing a nucleic acid such as a liposome or a cationic lipid, in addition to the aforementioned excipients. Alternatively, a vector carrying the nucleic acid can also be useful. Particularly, a composition in a form suitable for administration to a living body which contains the nucleic acid of the present invention carried by a suitable vector is suitable for in vivo gene therapy.

Host Cells

[116] Nucleic acids encoding an immune binding protein described herein (e.g., an antibody) can be cloned into an appropriate expression vector for expression of immune binding protein in a host cell. Host cells include, for example, bacterial, fungi, or mammalian host cells. The host cell can be a bacterium including, for example, Bacillus, such as B. lichenformis or B. subliHs: Pantoea, such as P. cilrea: Pseudomonas, such as P. alcaligenes,' Streptomyces, such as S. lividans or S. rubiginosus,' Escherichia, such as E. coli\ Enter obacter, Streptococcus,' Archaea, such as Methanosarcina mazer, or Corynebacterium, such as C. glutamicum.

[117] The host cells can be fungi cells, including, but not limited to, fungi of the genera Saccharomyces, Klyuveromyces, Candida, Pichia, Debaromyces, Hansenula, Yarrowia, Zygosaccharomyces, or Schizosaccharomyces . In some embodiments, the host cell is a fungi, including, among others, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces marxianus, Aspergillus terreus, Aspergillus niger, Pichia pastoris, Rhizopus arrhizus, Rhizobus oryzae, Yarrowia lipolytica, and the like. The eukaryotic cells can be algal, including but not limited to algae of the genera Chlorella, Chlamydomonas, Scenedesmus, Isochrysis, Dunaliella, Tetraselmis, Nannochloropsis, or Prototheca. The algae can be a green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.

[118] The eukaryotic cells can be mammalian cells, such as mouse, rat, rabbit, hamster, porcine, bovine, feline, or canine. The mammalian cells can be cells of primates, including but not limited to, monkeys, chimpanzees, gorillas, and humans. The mammalians cells can be mouse cells, as mice routinely function as a model for other mammals, most particularly for humans (see, e.g, Hanna, J. et al., Science 318: 1920-23, 2007; Holtzman, D.M. et al., J Clin Invest. 103(6):R15-R21, 1999; Warren, R.S. et al., J Clin Invest. 95: 1789-1797, 1995; each publication is incorporated by reference in its entirety for all purposes). Animal cells include, for example, fibroblasts, epithelial cells (e.g., renal, mammary, prostate, lung), keratinocytes, hepatocytes, adipocytes, endothelial cells, and hematopoietic cells. In some embodiments, the animal cells are adult cells (e.g., terminally differentiated, dividing or non-dividing) or embryonic cells (e.g., blastocyst cells, etc.) or stem cells. The animal cell can be a cell line derived from an animal or other source, such as a Chinese hamster ovary cell line (CHO cell), or murine myeloma cell lines (NS0, Sp2/0), or human cell lines including, for example, HEK293, HT-1080, or PER.C6.

[119] The mammalian cell can be a cell found in the circulatory system of a mammal, including humans. Exemplary circulatory system cells include, among others, red blood cells, platelets, plasma cells, T-cells, natural killer cells, B-cells, macrophages, neutrophils, or the like, and precursor cells of the same. As a group, these cells are defined to be circulating eukaryotic cells of the invention. The mammalian cells can be derived from any of these circulating eukaryotic cells. The immiuner binding proteins described herein may be used with any of these circulating cells or cells derived from the circulating cells. The mammalian cell can be a T-cell or T-cell precursor or progenitor cell. The mammalian cell can be a helper T-cell, a cytotoxic T-cell, a memory T-cell, a regulatory T-cell, a natural killer T-cell, a mucosal associated invariant T-cell, a gamma delta T cell, or a precursor or progenitor cell to the aforementioned. The mammalian cell can be a natural killer cell, or a precursor or progenitor cell to the natural killer cell. The mammalian cell can be a B-cell, or a plasma cell, or a B-cell precursor or progenitor cell. The mammalian cell can be a neutrophil or a neutrophil precursor or progenitor cell. The mammalian cell can be a megakaryocyte or a precursor or progenitor cell to the megakaryocyte. The mammalian cell can be a macrophage or a precursor or progenitor cell to a macrophage.

[120] A source of cells can be obtained from a subject. The subject may be any living organism. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Any number of T cell lines available in the art, may be used. T cells can be obtained from a unit of blood collected from a subj ect using any number of techniques known to the skilled artisan, such as Ficoll separation. Cells from the circulating blood of an individual can be obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. The cells collected by apheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. The cells can be washed with phosphate buffered saline (PBS). In an alternative aspect, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations. Initial activation steps in the absence of calcium can lead to magnified activation.

[121] Plant cells can be cells of monocotyledonous or dicotyledonous plants, including, but not limited to, alfalfa, almonds, asparagus, avocado, banana, barley, bean, blackberry, brassicas, broccoli, cabbage, canola, carrot, cauliflower, celery, cherry, chicory, citrus, coffee, cotton, cucumber, eucalyptus, hemp, lettuce, lentil, maize, mango, melon, oat, papaya, pea, peanut, pineapple, plum, potato (including sweet potatoes), pumpkin, radish, rapeseed, raspberry, rice, rye, sorghum, soybean, spinach, strawberry, sugar beet, sugarcane, sunflower, tobacco, tomato, turnip, wheat, zucchini, and other fruiting vegetables (e.g. tomatoes, pepper, chili, eggplant, cucumber, squash etc.), other bulb vegetables (e.g., garlic, onion, leek etc.), other pome fruit (e.g. apples, pears etc.), other stone fruit (e.g., peach, nectarine, apricot, pears, plums etc.), Arabidopsis, woody plants such as coniferous and deciduous trees, an ornamental plant, a perennial grass, a forage crop, flowers, other vegetables, other fruits, other agricultural crops, herbs, grass, or perennial plant parts (e.g., bulbs; tubers; roots; crowns; stems; stolons; tillers; shoots; cuttings, including un-rooted cuttings, rooted cuttings, and callus cuttings or callus-generated plantlets; apical meristems etc.). The term “plants” refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage and fruits.

CDR Grafted Antibodies

[122] CDR grafted forms of antibodies are chimeric immunoglobins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain CDR sequences derived from one immunoglobulin grafted into the framework sequences of a second immunoglobulin. CDR grafted antibodies include immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient antibody are replaced by residues from a CDR of another antibody (donor antibody) having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the recipient antibody are replaced by corresponding residues from the donor antibody. CDR grafted antibodies may also comprise residues which are found neither in the recipient antibody nor in the donor CDR or framework sequences. In general, the CDR grafted antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a donor antibody and all or substantially all of the FR regions are those of a recipient antibody consensus sequence. The CDR grafted antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a recipient antibody [Jones et al., Nature, 321 :522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992), all of which are incorporated by reference in their entirety for all purposes],

[123] Humanization is one type of CDR grafting to make a chimeric antibody. Methods for humanizing non-human antibodies are well known in the art. Generally, humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non- human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321 :522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239: 1534-1536 (1988), all of which are incorporated by reference in their entirety for all purposes], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567 which is incorporated by reference in its entirety for all purposes), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequences from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Multispecific Antibodies

[124] It may be desirable to generate multispecific (e.g. bispecific) antibodies having binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of SARS-CoV-2. Alternatively, an anti-SARS-CoV-2 arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2 or CD3), or Fc receptors for IgG (Fc gamma Receptor), such as FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD 16). Bispecific antibodies may also be used to localize cytotoxic agents. These antibodies possess an SARS-CoV-2-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-alpha, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies).

[125] According to another approach for making bispecific antibodies, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. See WO96/27011 published Sep. 6, 1996, which is incorporated by reference in its entirety for all purposes. [126] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, which is incorporated by reference in its entirety for all purposes, along with a number of cross-linking techniques.

[127] Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) (which is incorporated by reference in its entirety for all purposes) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. In yet a further embodiment, Fab'-SH fragments directly recovered from E. coli can be chemically coupled in vitro to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217 225 (1992) (which is incorporated by reference in its entirety for all purposes).

[128] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547 1553 (1992), which is incorporated by reference in its entirety for all purposes. The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444 6448 (1993) which is incorporated by reference in its entirety for all purpose, has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol. 152:5368(1994) which is incorporated by reference in its entirety for all purposes. Alternatively, the bispecific antibody may be a "linear antibody" produced as described in Zapata et al. Protein Eng. 8(10): 1057 1062 (1995) which is incorporated by reference in its entirety for all purposes.

[129] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991) which is incorporated by reference in its entirety for all purposes.

Modified Antibodies

[130] An anti-SARS-CoV-2 antibody can include a moiety that extends a half-life (T1/2) or/and the duration of action of the antibody. The moiety can extend the circulation T 1/2, blood T 1/2, plasma T1/2, serum T1/2, terminal T1/2, biological T1/2, elimination T1/2 or functional T1/2, or any combination thereof, of the antibody.

[131] An anti-SARS-CoV-2 antibody may be modified by a single moiety. Alternatively, an anti- SARS-CoV-2 antibody may be modified by two or more substantially similar or identical moieties or two or more moieties of the same type. An anti-SARS-CoV-2 antibody may include two or more moieties of different types, or two or more different types of moieties. Two or more anti-SARS- CoV-2 antibodies can also be attached to one moiety. The attachment between the anti-SARS- CoV-2 antibody and the moiety can be covalent or noncovalent.

[132] A polypeptide moiety can be recombinantly fused to the N-terminus or the C-terminus of the heavy chain or the light chain of an anti-SARS-CoV-2 antibody, optionally via a linker. The linker may contain about 4-30 amino acid residues. The linker may contain from about 6 or 8 amino acid residues to about 20 amino acid residues, or from about 6 or 8 amino acid residues to about 15 amino acid residues.

[133] A protracting moiety can be human serum albumin (HSA) or a portion thereof (e.g., domain III) that binds to the neonatal Fc receptor (FcRn). The HSA or FcRn-binding portion thereof can optionally have one or more mutations that confer a beneficial property or effect. In some embodiments, the HSA or FcRn-binding portion thereof has one or more mutations that enhance pH-dependent HSA binding to FcRn or/and increase HSA half-life, such as K573P or/and E505G/V547A. A protracting moiety can be an unstructured polypeptide.

[134] A protracting moiety can be a carboxy-terminal peptide (CTP) derived from the P-subunit of human chorionic gonadotropin (hCG). In the human body, the fourth, fifth, seventh and eight serine residues of the 34-aa CTP of hCG-P typically are attached to O-glycans terminating with a sialic acid residue. [135] A protracting moiety can be 1, 2, 3, 4, 5 or more moi eties of a synthetic polymer. The synthetic polymer can be biodegradable or non-biodegradable. Biodegradable polymers useful as protracting moieties include, but are not limited to, poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) and poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA). Non-biodegradable polymers useful as protracting moieties include without limitation polyethylene glycol) (PEG), polyglycerol, poly(A-(2-hydroxypropyl)methacrylamide) (PHPMA), polyoxazolines and poly(A-vinylpyrrolidone) (PVP). A synthetic polymer can be polyethylene glycol (PEG). PEGylation can be done by chemical or enzymatic, site-specific coupling or by random coupling.

[136] The protracting moieties can also include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, proly propylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

[137] The individual mass (e.g., average molecular weight), or the total mass, of the one or more synthetic polymer moieties can be about 10-50, 10-20, 20-30, 30-40 or 40-50 kDa, or about 10, 20, 30, 40 or 50 kDa. The individual mass (e.g., average MW), or the total mass, of the one or more synthetic polymer moieties also can be greater than about 50 kDa, such as about 50-100, 50-60, 60- 70, 70-80, 80-90 or 90-100 kDa, or about 60, 70, 80, 90 or 100 kDa. Moreover, the mass (e.g., average MW) of an individual synthetic polymer moiety can be less than about 10 kDa, such as about 1-5 or 5-10 kDa, or about 5 kDa. The individual mass (e.g., average MW), or the total mass, of the one or more synthetic polymer (e.g., PEG) moieties can be about 20 or 40 kDa.

Pharmaceutical Compositions [138] Antibodies specifically binding SARS-CoV-2 identified herein, as well as other immune binding proteins identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.

[139] Pharmaceutical compositions generally are prepared according to current good manufacturing practice (GMP), as recommended or required by, e.g., the Federal Food, Drug, and Cosmetic Act §501(a)(2)(B) and the International Conference on Harmonisation Q7 Guideline.

[140] Pharmaceutical compositions/formulations can be prepared in sterile form. For example, pharmaceutical compositions/formulations for parenteral administration by injection or infusion generally are sterile. Sterile pharmaceutical compositions/formulations are compounded or manufactured according to pharmaceutical-grade sterilization standards known to those of skill in the art, such as those disclosed in or required by the United States Pharmacopeia Chapters 797, 1072 and 1211, and 21 Code of Federal Regulations 211.

[141] Pharmaceutically acceptable excipients and carriers include pharmaceutically acceptable substances, materials and vehicles. Non-limiting examples of types of excipients include liquid and solid fillers, diluents, binders, lubricants, glidants, surfactants, dispersing agents, disintegration agents, emulsifying agents, wetting agents, suspending agents, thickeners, solvents, isotonic agents, buffers, pH adjusters, absorption-delaying agents, stabilizers, antioxidants, preservatives, antimicrobial agents, antibacterial agents, antifungal agents, chelating agents, adjuvants, sweetening agents, flavoring agents, coloring agents, encapsulating materials and coating materials. The use of such excipients in pharmaceutical formulations is known in the art. For example, conventional vehicles and carriers include without limitation oils (e.g., vegetable oils such as olive oil and sesame oil), aqueous solvents {e.g., saline, buffered saline (e.g., phosphate-buffered saline [PBS]) and isotonic solutions (e.g., Ringer’s solution)}, and organic solvents (e.g., dimethyl sulfoxide [DMSO] and alcohols [e.g., ethanol, glycerol and propylene glycol]). Except insofar as any conventional excipient or carrier is incompatible with an anti-SARS-CoV2 antibody or a fragment thereof, the disclosure encompasses the use of conventional excipients and carriers in formulations containing an anti-SARS-CoV2 antibody or a fragment thereof. See, e.g., Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania) (2005); Handbook of Pharmaceutical Excipients, 5th Ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical Additives, 3rd Ed., Ash and Ash, Eds., Gower Publishing Co. (2007); and Pharmaceutical Pre-formulation and Formulation, Gibson, Ed., CRC Press (Boca Raton, Florida) (2004). [142] Appropriate formulation can depend on various factors, such as the route of administration chosen. Potential routes of administration of a pharmaceutical composition comprising an anti- SARS-CoV2 antibody or a fragment thereof include without limitation oral, parenteral (including intradermal, subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intraperitoneal, intramedullary, intrathecal and topical), intracavitary, and topical (including dermal/epicutaneous, transdermal, mucosal, transmucosal, intranasal [e.g., by nasal spray or drop], intraocular [e.g., by eye drop], pulmonary [e.g., by oral or nasal inhalation], buccal, sublingual, rectal [e.g., by suppository], and vaginal [e.g., by suppository]). Topical formulations can be designed to produce a local or systemic therapeutic effect. In certain embodiments, an anti-SARS-CoV2 antibody or a fragment thereof is administered parenterally (e.g., intravenously, subcutaneously, intramuscularly or intraperitoneally) by injection (e.g., as a bolus) or by infusion over a period of time.

[143] Excipients and carriers that can be used to prepare parenteral formulations include without limitation solvents (e.g., aqueous solvents such as water, saline, physiological saline, buffered saline [e.g., phosphate-buffered saline], balanced salt solutions [e.g., Ringer’s BSS] and aqueous dextrose solutions), isotonic/iso-osmotic agents (e.g., salts [e.g., NaCl, KC1 and CaC12] and sugars [e.g., sucrose]), buffering agents and pH adjusters (e.g., sodium dihydrogen phosphate [monobasic sodium phosphate]/di sodium hydrogen phosphate [dibasic sodium phosphate], citric acid/sodium citrate and L-histidine/L-histidine HC1), and emulsifiers (e.g., non-ionic surfactants such as polysorbates [e.g., polysorbate 20 and 80] and pol oxamers [e.g., pol oxamer 188]). Protein formulations and delivery systems are discussed in, e.g., A. J. Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3rd Ed., CRC Press (Boca Raton, Florida) (2015).

[144] The excipients can optionally include one or more substances that increase protein stability, increase protein solubility, inhibit protein aggregation or reduce solution viscosity, or any combination or all thereof. Examples of such substances include without limitation hydrophilic amino acids (e.g., arginine and histidine), polyols (e.g., myo-inositol, mannitol and sorbitol), saccharides {e.g., glucose (including D-glucose [dextrose]), lactose, sucrose and trehalose}, osmolytes (e.g., trehalose, taurine, amino acids [e.g., glycine, sarcosine, alanine, proline, serine, L- alanine and y-aminobutyric acid], and betaines [e.g., trimethylglycine and trimethylamine N- oxide]), and non-ionic surfactants {e.g., alkyl polyglycosides, ProTek® alkylsaccarides (e.g., a monosaccharide [e.g., glucose] or a disaccharide [e.g., maltose or sucrose] coupled to a long-chain fatty acid or a corresponding long-chain alcohol), and polypropylene glycol/polyethylene glycol block co-polymers (e.g., poloxamers [e.g., PluronicTM F-68], and Genapol® PF-10 and variants thereof)}. Because such substances increase protein solubility, they can be used to increase protein concentration in a formulation. Higher protein concentration in a formulation is particularly advantageous for subcutaneous administration, which has a limited volume of bolus administration (e.g., < about 1.5 mL). In addition, such substances can be used to stabilize proteins during the preparation, storage and reconstitution of lyophilized proteins. Formulations and excipients for inhalation delivery are known in the art including, for example, those described in US Patent No. 5,898,028 which is hereby incorporated by reference in its entirety for all purposes.

[145] For parenteral (e.g., intravenous, subcutaneous or intramuscular) administration, a sterile solution or suspension of an anti-SARS-CoV2 antibody in an aqueous solvent containing one or more excipients can be prepared beforehand and can be provided in, e.g., a pre-filled syringe. Alternatively, an anti-SARS-CoV2 antibody can be dissolved or suspended in an aqueous solvent that can optionally contain one or more excipients prior to lyophilization (freeze-drying). Shortly prior to parenteral administration, the lyophilized anti-SARS-CoV2 antibody stored in a suitable container (e.g., a vial) can be reconstituted with, e.g., sterile water that can optionally contain one or more excipients. If the anti-SARS-CoV2 antibody is to be administered by infusion (e.g., intravenously), the solution or suspension of the reconstituted anti-SARS-CoV2 antibody can be added to and diluted in an infusion bag containing, e.g., sterile saline (e.g., about 0.9% NaCl).

[146] Excipients that enhance transmucosal penetration of smaller proteins include without limitation cyclodextrins, alky saccharides (e.g., alkyl glycosides and alkyl maltosides [e.g., tetradecylmaltoside]), and bile acids (e.g., cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid, glycodeoxycholic acid, chenodeoxycholic acid and dehydrocholic acid).

[147] Excipients that enhance transepithelial or transdermal penetration of smaller proteins include without limitation chemical penetration enhancers (CPEs, including fatty acids [e.g., oleic acid]), cell-penetrating peptides {CPPs, including arginine-rich CPPs [e.g., polyarginines such as R6-R11 (e.g., R6 and R9) and TAT -related CPPs such as TAT(49-57)] and amphipathic CPPs [e.g., Pep-1 and penetratin]}, and skin-penetrating peptides (SPPs, such as the skin-penetrating and cellentering [SPACE] peptide). Transdermal penetration of smaller proteins can be further enhanced by use of a physical enhancement technique, such as iontophoresis, cavitational or non-cavitational ultrasound, electroporation, thermal ablation, radio frequency, microdermabrasion, microneedles or jet injection. US 2007/0269379 provides an extensive list of CPEs. F. Milletti, Drug Discov. Today, 17:850-860 (2012) is a review of CPPs. R. Ruan et al., Ther. Deliv., 7:89-100 (2016) discuss CPPs and SPPs for transdermal delivery of macromolecules, and M. Prausnitz and R. Langer, Nat. Biotechnol., 26: 1261-1268 (2008) discuss a variety of transdermal drug-delivery methods.

[148] An anti-SARS-CoV-2 antibody can be delivered from a sustained-release composition. As used herein, the term “sustained-release composition” encompasses sustained-release, prolonged- release, extended-release, slow-release and controlled-release compositions, systems and devices. Protein delivery systems are discussed in, e.g., Banga (supra). A sustained-release composition can deliver a therapeutically effective amount of an anti-SARS-CoV2 antibody over a prolonged time period. In some embodiments, a sustained-release composition delivers an anti-SARS-CoV2 antibody over a period of at least about 3 days, 1 week, 2 weeks, 3 weeks, 1 month (4 weeks), 6 weeks, 2 months, 3 months or longer. A sustained-release composition can be administered, e.g., parenterally (e.g., intravenously, subcutaneously or intramuscularly).

[149] A sustained-release composition of a protein can be in the form of, e.g., a particulate system, a lipid or oily composition, or an implant. Particulate systems include without limitation nanoparticles, nanospheres, nanocapsules, microparticles, microspheres and microcapsules. Nanoparticulate systems generally have a diameter or an equivalent dimension smaller than about 1 pm. In certain embodiments, a nanoparticle, nanosphere or nanocapsule has a diameter or an equivalent dimension of no more than about 500, 400 or 300 nm, or no more than about 200, 150 or 100 nm. In some embodiments, a microparticle, microsphere or microcapsule has a diameter or an equivalent dimension of about 1-200, 100-200 or 50-150 pm, or about 1-100, 1-50 or 50-100 pm. A nano- or microcapsule typically contains the therapeutic agent in the central core, while the therapeutic agent typically is dispersed throughout a nano- or microparticle or sphere. In certain embodiments, a nanoparticulate system is administered intravenously, while a microparticulate system is administered subcutaneously or intramuscularly.

[150] In some embodiments, a sustained-release particulate system or implant is made of a biodegradable polymer or/and a hydrogel. In certain embodiments, the biodegradable polymer comprises lactic acid or/and glycolic acid [e.g., an L-lactic acid-based copolymer, such as poly(L- lactide-co-glycolide) or poly(L-lactic acid-co-D,L-2-hydroxyoctanoic acid)]. Non-limiting examples of polymers of which a hydrogel can be composed include polyvinyl alcohol, acrylate polymers (e.g., sodium polyacrylate), and other homopolymers and copolymers having a relatively large number of hydrophilic groups (e.g., hydroxyl or/and carboxylate groups). The biodegradable polymer of the particulate system or implant can be selected so that the polymer substantially completely degrades around the time the period of treatment is expected to end, and so that the byproducts of the polymer’s degradation, like the polymer, are biocompatible.

[151] Alternatively, a sustained-release composition of a protein can be composed of a non- biodegradable polymer. Examples of non-biodegradable polymers include without limitation poloxamers (e.g., poloxamer 407). Sustained-release compositions of a protein can be composed of other natural or synthetic substances or materials, such as hydroxyapatite. [152] Sustained-release lipid or oily compositions of a protein can be in the form of, e.g., liposomes, micelles (e.g., those composed of biodegradable natural or/and synthetic polymers, such as lactosomes), and emulsions in an oil.

[153] A sustained-release composition can be formulated or designed as a depot, which can be injected or implanted, e.g., subcutaneously or intramuscularly. A depot can be in the form of, e.g., a polymeric particulate system, a polymeric implant, or a lipid or oily composition. A depot formulation can comprise a mixture of a protein and, e.g., a biodegradable polymer [e.g., poly(lactide-co-glycolide)] or a semi-biodegradable polymer (e.g., a block copolymer of lactic acid and PEG) in a biocompatible solvent system, whether or not such a mixture forms a particulate system or implant.

[154] A pharmaceutical composition can be presented in unit dosage form as a single dose wherein all active and inactive ingredients are combined in a suitable system, and components do not need to be mixed to form the composition to be administered. The unit dosage form generally contains an effective dose of the therapeutic agent. A representative example of a unit dosage form is a single-use pen comprising a pre-filled syringe, a needle and a needle cover for parenteral (e.g., intravenous, subcutaneous or intramuscular) injection of the therapeutic agent.

[155] Alternatively, a pharmaceutical composition can be presented as a kit in which the therapeutic agent, excipients and carriers (e.g., solvents) are provided in two or more separate containers (e.g., ampules, vials, tubes, bottles or syringes) and need to be combined to form the composition to be administered. The kit can contain instructions for storing, preparing and administering the composition (e.g., a solution to be injected intravenously or subcutaneously).

Methods for Making Immune Binding Proteins

[156] Suitable host cells for making immune binding proteins recombinantly (e.g., anti-SARS- CoV-2 antibodies) include higher eukaryote cells described herein, including vertebrate host cells. Propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV 1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture. Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BEK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather. Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3 A, ATCC CRL 1442); human lung cells (W138. ATCC CCL 75): human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562. ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells: and a human hepatoma line (Hep G2).

[157] The host cells used to produce the immune binding proteins described herein (e.g., anti- SARS-CoV-2 antibodies) may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM). Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. No. Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

[158] Anti-SARS-CoV-2 antibodies made recombinantly as described above, will typically have altered glycosylation from naturally occurring human antibodies. For example, if the anti-SARS- CoV-2 antibodies are made in CHO cells, the glycosylation on the full-length antibodies will be non-human, and can change biochemical properties of the antibodies and change the half-life of the antibodies.

[159] The nucleic acids encoding the anti-SARS-CoV-2 antibodies and used to recombinantly produce the anti-SARS-CoV-2 antibodies can be codon optimized for the host cell used to recombinantly make the antibodies. The codon optimization can be done on at least one or more codons of the nucleic acid to make a non-naturally occurring nucleic acid. Methods for codon optimizing nucleic acids for recombinant production are well known in the art.

Combination Therapies

[160] As noted above, the methods herein, include administering to the subject one or more additional therapeutic agents in combination with an antibody or other immune binding proteins obtained (e.g., anti-SARS-CoV-2 antibody). As used herein, the expression “in combination with” means that the additional therapeutic agents is/are administered before, after, or concurrent with the pharmaceutical composition comprising the immune binding proteins described herein (e.g., anti- SARS-CoV-2 antibody). The term “in combination with” also includes sequential or concomitant administration of the immune binding protein described herein and a second therapeutic agent (which could be a different immune binding protein described herein).

[161] Combination therapies may include an anti-SARS-CoV antibody and any additional therapeutic agent that may be advantageously combined with an antibody described herein, or with a biologically active fragment of an antibody described herein. For example, a second or third therapeutic agent may be employed to aid in reducing the viral load in the lungs, such as an antiviral, for example, Remdesivir (Veklury), ribavirin, nucleoside analogs, etc. The antibodies may also be used in conjunction with other therapies, including a toxoid, a vaccine specific for SARS-CoV-2, a second antibody specific for SARS-CoV-2, or an antibody specific for another SARS-CoV-2 antigen. The additional therapeutic agent can also be one that ameliorates certain symptoms of SARS-CoV-2, such as, for example, cytokine storm, fever, inflammation, etc. Additional therapeutic agents can include, for example, dexamethasone, other corticosteroids, etc.

Applications

[162] The immune binding proteins described herein can be used in therapies for infectious diseases, cancer, allergies, and autoimmune diseases. The methods described herein can be used to make repertoires of immune binding proteins from subjects that have been challenged/infected with an infectious agent. The immune binding proteins described herein can be used in therapies to treat subjects infected with an infectious agent such as coronavirus (e.g., SARS-CoV-2). Addition of the exogenous immune binding protein (e.g., anti -SARS-CoV-2 antibody) helps the subject’s body accelerate its own immune response to a pathogen, in effect “transplanting” the immunity from one individual to another. The immune binding proteins described herein can be used prophylactically to provide protection to those individuals who are particularly susceptible to a disease or particularly susceptible to bad outcomes from a disease. The immune binding proteins described herein can also be used in diagnostic applications. The immune binding proteins described herein can provide information on a subject’s response to a therapy. The immune binding proteins described herein can provide information on a subject’s response to an antibody therapy, small molecule drug therapy, biologic therapy, or cellular immunotherapy.

[163] The immune binding proteins (e.g., anti-SARS-CoV-2antibodies) can be obtained from a subject that neutralized an infectious agent and overcame the infection. The infectious agent can be a bacterial strain of Staphylococci, Streptococcus, Escherichia coli, Pseudomonas, or Salmonella. The infectious agent canbe a Staphylococcus aureus, Neisseria gonorrhoeae, Streptococcus pyogenes, Group A Streptococcus, Group B Streptococcus (Streptococcus agalactiae), Streptococcus pneumoniae, and Clostridium tetani. The infectious agent can be a bacterial pathogen that may infect host cells including, for example, Helicobacter pyloris, Legionella pneumophiHa. a bacterial strain of Mycobacteria sps. (e.g. M. tuberculosis, M. avium, M. intr acellular e, M. kansaii, or M. gordonea). Neisseria meningitides, Listeria monocytogenes, R. rickettsia, Salmonella spp., Brucella spp., Shigella spp., or certain E. coli strains or other bacteria that have acquired genes with invasive factors. The infectious agent can be a bacterial pathogen that is antibiotic resistant.

[164] The infectious agent can be a viral pathogen including, for example, coronavirus (e.g., SARS-CoV-2), Ebola, Zika, RSV, Retroviridae (e.g. human immunodeficiency viruses such as HIV-1 and HIV-LP), Picornaviridae (e.g. poliovirus, hepatitis A virus, enterovirus, human coxsackievirus, rhinovirus, and echovirus), rubella virus, coronavirus, vesicular stomatitis virus, rabies virus, ebola virus, parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus, influenza virus, hepatitis B virus, parvovirus, Adenoviridae, Herpesviridae [e.g. type 1 and type 2 herpes simplex virus (HSV), varicella-zoster virus, cytomegalovirus (CMV), and herpes virus], Poxviridae (e.g. smallpox virus, vaccinia virus, and pox virus), or hepatitis C virus.

[165] The immune binding proteins described herein can be used to boost the immunity of a subject against an infectious disease (e.g., SARS-CoV-2). For example, in coronavirus infections the body responds within 7-10 days to a challenge; however, in immunocompromised patients such as the elderly or subjects with other underlying risk factors, the immune response timing or extent may be insufficient to fight off the infection, resulting in severe complications and possibly death. By boosting the immune system with antibodies designed to neutralize the relevant strain of coronavirus, the infection in the subject can treated. The immune binding proteins described herein (e.g., anti-SARS-CoV-2 antinbodies) are used to treat infected patients and/or passively immunize vulnerable populations facing an outbreak. The immune binding proteins described herein can be administered prophylactically to protect subjects from infection (e.g., by SARS-CoV-2). Such prophylactic administration of the immune binding proteins can protect at risk groups of subjects from a disease.

[166] The infectious agent can be a coronavirus (e.g., SARS-CoV-2), a herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster, Epstein-Barr, cytomegalovirus (CMV), or Kaposi’s sarcoma viruses. HSV-1 primarily causes oral herpes, ocular herpes, and herpes encephalitis, and occasionally causes genital herpes; HSV-2 primarily causes genital herpes but can also cause oral herpes; varicella zoster causes chickenpox and shingles; Epstein-Barr causes mononucleosis and is associated with several cancers including Burkitt’s lymphoma; CMV causes mononucleosis-like syndrome and congenital/neonatal morbidity and mortality. Some of the herpesviridae, and in particular HSV-1, have been associated with and proposed as causative agents for Alzheimer’s Disease. In some embodiments, immune binding proteins of the invention can be used to treat and/or passively immunize against these herpesviridae. An injection or topical application of an antibody against HSV-1 or HSV-2 can be employed to reduce the incidence or severity of the effects of herpes outbreaks.

[167] The immune binding proteins described herein can be useful for treating subjects with autoimmune diseases or whom have cytokine storm response to pathogen infections (e.g., SARS- CoV-2). The autoimmune disease can be rheumatoid arthritis, lupus, celiac disease, Sjorgren’s syndrome, polymyalgia rheumatica, multiple sclerosis, ankylosing spondylitis, Type 1 diabetes, and the like. The immune binding proteins described herein bind the antigen target of the autoimmune disease or the SARS-CoV-2 without triggering the autoimmune/cytokine storm reaction. For example, the immune binding protein could be an antibody without an Fc region, or could be an antibody in a format that does not interact with the effector cells that are associated with the autoimmune disease. The immune binding protein described herein binds to the autoimmune antigen without triggering an autoimmune reaction and this binding can prevent the subject’s immune system from reacting with the autoimmune antigen reducing the autoimmune disease (this can be a competitive inhibition reaction).

[168] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

EXAMPLES

Example 1 Antibodies Against Coronavirus (SARS-CoV-2)

[169] The work flow of FIG. 3 was adapted for making antibodies against coronavirus SARS- CoV-2. See, for example, USSN 16/826,189 filed March 21, 2020, which is hereby incorporated by reference in its entirety for all purposes. In this work flow, blood/serum samples are obtained from patients who have mounted an immune response to SARS-CoV-2 virus (from contracting SARS-CoV-2 by exposure to other infected patients). A solution of Pierce 1 micron beads bound to SARS-CoV-2 S1+S2 were added to the substrate, 3um BangsLabs COMPEL blue fluorescent beads loaded with a predetermined SARS-CoV-2 antigen (in some assays SARS-CoV-2 SI protein, in others SARS-CoV-2 E+M+S1+S2 protein), 3 um BangsLabs COMPEL green magnetic beads loaded with a separate predetermined SARS-CoV-2 antigen (in some assays SARS-CoV-2 RBD, in others SARS-CoV-2 S2 protein), 6um COMPEL blue magnetic beads loaded with a separate predetermined SARS-CoV-2 protein (in some assays SARS-CoV-2 Receptor Binding Domain). The blood/serum was depleted of T-cells and these T-cell depleted PBMC’s were loaded onto a substrate. In some cases, PBMC’s from blood were cultured to differentiate them into plasma cells before loading onto substrate. The cells and beads and secondary antibody were incubated for 24 hours under appropriate culture conditions, with a goat anti-human Fab antibody bound to R- phycoerythrin (“secondary antibody”). The microscope was used to identify halos of fluorescent beads that captured secreted antibodies from proximal cells due to antibody/antigen interactions and were stained with the secondary antibody. In this manner it was possible to automatically demultiplex antigen binding based on the secondary antibody fluorescent image pixels masked by positive pixels from the green or blue channels, and optionally masked by pixels positive using a Top Hat transform to further demultiplex antigen specificity by size. Cells with halos were selected with the device and placed into 96 well plates where subsequent molecular biology results in amplification and sequencing of immune receptor nucleic acids.

[170] After picking single cells into lysis buffer, cells were lysed at 70C in the presence of poly dT primer. RT buffer and reverse transcriptase were added and single cell cDNA produced at 55C. Gene specific amplification of heavy and light chains was performed after the addition of DNA polymerase (Kapa HiFi), buffer and primers and PCR thermal cycling. Amplified genes were barcoded with well specific barcodes in a subsequent PCR reaction, all cDNA’s for a single chain from a plate pooled, chain/plate libraries barcoded with chain/plate specific barcodes in a subsequent PCR reaction, and then chain/plate libraries normalized and pooled before loading on an Illumina MiSeq sequencer. Reads were separated by their plate/well/chain and put through an analysis pipeline that involved clustering reads based on sequence entropy to make a consensus assembly, consensus sequences found by aligning all reads in a well/chain/plate barcode group to each assembly and making basecalls by consensus, and then annotating each sequence by alignment with IgBlast against a human germline reference database. Paired antibody genes were then synthesized, cloned into an expression vector and expressed in HEK293 cells and/or as ScFv fragments. Full length antibodies were assayed for binding with ForteBio and Luminex assays.

[171] Results of antigen binding for antibodies 1-402 are show in Table 2.

Example 2 Binding Affinity of Anti-SARS-CoV-2 Antibodies

[172] Affinity of selected anti-SARS-CoV-2 antibodies was measured using mean fluorescence intensity. SARS-CoV-2 antigens were conjugated to Luminex beads and binding assays were performed on a Luminex200 instrument based on the manufacturer's protocol. The following antigens were tested for binding affinity: SI (Sino Biological), S2 (Sino Biological), SI + S2 (Sino Biological), RBD (Sino Biological), NAC SI (The Native Antigen Company), NAC Mosaic (The Native Antigen Company). [173] Antibodies were attached to a ForteBio AHC antibody probe according to manufacturer’s recommended protocol, equilibrated and then measured against antigens. Signals from a reference sensor were subtracted from the binding measurement and a curve for a 2: 1 kinetic model was fit to the data.

[174] The MFI data was used to calculate the Kd for binding to RBD.

[175] The anti-SARS-CoV-2 antibodies 219, 220 and 226 each bound to the SARS-CoV-2 RBP (receptor binding domain) with affinities of less than 1 picomolar.

Example 3, Development of masked anti-SARS-CoV-2 proteins for diagnostic assays and vaccines

[176] Antibodies discovered in the sequence listing are used to bind their respective proteins at their respective epitopes. Once these antibodies have bound their particular epitopes, a thiol and/or amine reactive PEGylation reagent at ImM is introduced to chemically react with amino acid side chains that are not masked by the antibody binding its epitope. The mixture is added to a Tris and/or DTT buffer to quench the PEGylation reagent and buffer exchanged. The antibody-antigen interaction is broken with heat and/or changes in pH and filtered over a Protein A/G column to remove the blocking antibodies. The resulting protein is PEGylated at all regions except the antibody binding epitope. The protein is used for vaccination in order to elicit an immune response to the original binding epitope and/or diagnostic purposes which seek to identify antibodies that bind the same epitope as the original masking antibody. Example 4, Development of an antibody-adjuvant vaccine

[177] Antibodies discovered in the sequence listing can be used to bind their respective proteins at their respective epitopes. The antibody/antigen mixture is used as a vaccine to elicit antibody responses at the sites unbound by the antibodies and/or improve TCR responses to the bound antigen through macrophage/dendritic cell engulfment of the antibody-antigen complex and crosspresentation of antigen peptides.

Example 5: Neutralization of SARS-CoV-2 by Anti-SARS-CoV-2 Antibodies

[178] Anti-SARS-CoV-2 antibodies were tested for neutralization activity in an in vitro assay. See, E.g., Crawford et al, Protocol and reagents for pseudotyping lentiviral particles with SARS- CoV2 Spike protein for neutralization assays, 2020, Viruses doi: 19.3390/vl2050513, which is hereby incorporated by reference in its entirety for all purposes. Lentivirus was engineered to express the SARS-CoV-2 spike (1+2) protein, and antibodies were tested for inhibition of infection in HEK293 cells. In this assay the pseudo typed lentivirus infect the HEK293 cells using the spike protein binding to ACE2 on the HEK293 cells. SC2 antibodies 3705, 3417, 3387, and 3396 all showed neutralization of SARS-CoV-2 in this in vitro assay. In this assay, the SC2 antibody 3705 showed 100% neutralization of infection, SC2 antibody 3417 showed about 70% neutralization, SC2 antibody 3396 showed about 50% neutralization, and SC2 antibody 3387 showed about 45% neutralization.

[179] A bar graph of virus neutralization by SC2 antibodies 3705, 3417 and 3387 is shown in FIG. 2. A line graph showing virus neutralization by SC2 antibodies 3705, 3417, and 3396 is shown in FIG. 3.

Example 6: Binding of Spike Protein Variants by Anti-SARS-CoV-2 Antibodies

[180] Mutant SARS-CoV-2 SI proteins and SARS-CoV-1 S protein were conjugated separately to Luminex beads with EDC-NHS chemistry. SC2 antibody 3387 was incubated with antigen conjugated beads and antibody binding was detected using PE conjugated anti-human Fab antibody and a Luminex 200 instrument.

[181] Spike protein with mutations D614G and E484K (Sweden-1 variant of European variant B- 1), or D614G,V445I,H655Y,and E583D (England/Bristol variant of European variant B-l), or G485S (related to Australia-1 variant), or N501Y (South African variant Bl.1), or S494P, or V483K, or R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P were tested. Spike protein from Wuhan strains and Omicron strains was also tested.

[182] SC2 antibody 3387 was able to bind each of these mutants spike proteins with affinity similar to that of the wild-type spike protein. SC2 antibody 3387 bound to Omicron with a Kd of 409 pM, and Wuhan with a Kd of 784 pM. Example 7: Binding of Alpha. Beta, Gamma. Kappa, and Delta Variants by Anti-SARS-CoV-2 Antibodies

[183] Binding of C+SC antibody 3387 to other SARS-CoV-2 variants was assessed as in Example

6. Antigens from the following variants were tested: B.1.1.17 (Alpha) SI, B.1.1.28 (Gamma) S1+S2, 20H/501Y.V2 (Beta) SI, B.1.617 (Kappa) RBD, B.1.617.2 (Delta) RBD, Omicron RBD, Wuhan RBD, S1+S2 S494P, S1+S2 V483A, S1+S2

R683A+R685A+F817P+A892P+A899P+A942P+ K986P+V987P, S1+S2 G485S, S1+S2 D614G, S1+S2 E484K, S1+S2 D614G+V445I+H655Y+E583D, S1+S2 L452R+T478K.

[184] SC2 antibody 3387 was able to bind each of these mutants antigens with affinity similar to that for wild-type antigen. EC50 (half maximal binding) was measured for binding of these variants by SC2 antibody 3387: beta (150 ng/ml); alpha (86 ng/ml); gamma (140 ng/ml); kappa (56 ng/ml); delta (46 ng/ml); omicron (35 ng/ml); and Wuhan (60 ng/ml).

Example 8: Neutralization of Delta Variant by Anti-SARS-CoV-2 Antibodies

[185] An ACE2 expressing HEK293T cell line (“LentiX ACE2.S4”) was constructed by packaging pCMV-AC-GFP (Origene) into lentivirus and transducing HEK293T’s. LentiX ACE2.S4 cells were grown to 85% confluency, and seeded in 96-well plates at 15k cells/well. Anti- SARS-CoV-2 antibody (SC2 antibody 3387) or a nonspecific antibody was added to wells prior to inoculation with SARS-CoV-2 Delta Variant pseudovirus (eEnzyme). The results of this are shown in FIG. 4. SC2 antibody 3387 neutralized the delta variant and greatly reduced infection of cells. Example 9: Neutralization of SARS-CoV-2

[186] Calu-3 cells were grown to confluency, and anti-SARS-CoV-2 antibody was added to the media. 40pL SARS-CoV-2 virus at a target MOI of 0.05 was added to the Calu-3 cells. After 24 hours, the supernatant was removed for TCID50 assays. Vero E6 cells were seeded at 10k cells in lOOpL per well. Infected cell culture supernatant was diluted with 950 pL D10 media, and then serial diluted. After 72 hours, wells with complete cytopathic effect were counted.

[187] Full length IgGl formatted AUG-3387 and its ScFv formatted version, AUG-3705, were tested for neutralization activity. AUG-3705 demonstrated somewhat higher efficacy in these assays over AUG-3387, indicating the improved avidity of the dimeric IgGl did not improve neutralization enough to compensate for the higher molarity of AUG-3705 at the same concentration. See FIG. 5.

Example 10: Efficacy of Anti-SARS-CoV-2 Antibodies in Hamsters

[188] Group 1 male, Syrian Golden Hamsters received a single IP administration of sterile saline solution. Syrian Hamsters in Groups 3 and 4 received a single IP administration of SC2 antibody 3387 solution. 24-48 hours later the Hamsters were inoculated with SARS-CoV-2 (Wuhan-1), and four days after inoculation the viral load in the Hamsters was measured.

[189] The results from the Hamster study are shown in FIG. 6. As the dose of SC2 antibody 3387 antibody is increased, the viral titer of the Wuhan- 1 variant is decreased by 1-2 logs. [190] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[191] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein.

Such equivalents are intended to be encompassed by the following claims.

Seq Ab Amino Acid Sequence

ID No

99 1

EVQLVESGGGLVQPGGSLRLSCAASGFTLNNYWMHWVRQAPGKGPVWVSRINSDGSSTSYADSVKGRF

TISRDNAKNTLFLQMNSLRAEDTAVYHCAREVRSAAGYFDYWGQGTLVTVSS

100 1

DIQMTQSPSSVSASVGDRVTITCRASQGISNWLTWYQHKPGTAPKLLIYGASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQANTFPLTFGGGTKVEIK

101 2

EVQLLESGGGLVQPGGSLRLSCAASGFI FSDYAMSWVRQAPGKGLEWVAVINNGGGSVYYADSVKGRF

TISRDNSKNTLHLQMNSLRTDDTAVYYCAKFRGETHLVWYFDRWGRGTLVTVSS

102 2

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

103 3

QVQLVQSGAEVMQVGASVKVSCTTSGFI FISHYMHWVRQAPGQGLEWMGIITPANTTKYSQRFQGRVT

MTSDASTSTVYMELSSLRSEDTAVYYCAREWGELDSSVFDYWGQGTLVTVSA

104 3

QSVLTQPPSVSGAPGQRVTISCNGSSSNIGAGYDVHWYQHFPGSAPKLLMYGNKNRPSGVPDRISASK

SDSSASLAITGLRGEDEADYYCQSYDNSLSVWVFGGGTKLTVL

105 4

QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWNWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

ISVDTSKKQFSLKLSSVTAADTAVYYCARKFEQWGQGTLVTVSS

106 4

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPTWTFGQGTKVEIK

107 5

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

108 5

DIQMTQSPSTLSASVGDRVSITCRASQSISSWLAWYQQKPGKAPNLLIYTASNLESGVPARFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNTYPWTFGQGTKVEVK

109 6

QVQLVQSGAEVKRPGASVKISCKTSGYTFTNYAVHWLRQAPGQGLEWMGWINGGTGHTKYSRKFQGRV

TITRDTSASTAYMEVHSLRSEDTAVFYCAGSPTYYSWFDPWGQGTQVIVSS

110 6

QAVVTQEPSLTVSPGGTVTLTCASSTGAVTSGYYPNWFQQKPGQAPRALIYSTSNKHSWTPARFSGSL

LGGKAALTLSGVQPEDEAEYYCLLYYGGAWVFGGGTKLTVL

111 7

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

112 7

QSALTQPPSVSGSPGQSITITCTGTSSDVGGYQYVSWYQQHPGKAPKVIIYDVSYRPSGFSNRFSGSK

SGNTASLTISGLQTEDEAEYYCSSYTRSGTYVFGTGTEVTVL

113 8

EVQLLESEGGLVQPGGSLRLSCAASGFI FSDYAMSWVRQAPGKGLEWVAVINNGGGSVYYADSVKGRF

TISRDNSKNTLHLQMNSLRTDDTAVYYCAKFRGETHLVWYFDRWGRGTLVTVSS

114 8

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSPWTFGPGTKVDIK

115 9

QLQLQESGPGLVKPSETLSLTCTVSRGSISSSAYYWGWVRQPPGKGLEWIGSINYNGNTYYTSSLKSR

LTISVDTSRNQFSLKLSSVTAADTAVYYCARIIISGSNWFDPWGQGTLVTVSS

116 9 QAVVTQEPSLTVSPGGTVTLTCASSTGAVTSGYYPNWFQQKPGQAPRALIYSTSNKHSWTPARFSGSL

LGGKAALTLSGVQPEDEAEYYCLLYYGGAWVFGGGTKLTVL

117 10

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

118 10

EIVMTQSPATLSVSPGERATLSCRASQSVGNSLAWYQQKPGQPPRLLIYDASTRATGIPASFSGIGSG

TEFTLTISSLQPEDFAAYHCQQYYNWPLTFGGGTKVEIK

119 11

EVQLVQSGAEVKNLGESLKISCKASGYTFTSYWIGWVRQMPGKGLEYMGIVYPGGSDTRYSPSFQGQV

TISADKSISTAYLQWNTLKASDTAMYYCVRAAYGLGGITGPWGQGTLVTVSS

120 11

QSALTQPPSVSGSPGQSITITCTGTSSDVGGYQYVSWYQQHPGKAPKVIIYDVSYRPSGVSNRFSGSK

SGNTASLTISGLQTEDEAEYYCSSYTRSGTYVFGTGTEVTVL

121 12

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCAKAGTYYYDSSGYTHYWGQGTLVTVSS

122 12

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPTWTFGQGTKVEIK

123 13

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

124 13

DVQMTQSPSTLSASVGDRVTITCRASQSITSRLAWYQQKPGKAPKVLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGQGTKVEIK

125 14

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

126 14

DVQMTQSPSTLSASVGDRVTITCRASQSITSRLAWYQQKPGKAPKVLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGQGTKVEIK

127 15

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

128 15

QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

129 16

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

130 16

QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

131 17

QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRV

TISVDKSKNQFSLKLSSVTAADTAVYYCARVLNISWADAFDIWGQGTMVTVSS

132 17

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPPYTFGQGTKLEIK

133 18

QMQLVESGGGVVQPGRSLRLSCAVSGFTFSNYGMNWVRQAPGKGLEWVADISFDGSERHYADSVKGRF

TISRDNSKNTLYLQMNNLRAEDTAVYYCAKPLIAARPPDSWGQGTLVTVSS

134 18 QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

135 19

EVQLLESGGGLVQPGGSLRLSCAASGFI FSDYAMSWVRQAPGKGLEWVAVINNGGGSVYYADSVKGRF

TISRDNSKNTLHLQMNSLRTDDTAVYYCAKFRGETHLVWYFDRWGRGTLVTVSS

136 19

DIQMTQSPSTLSASVGDRVSITCRASQSISSWLAWYQQKPGKAPNLLIYTASNLESGVPARFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNTYPWTFGQGTKVEVK

137 20

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

138 20

QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

139 21

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDKIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

140 21

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK

141 22

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

142 22

EIVLTQSPGTLSLSPGERAALSCRASQSLSSTYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTIRRLEPEDFAVYYCQHFGTFGQGTTVEIK

143 23

EVQLVESGGGLVKPGGSLRLSCAASGFTFNSYSMNWVRQAPGKGLEWVSSITSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRADDTAVYYCARASKQYYYYYYMDVWGKGTTVTVSS

144 23

VIVLTQSPGTLSLSPGDRGTLSCTASQFVRNRDLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGGGS

GTDFTLTISRLEPEDCAVYFCLQYASSPMTFGQGTKVEIK

145 24

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

146 24

DIQMTQSPSTLSASVGDRVSITCRASQSISSWLAWYQQKPGKAPNLLIYTASNLESGVPARFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNTYPWTFGQGTKVEVK

147 25

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

148 25

EIVLTQSPGTLSLSPGERAALSCRASQSLSSTYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTIRRLEPEDFAVYYCQHFGTFGQGTTVEIK

149 26

QVQLVQSGAEVMQVGASVKVSCKASEFTFTTYHLHWVRQAPGQGLEWMGIISPTGGSATYAQKFQGRV

TMTRDTSTRTVYMELSSLRSEDTAVYFCARDLGGSYYFDYWGQGTLVTVSS

150 26

EIVLTQSPATLSLSPGERATLSCRASQSLSTYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFSLTISSLEPEDFAVYYCQQRSDWPRTFGQGTKLEIK

151 27

QVQLQESGPRLVKPSQTLSLTCTVSGGSMTRGYFYWSWIRQHPGKGLEWIGSIYHSGTTFYNASLQSR

LAMSIDTSSKQFSLMLTSVTAADTAIYFCARDRTSVVGGGMDPWGQGI LVTVST

152 27 EIVLTQSPATLSLSPGDSATLSCRATHSVSSSYLTWYQQKPGQAPRLLIYGTSIRATGVPARFSGSGS

GTDFTLTISRLEAEDFAVYYCQRYSNSPPMYAFGQGTQLTIK

153 28

QVQLVESGGGVAQPGTSLRLSCEGSGFMFSGHGMHWVRQAPGKGLEWVAVVSAAGGTQYYAESVKGRF

TISRDNSRNTMTLQMNSLRPDDTALYYCTKEGDDSAYLAFDIWGQGTMVTVSS

154 28

ETVLTQSPATLSLSPGERATLSCRASQSIANNLAWYRQKPGQPPRLLIYGASTRATGVPARLTGSGSG

TDFTLTITSLEPEDFAVYYCQHRSHWPPGGTFGQGTKLEIK

155 29

EVQLVQSGAEVKNLGESLKISCKASGYTFTSYWIGWVRQMPGKGLEYMGIVYPGGSDTRYSPSFQGQV

TISADKSISTAYLQWNTLKASDTAMYYCVRAAYGLGGITGPWGQGTLVTVSS

156 29

DVQMTQSPSTLSASVGDRVTITCRASQSITSRLAWYQQKPGKAPKVLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGQGTKVEIK

157 30

QVQLVESGGGVVPPGRSLRLSCEGLGFI FSDYTMAWVRQAPGKGLEWGALISHDGSTKRSADSVEGRF

SISRDNSKNLVHLHMDSLRAEDTAVYFCVRDHFLRLIREIWDNWGQGTQVTVSS

158 30

QSVLTQPPSVSGAPGQRVTISCNGSSSNIGAGYDVHRYQHFPGSAPKLLMYGNKNRPSGVPDRISASK

SDSSASLAITGLRGEDEADYYCQSYDNSLSVWVFGGGTKLTVL

159 31

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLKCMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWXANWGRGTLVTVSS

160 31

DVQMTQSPSTLSASVGDRVTITCRASQSITSRLAWYQQKPGKAPKVLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGQGTKVEIK

161 32

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

162 32

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

163 33

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

164 33

QAVVTQEPSLTVSPGGTVTLTCASSTGAVTSGYYPNWFQQKPGQAPRALIYSTSNKHSWTPARFSGSL

LGGKAALTLSGVQPEDEAEYYCLLYYGGAWVFGGGTKLTVL

165 34

EVQLVESGGGLVQPGGSLRLSCAASGFSFNYDWMHWVRQAPGEGPVWVSCINGDGSTIRYGESVKGRF

TISRDNAKNTLYLQMNSLRLEDTAVYFCVRGAGYI LSYWGPGTVVTVSS

166 34

EVVLTQSPATLSFSPGERATLSCRASQYVSTSVSWYQHRPGQAPRLLFFDVSRRATGIPDRFNGSGSG

TAFNLTISSLEPEDLAVYYCHQRYNWPATFGPGTKVEIK

167 35

QVQLVQSGAEVMQVGASVKVSCKASEFTFTTYHLHWVRQAPGQGLEWMGIISPTGGSATYAQKFQGRV

TMTRDTSTRTVYMELSSLRSEDTAVYFCARDLGGSYYFDYWGQGTLVTVSS

168 35

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK

169 36

EVQLVESGGGLVQPGGSLRLSCAASGFSFNYDWMHWVRQAPGEGPVWVSCINGDGSTIRYGESVKGRF

TISRDNAKNTLYLQMNSLRLEDTAVYFCVRGAGYI LSYWGPGTVVTVSS

170 36 EIVLTQSPGTLSLSPGERAALSCRASQSLSSTYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTIRRLEPEDFAVYYCQHFGTFGQGTTVEIK

171 37

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

172 37

QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

173 38

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

174 38

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK

175 39

EVQLVESGGGLVQPGGSLRLSCAASGFSFNYDWMHWVRQAPGEGPVWVSCINGDGSTIRYGESVKGRF

TISRDNAKNTLYLQMNSLRLEDTAVYFCVRGAGYI LSYWGPGTVVTVSS

176 39

QSVLTQPPSVSAAPGQKVTISCSGSDSNIGKNYVCWYQSLPGTAPKLLMFDNSKRPSGIPDRFSASKS

GTSAALVITGLQTGDEADYYCGTWDSSLYAGVFGGGTRLTVL

177 40

EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWINWVRQMPGKGLLEWVGRIDPTDSYTNYSPSFQGH

VSISADKSISTAYLQWSSLKASDTAMYYCARHSDFWSGYPDVWGKGTTVTVSS

178 40

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSPTFGQGTKVEIK

179 41

QVQLVQSGAEVKRPGASVKISCKTSGYTFTNYAVHWLRQAPGQGLEWMGWINGGTGHTKYSRKFQGRV

TITRDTSASTAYMEVHSLRSEDTAVFYCAGSPTYYSWFDPWGQGTQVIVSS

180 41

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

181 42

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

182 42

DIQMTQSPSTLSASVGDRVSITCRASQSISSWLAWYQQKPGKAPNLLIYTASNLESGVPARFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNTYPWTFGQGTKVEVK

183 43

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

184 43

EVVLTQSPATLSFSPGERATLSCRASQYVSTSVSWYQHRPGQAPRLLFFDVSRRATGIPDRFNGSGSG

TAFNLTISSLEPEDLAVYYCHQRYNWPATFGPGTKVEIK

185 44

EVQLVQSGVEVKKPGESLKISCKVSGYI FSTYWIGWVRQLPGKGLECMGII FPSDSDTSYSAPFQGQV

TISVDKSINTAYLQWSSLKASDTAMYFCARQDSRGIQYWGRGTLVTVSS

186 44

EIVLTQSPATLSLSPGERATLSCRSSQSVGRYLAWYQQKPGQAPRLLVYDSSARATGIPARFSGSGSE

TDFTLTINSLEPEDFAVYYCQQRSNWPLTFGGGTKVEFK

187 45

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

188 45 DIQMTQSPSTVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGSGSG

TEFTLTISSLQPDDCATYYCQQYNYYSFGQGTKVEIR

189 46

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

190 46

DIQMTQSPSTVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGSGSG

TEFTLTISSLQPDDCATYYCQQYNYYSFGQGTKVEIR

191 47

QITLKESGPTLVKPTQTLTLTCTFSGFSFTTTGVGVGWIRQPPGKALEWLALINWDDDKRYSPSLKSR

LTITKDTSKNQVVLTMTNMDHADTATYYCAHRRPYPSFEYWGQGTLVTVSS

192 47

DIQLTQSPSFLSASIGDRVTITCRASQGISRFLAWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSG

TEFTLTINSLHPEDFATYYCQQLKSYPYTFGQGTKLDIK

193 48

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

194 48

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

195 49

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

196 49

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSPRVFGTGTKVTVL

197 50

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

198 50

GIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRGTGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCHQYGSSPFI FGPGTKVDIK

199 51

EVQLVESGGGWTGPGGSLRLSCVTSGFTFSSYEMTWVRQAPGRGLEYISYIDTDARRI LYADSVKGRF

AISRDDAKNSLYLQMNSLRAEDTAVYYCARDAEHNYGPVFDYWGQGI LVSVSS

200 51

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSLYTFGQGTKLEIK

201 52

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

202 52

EIVMTQSPATLSVSPGERATLSCRASQSVGNSLAWYQQKPGQPPRLLIYDASTRATGIPASFSGIGSG

TEFTLTISSLQPEDFAAYHCQQYYNWPLTFGGGTKVEIK

203 53

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

204 53

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIAARFSGSGSG

TEFTLTISSLQSEDVAVYYCQQYNNWPVITFGPGTKVDIR

205 54

EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPDESDTRYSPSFQGQV

TISAVKSISTAYLQWRSLKASDTAMYYCARQTDGKSWLDPWGQGTLVTVSS

206 54 EIVLTQSPATLSLSPGERATLSCRATESVGSYVAWYQQRPGQAPRLLIHDVSHRATGVPARFSGSGSE

TDFTLTISSLEPEDFAIYYCQQRTDLFTFGPGTKVEIT

207 55

QVQLQESGPGLVKPSQTLSVTCSVSGASITSDDYYWSWIRQSPGQGLEWIGYISNTGNTYYNPSLKSR

LTISPDTSKNQISLMLTSVTAADTAVYFCVRVRREWQLPGGGCLDYWGQGALVTVSS

208 55

QSALTQPASVSGSPGQSITISCTGSSSNVGSYNLVSWYQQYPGEAPKLMIYEVTKRPSGVSTRFSGSK

SGNTASLTISGLQAEDETDYYCCSYAGSSTYVFGTGTKVTVL

209 56

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARGIVPAAIYYGMDVWGQGTTVTVSS

210 56

DIQMTQSPSSLSASVGDRVTITCRASQTI FRFVNWYQHKPGRAPNVLIYAASSLRSGVPSRFSGAGSG

TEFTLTISSLQPEDFATYYCQQSYTTPWTFGQGTHVDIK

211 57

EVQLVQSGAEVKKPGESLKISCQTSGYNFINYWIGWVRQMPGEGLEWMGIIYPGDSDSRYSPSFQGQV

TISADKSINTAYLQWSSLKASDTAIYYCARLVDTAMINAFDIWGQGTMVIVSS

212 57

EIVLTQSPSTLSLSPGERATLSCRASQSVLSNYFAWYQQKHGQAPRLLIYGASRRATGIPDRFSGSGS

GTDFALTISRLEPEDFAMYYCQLYGFSYPFGQGTKLEVK

213 58

QVQLVQSGAEVMQVGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWINTYNGNTNYAQKLQGRV

TMTTDTSTTTAYMELRSLRSDDTAVYYCARVAVGYCSGGSCYYFDYWGQGTLVTVSS

214 58

SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGN

TATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL

215 59

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQV

TISADKSISTAYLQWSSLKASDTAMYYCARLQWLRDGGDFDYWGQGTLVTVSS

216 59

ETVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSFTFGPGTKVEIK

217 60

QVQLQQWGAGLLKPSETLSLTCAVYGGSVSGYYWSWIRQPPGKGLQWIGEINHSGSTNYSPSLRSRVT

I LLDTSKKQFSLKLSSVTAADTAVYYCARGRSETYGVPERVRLDPWGQGTLVTVSS

218 60

DIQMTQSPSTVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGSGSG

TEFTLTISSLQPDDCATYYCQQYNYYSFGQGTKVEIR

219 61

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

220 61

EIVLTQSPATLSVSPGDRATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTISSLQSEDFAVYYCQQYNDWPPMYTFGQGTKLEIK

221 62

QVQLQESGPGLVKPSQTLSVTCSVSGASITSDDYYWSWIRQSPGQGLEWIGYISNTGNTYYNPSLKSR

LTISPDTSKNQISLMLTSVTAADTAVYFCVRVRREWQLPGGGCLDYWGQGALVTVSS

222 62

DIQMTQSPSTVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGSGSG

TEFTLTISSLQPDDCATYYCQQYNYYSFGQGTKVEIR

223 63

QVLLVESGGGLVKPGGSLRLSCTASGFTFSDYYMIWIRQAPGKGLEWISSISSRSTYIKYADSVKGRF

TISRDNAKNSLYLQMNSLRVEDTAVYYCASGKQWLVGIYDFDSWGQGTLVTVSS

224 63 DIQMTQSPSSLSASVGDRVTITCRASHNIGIWLAWYQQKPGKGPKLLIHRASTLENGVPSRFSGSRSG

TEFTLTITSLQPDDFATYYCQQYNSYLYTFGQGTKLEIK

225 64

QVQLQQWGAGLLKPSETLSLTCAVYGGSVSGYYWSWIRQPPGKGLQWIGEINHSGSTNYSPSLRSRVT

I LLDTSKKQFSLKLSSVTAADTAVYYCARGRSETYGVPERVRLDPWGQGTLVTVSS

226 64

DIQMTQSPSSLSASVGDRVTITCRASHNIGIWLAWYQQKPGKGPKLLIHRASTLENGVPSRFSGSRSG

TEFTLTITSLQPDDFATYYCQQYNSYLYTFGQGTKLEIK

227 65

QVQLVQSGAEVMQVGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWINTYNGNTNYAQKLQGRV

TMTTDTSTTTAYMELRSLRSDDTAVYYCARVAVGYCSGGSCYYFDYWGQGTLVTVSS

228 65

DIQMTQSPSTVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGSGSG

TEFTLTISSLQPDDCATYYCQQYNYYSFGQGTKVEIR

229 66

EVQLVESGGGLVKPGGSLKLSCAASGFNLHSYTMNWVRQAPGKGLEWVSFITSDSRKTFYADSVRGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGVEWDTSTNWFASWGQGTLVTVSS

230 66

EIVMTQSPATLSVSPGERATLSCRASQSVGNSLAWYQQKPGQPPRLLIYDASTRATGIPASFSGIGPG

TEFTLTISSLQPEDFAAYHCQQYYNWPLTFGGGTKVEIK

231 67

QVQLQESGPGLVKPSGTLSLTCAVSGDSISSSHWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRV

TISRDKSKNHFSLKLNSVTAADTAVYFCARRPLNMMFDFWGQGTLVNVSS

232 67

EIVLTQSPATLSLSPGERATLSCRASRSVSTYLAWYQQKPGQAPRLLIYDASNRASGIPSRFSGSGSG

TDFTLTISSLEPEDFAVYYCQQCYSGPPWTFGQGTKVENK

233 68

EVHLSESGGGLIHPGGSLRLSCAASGFSFRSYAMAWARQAPGKGLEWVSCINGVGGYIHYADSVRGRF

TISRDNSINTLYLQMDSLRVEDTAVYYCAKWGPYSGSQYFEYWGQGTLLSVSS

234 68

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGGGTKVEIK

235 69

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

236 69

QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKS

GTSASLAISGLRSEDEADYYCAAWDDSLSGYWVFGGGTKLTVL

237 70

QINLKESGPPLVKPTQTLTLICTFSGFSLSTRGVYWGWIRHPPGKALEWIAFVYYTDDTRYNPSLKSR

LTISVDTSKNQLSLKLSTVNAVDTAVYYCARGSKLAGHSGYWGQGTLVTVSS

238 70

DIQMTQSPSSLSASVGDRVTITCRASHNIGIWLAWYQQKPGKGPKLLIHRASTLENGVPSRFSGSRSG

TEFTLTITSLQPDDFATYYCQQYNSYLYTFGQGTKLEIK

239 71

QVQLVQSGAEVMQVGASVRVSCKASGYTFISYGISWVRQAPGQGLEWMGWISAYNDNTKYAQKLQGRV

TLTTDTSTSTAYMELRSLRSDDTAVYYCARDGGSYGWGYWGQGTLVTVSS

240 71

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSLTFGGGTKVEIK

241 72

EVQLVESGGGLVQPGGSLRLSCAASGFTLNNYWMHWVRQAPGKGPVWVSRINSDGSSTSYADSVKGRF

TISRDNAKNTLFLQMNSLRAEDTAVYHCAREVRSAAGYFDYWGQGTLVTVSS

242 72 EIVLTQSPATLSLSLGERATLSCRASQTVRSNYLAWYQQKPGLAPRLLIYDASIRVAGIPDRFTGSGS

GTDFTLTISRLEPEDFAVYYCQQFGASPPALTFGGGTKVEIR

243 73

EVQLVESGGGLVQPGGSLRLSCAASGFTLNNYWMHWVRQAPGKGPVWVSRINSDGSSTSYADSVKGRF

TISRDNAKNTLFLQMNSLRAEDTAVYHCAREVRSAAGYFDYWGQGTLVTVSS

244 73

QSALTQPPSVSGSPGQSITITCTGTSSDVGGYQYVSWYQQHPGKAPKVIIYDVSYRPSGVSNRFSGSK

SGNTASLTISGLQTEDEAEYYCSSYTRSGTYVFGTGTEVTVL

245 74

QVQLVQSGAEVREPGSSVKVSCKASGDTLSNSAISWVRQAPGQGLEWMGRIIPMFGMASYSQKFQGRI

TISADKSTRTVYMELSSLTSEDTAVYYCARGGGTWAPFDPWGQGTQLTVSS

246 74

QSVLTQPPSASGTPGQRVTISCSGSGSNIGNNFVYWYQQLPGTAPKLLIYRIDQRPSGVPDRFSGSKS

GTSASLAISGLRSEDEADYYCAAWDDSLSGPVFGGGTKLTVL

247 75

QVLLVESGGGLVKPGGSLRLSCTASGFTFSDYYMIWIRQAPGKGLEWISSISSRSTYIKYADSVKGRF

TISRDNAKNSLYLQMNSLRVEDTAVYYCASGKQWLVGIYDFDSWGQGTLVTVSS

248 75

EIVLTQSPATLSLSPGERANLSCRASQSVNRYLAWYQQKPGQAPRLLIYDASNRATGVPVRFNGSGSG

TDFTLTISSLEPEDFAVYYCQQRTNWPLTFGGGTKVEIK

249 76

QVLLQESGPGLVKASETLSLTCTVSNGSINTSSYYWNWFRQPPGKGLEWIGTIYYTGDTYYSASLKSR

VTISIHRSKSQFSLKLSTVTAADTAVYYCARDPYNWNLFVADSFDVWGLGTMVTVSS

250 76

DIQMTQSPSTLSASVGDRVTITCRASQRISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYHSYSWTFGQGTKVEIK

251 77

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLECVSYISSSSSTIYYADSVKGRF

TISRDNAKNTLYLQMNSLGAEDTAVYYCASLYDTXI LWGQGTLVTVSS

252 77

QSALTQPASVSGSPGQSITIPCTGTSSDVGSYNHVSWYQQHPGKAPKLIIYEVSMRPSGVSNRFSGSK

SGNTASLTISGLQTEDEADYYCCSYGGDVYVWVIGGGTKLTVL

253 78

EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISGGSTYIYYADSLKGRF

TISRDNAKNSLYLQMNSLSAEDTAVYYCAKPLAAAGLLALDFWGQGTQVTVSS

254 78

QSVLTQPASVSGSPGQSITISCTGTISDFGGYNYVSWYQHHPGKAPKLIIYEVSSRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCNSYTSSGTRVFGGGTKLTVL

255 79

QVQLVQSGAEVMQVGASVRVSCKASGYTFTNHPIDWVRQAPGQGLEWMGIINPSGGGVRFAQKFQGRV

TLTTDTSTSTVYMELSSLTSDDTAVYFCARGAGRDVYKSI LAWFDYWGQGTLVTVSS

256 79

DIQMTQSPSSVSASVGDRVTITCRASQGISNWLTWYQHKPGTAPKLLIYGASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQANTFPLTFGGGTKVEIK

257 80

EVQLVESGGGLVQPGGSLRLSCAASGFTLNNYWMHWVRQAPGKGPVWVSRINSDGSSTSYADSVKGRF

TISRDNAKNTLFLQMNSLRAEDTAVYHCAREVRSAAGYFDYWGQGTLVTVSS

258 80

DIVLTQSPGTLSLSPGESATLSCRASQSVNNDYIAWYQQKPGQAPRLLIYGASSRASGIPDRFDGSGS

GTDFTLTIRRLEPDDFAVYYCHQYITLPLTFGGGSKVEIR

259 81

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARGIVPAAIYYGMDVWGQGTTVTVSS

260 81 EIVLTQSPATLSLSPGERATLSCRASRSVSTYLAWYQQKPGQAPRLLIYDASNRASGIPSRFSGSGSG

TDFTLTISSLEPEDFAVYYCQQCYSGPPWTFGQGTKVENK

261 82 EVQLEQSGAEVKKPGESLKISCKVSGYI FTAHWISWVRQMPGKGLEWMGRIDPNESYANYNPSFEGHV

TLSTDKSTDTAYLQWSSLKASDTAIYYCVRQWDGRTTGARGWYHYYHMDFWGTGTAVTVST

262 82

SYELTQPSSVSVSPGQTARITCSGDVLAKKYARWFQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGT

TVTLTISGAQVEDEADYYCYSAADNNWVFGGGTKLTVL

263 83 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

264 83

EIVLTQSPGTLSLSPGERATLSCRASQSVSTRHLAWYQQKPGQAPRLLIYAASRRATGIPDRFSGSGS

GTDFTLTISSLEPEDFAVYYCQQYGTSPYTFGQGTKLEIK

265 84

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQSPGKGLEWVSYISGSGGTIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARDRSISWTYYYYYMDVWGKGNPGHRLL

266 84 EIVLTQSPATLSLSPGERATLSCRASRSVSTYLAWYQQKPGQAPRLLIYDASNRASGIPSRFSGSGSG

TDFTLTISSLEPEDFAVYYCQQCYSGPPWTFGQGTKVENK

267 85

EVQLVESGGGLVKPGGSLRLSCAASGFSLRSYSMNWVRLAPGKGLERVSSISSSRSYLYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARDQEFNYYDSSGHFDYWGQGTLVTVSS

268 85 EIVMTQSPGTLSVSPGEGATLSCRASQSVGSKLAWYQQKQGQAPRLLIYGASTRATGTPARFSGSGSG

TEFTLTISSLQSEDFAVYYCQQYDNWPPYTFGQGTKLQIN

269 86

EVQLVESGGSLVKPGGSLRLSCVGSGFTFSNYSMNWVRQAPGRGLEWVSSISSSDYIYYSDSVKGRFT

ISRDSAKNSVYLHMDGLRPEDTAVYFCASAPEGLNVLRAFGVVTPTNYYFLGMDVWGRGTTVTVSS

270 86

EIVMTQSPATLSVSPGERATLSCRASQSVSTNLAWYQQKPGQAPRLLVYGPSTRATGIPARFSGSGSG

TEFTLTISSLQSEDFAIYYCKHYYNRPPYTFGQGTRVEIK

271 87 QVQLVQSGAEVRKPGSSTKVSCKASGGTFTSYGISWVRQAPRQGLEWLGGIIPLFDTTNYAQKFQGRV

TITADRSTSTAYMELCRLRSEDTAVYYCATLSLRTPVPYDFWSKYWGQGTLVTVSS

272 87 EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPSLLIYDASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYHCQQYGTSPGTFGQGTKVEIK

273 88

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYRPSLQGQV

TISADKSISTAYLQWSSLKASDTAIYYCARQMGRIWPHDAFDIWGRGTMVTVSS

274 88

EIVLTQSPGTLSLSPGERTTLSCRASQTVSNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDSAVYYCQQYAGSLPTFGGGTKVEIK

275 89

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

276 89

DIQMTQSPSTLSASVEDRVTITCRASQSINKWVAWYQQKPGKAPI LLIYDASNLQTGVPSRFSGSGSG

TEFSLAISSLQPDDFATYYCQQYQSYPYTFGQGTKLEIK

277 90 QLQLQESGPGLVKPSETLSLTCTVSGGSINSDSYYWGWIRQPPGKGLEWIGTI FYSGSTYYNPSLKSR

VTLSVDTSKNQFSLKLNSVTAADTALYYCATHPPTLAARPWDHWGQGTLVTVSS

278 90 EIVLTQSPGTLSLSPGERTTLSCRASQTVSNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDSAVYYCQQYAGSLPTFGGGTKVEIK

279 91

EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISGGSTYIYYADSLKGRF

TISRDNAKNSLYLQMNSLSAEDTAVYYCAKPLAAAGLLALDFWGQGTQVTVSS

280 91

EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPSLLIYDASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYHCQQYGTSPGTFGQGTKVEIK

281 92

QVQLEDLGAEVRKPGSSVKVSCKASGGTFTSYGISWVRQAPGQGLEWLGGIIPLFDTTNYAQKFQGRV

TITADRSTSTAYMELSRLRSEDTAVYYCATLSLRTPVPYDFWXKYWGQGTLVTVSS

282 92

EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPSLLIYDASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYHCQQYGTSPGTFGQGTKVEIK

283 93

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

284 93

DIQMTQSPSSVSASVGDRVIITCRASQYISSELVWYQQKPGKAPKVLIYAASNLQSGVPSRFSGSGSG

TDFTLTIRGLQLEDCATYYCQQANTFLTFGPGTMVDIK

285 94

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

286 94

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKAGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYFCQRYDTSQGTFGQGTKLDIK

287 95

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

288 95

KIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPWLLIYGAVSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

289 96

QVQLVESGGSVVQPGRSLRLSCVAPGFTFSKSAIHWVRPAAGKVLELVAVVTYDGGAKYYADSVKGRF

TISRDNSENTLYLQMNSLRPEDTAVYFCAREWNYDSSPTYDFWGQGTLVTVSS

290 96

EIVMTQSPGTLSVSPGEGATLSCRASQSVGSKLAWYQQKQGQAPRLLIYDASTRATGTPARFSGSGSG

TEFTLTISSLQSEDFAVYYCQQYDNWPPYTFGQGTKLQIN

291 97

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

292 97

QSALTQPASVSGSPGQSITISCTGTSSDFGGYNSVSWYQHHPGKAPKLIIYDVSNRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTGSAPLYVFGIGTKVTVL

293 98

EVQLVESGGGLVKPGGSLRLSCAASGFTFSYYTVTWVRQAPGKGLEWVSSISSSSSYIIYADSVKGRF

TMSRDNAKNSLYLQMNSLRAEDTAVYYCARDHYYDSSGYYYEVGMDVWGQGTTVTVSS

294 98

KIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPWLLIYGAVSRATGIPDRFSGSGS

GTDFTLTISRLEPEDSAVYYCQQYGGSLPTFGGGTKVEIK

295 99

QVQLEDLGAEVRKPGSSVKVSCKASGGTFTSYGISWVRQAPGQGLEWLGGIIPLFDTTNYAQKFQGRV

TITADRSTSTAYMELSRLRSEDTAVYYCATLSLRTPVPYDFWXKYWGQGTLVTVSS

296 99 DIQMTQSPSTLSASVGDRVTITCRASQSFNGWLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQHYVFGQGTKVEVK

297 100

QVQLVQSGAEVRKPGSSVKVSCKASGGTFTSYGISWVRQAPGQGLEWLGGIIPLFDTTNYAQKFQGRV

TITADRSTSTAYMELSRLRSEDTAVYYCATLSLRTPVPYDFWSKYWGQGTLVTVSS

298 100

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTITSLQSEDFAVYYCQQYNDWPPLTFGGGTKVEIK

299 101

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

300 101

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTITSLQSEDFAVYYCQQYNDWPPLTFGGGTKVEIK

301 102

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGRGLDWVAVISYDDSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDQGRPSYYDFWGGYHPSTNLRPVXDYWGQGTLVTVSS

302 102

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDATNLETGVPSRFSGSGSG

TDFTFTINSLQPEDIATYYCQHYDNLPRVTFGPGTKVDIR

303 103

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNHAMSWVRQAPGKGLEGVSGISHSGRSTYFADSVKGRF

TISRDNSKNTLYLQMNSLRVEDTAVYYCAKVKITI FGMVPXDYWGQGI LVTVSS

304 103

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDATNLETGVPSRFSGSGSG

TDFTFTINSLQPEDIATYYCQHYDNLPRVTFGPGTKVDIR

305 104

QVQLVAAGGGVDQPGWSLRLSCTASGFTFSTYGMHWVRQAPGKGLGWVGVISYDGRNKYADSVKGRFT

ISRDNSKNTLYLQADTLRPEDTAVYYCARGWAGVTVPGTHEFDYWGRGTVVTVSS

306 104

QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTYSGHFPFWFQQKPGQAPRTLIYDTDNKHSWTPARFSGS

LLGGKAALTLSGAQPDDEADYYCLLAYSDIRI FGGGTKLTVL

307 105

QVQLEDLGAEVRKPGSSVKVSCKASGGTFTSYGISWVRQAPGQGLEWLGGIIPLFDTTNYAQKFQGRV

TITADRSTSTAYMELSRLRSEDTAVYYCATLSLRTPVPYDFWXKYWGQGTLVTVSS

308 105

EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPSLLIYDASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYHCQQYGTSPGTFGQGTKVEIK

309 106

EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISGGSTYIYYADSLKGRF

TISRDNAKNSLYLQMNSLSAEDTAVYYCAKPLAAAGLLALDFWGQGTQVTVSS

310 106

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTITSLQSEDFAVYYCQQYNDWPPLTFGGGTKVEIK

311 107

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

312 107

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSG

TEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK

313 108

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQGTGLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

314 108 AIQLTQSPSSLSASVGDRVTITCRSSLGISSALAWYQQKPGKAPKLLIYHASNLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQFSSYPITFGGGTKVEIK

315 109

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNHAMSWVRQAPGKGLEGVSGISHSGRSTYFADSVKGRF

TISRDNSKNTLYLQMNSLRVEDTAVYYCAKVKITI FGMVPYDYWGQGI LVTVSS

316 109

QSVLTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYQQLPGTAPKLLDYGNSDRPTGVTDRFSGSR

SGASASLAITGLQAEDEADYYCQSYDRSLSGVVFGGGTKLTVL

317 110

EVQLVQSGTEVKKPGESLKISCKGSGYAFFGYWIGWVRQMPGKGLEWIGLIYPDDSQSRYSPSFQGQV

TMSADKSINTAYLQWGSLRASDSAMYFCARFGGPRLESTYFDYWGQGTLVTVSS

318 110

QSALTQPASVSGSPGQSIAISCSGTSSDVGGYDYVSWYQHHPGKAPRLMISEVSNRPSGVPDRFSGSK

SGNTASLTISGLQAEDESDYYCSSYTSTSTFWVFGGGTKLTVL

319 111

QLQLQESGPGLVKPSETLSLTCTVSGGSINSDSYYWGWIRQPPGKGLEWIGTI FYSGSTYYNPSLKSR

VTLSVDTSKNQFSLKLNSVTAADTALYYCATHPPTLAARPWDHWGQGTLVTVSS

320 111

QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTYSGHFPFWFQQKPGQAPRTLIYDTDNKHSWTPARFSGS

LLGGKAALTLSGAQPDDEADYYCLLAYSDIRI FGGGTKLTVL

321 112

EVLLVESGGGLVQPGGSLRLSCAASGFTFSEHFIDWVRQAPGKGLEWVGRSTNKANRYNTEYAASVKG

RFTISRDDSKNSVYLQMNSLKTEDTAVYYCSRRKVVIHGPSDLWGQGTMVTVSS

322 112

EIVLSQSPGTLSFSPGERATLSCRASQSVRYNYLAWYQQKPGQAPRLLIYHTSIRATGIPDRFRGSGS

GTDFI LTISRLEPEDFAVYYCQHYGASSTFGPGTKVDIK

323 113

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

324 113

EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPSLLIYDASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYHCQQYGTSPGTFGQGTKVEIK

325 114

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

326 114

QSVLTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYQQLPGTAPKLLDYGNSDRPTGVTDRFSGSR

SGASASLAITGLQAEDEADYYCQSYDRSLSGVVFGGGTKLTVL

327 115

QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRV

TISVDKSKNQFSLKVNSVTAADTAVYFCARVQSELDRSSRYSLYYYGMDVWGQGPIGL

328 115

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSG

TEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK

329 116

EVQLVQSGAEVKKPGESLRISCQGSGYSFTTYWITWVRQMPGKGLEWMGRSDPSDSYSNYSPSFQGRV

IMSFEKSTNTAYLQWTSLKASDTAIYYCARHDISGFYLPNWGQGTLVTVSS

330 116

EIVLTQSPGTLSLSPGERTTLSCRASQTVSNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDSAVYYCQQYAGSLPTFGGGTKVEIK

331 117

QVQLVESGGGVVQPGRSLRLSCTASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGRNKYADSVKGRFT

ISRDNSKNTLYLQADTLRPEDTAVYYCARGWAGVTVPGTHEFDYWGRGTVVTVSS

332 117 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQRPGKAPKLLIYDASSLESGVPSRFSGSGYG

TEFTLTISGLQPDDFATYYCQHYNNFPESFGQGTRVEIK

333 118

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEGVSGISHSGRSTYFADSVKGRF

TISRDNSKNTLYLQMNSLRVEDTAVYYCAKVKITI FGMVPYDYWGQGI LVTVSS

334 118

KIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPWLLIYGAVSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

335 119

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTTGVGVGWIRQPPEKALECLAFIYWDDDKRYSPSLESR

LTITKGTSENQVVLTMTNMDPVDTATYYCAVIGEQYFGSGSWYFDYWGQGALVSVSS

336 119

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTITSLQSEDFAVYYCQQYNDWPPLTFGGGTKVEIK

337 120

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYVISWVRQAPGQGLEWMGGIIPMFDTTHYTQKFQGRL

TITADESTSTAYMDLSSLRSDDTAVYYCARLIPRNYYDSSGYSSQDYWGQGTLVTVSS

338 120

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSG

TEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK

339 121

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISYVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREYTVGGI FGFWGQGTLVTVSS

340 121

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSG

TDFTFTISSLQPEDIATYYCQQYDNLPPFTFGPGTKVDIK

341 122

EVQLVQSGAEGKKPGESLKISCKGSGYDFANQWIGWVRQLPGKGPEWMGIIYPGDSDTRYSPSFQGQV

TISADKSITTAYLHWTSLKASDTAMYYCARHKGSDIATPTRGGFDIWGQGTMVTVSL

342 122

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGQVPNLLIYAASTLQSGVPSRFSGSGSG

TDFTLTITSLQPEDVATYYCQNYNSAPLTFGGGTKVGIK

343 123

QVQLVESGGGVVQPGRSLRLSCQASGFTFNRYGMHWVRQAPGKGLEWLALIWYDGSEKYYADSVKDRF

TISRDNSKNMLFLQMNNLRAEDTAVYYCAKVTLTSYGDFGHEDYWGQGTLVTVSS

344 123

QSELTQPPSASGTPGQRITISCSGSSSNIGSNYVYWYQQFPGTTPKLLIYRNDQRPSGVPDRLSGSKS

GTSASLAISGLRSEDEADYYCASWDDSVGGPRFGTGTKVTVL

345 124

EVQLVESGGGLVQPGGSLRLSCTAPRFTLSSYSMNWVRQAPGKGLEWVSYISSSSDTMYYADSVKGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCVTRXFYWGQGTLVTVSS

346 124

QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGAAPKLLIYDNNKRPSGIPDRFSGSKS

GTSATLGITGLQTGDEADYYCGTWDSSLSALFGGGTKLTVL

347 125

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

348 125

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSVS

RTDFTLRIHGLESGDFAVYYCQQYGSLPQTFGEGSKVEIR

349 126

EVQLLESGGGLVQPGGSLRLSCAASGFTFNIYAINWVRQAPGKGLEWVSSISGSGDSAYYADSVKGRF

TISRDNSKNTVFLQMNSLTAEDTAVYYCAKQYCTNGVCYTDYYFYNHMDVWGKGTTVTVSS

350 126 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSG

TDFTFTISSLQPEDIATYYCQQYDNLPPFTFGPGTKVDIK

351 127

EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYLMHWVRQAPGKGLVWVSRVNSDGNDRKYADSVKGRF

IISRDNAKKTIYLQMNSLRAEDTAVYYCANRAGWGQGTLVTVSS

352 127

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSG

TDFTFTISSLQPEDIATYYCQQYDNLPPFTFGPGTKVDIK

353 128

QVQLEDLGAEVKKPGASVKISCKASGYI FTSYAVHWVRQAPGQRLEWMGWINAGNGETKYSQKFQGRV

TITRDTSASTAYMEMSSLRSEDTAVYYCAREPPYYDFDDYWGQGTLVTVSS

354 128

GIQMTQSPSTLSASVGDRVTITCRASQSMNSWLAWYQQKPGKAPKLLIYEASTLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNTYSWTFGRGTKVEIK

355 129

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEWMGRIIPI LGIVNYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARGFVGATTDAEMSNWGQGTLVTVSS

356 129

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK

357 130

EVQLLESGGGLVQPGGSLRLSCVVSGFTFPNSAFSWVRRAPGRGLEWVSTVSANGFSTYYADAVEGRF

TISRDNAKDTLYLQMDTLRVDDTAVYYCAKTAPWVHLWFSPDWDYWGQGSLVTVSS

358 130

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK

359 131

QVQLVESGGSVVQPGRSLRLSCVASGFTFSKYAMHWVRQAPGKGLEWVAVVTYDGGAKYYADSVKGRF

TISRDNSENTLYLQMNSLRPEDTAVYFCAREWNYDSSPTYDFWGQGTLVTVSS

360 131

QSALTQPASVSGSPGQSITISCTGTSSDIGGYYYVSWYQQHPGQAPKLII FDVSDRPSGISNRFSGSK

SGNTASLTISGLQAEDEAHYFCSSYTSGSTLDVVFGGGTKLTVL

361 132

EVQLIQSGSEIKKPGESLKISCKGSGYRFSAYWLAWVRQMPGKGLECMGVIYPGDSDTIYNPAFVGQV

TISADKSTNTAYLQWSSLKASDTATYYCARQQGVQLWFANWGRGTLVTVSS

362 132

DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSG

TDFTFTISSLQPEDIATYYCQQYDNLPPFTFGPGTKVDIK

363 133

QVQLQESGAGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQYPGKDLEWIGYIYSSGSTYYNPSLKSG

IIISVDTSKNQFSLKLTSVTAADTAVYYCARDPSSGSHGAAFDIWGQGTMVTVSS

364 133

DIQMTQSPSSLSASVGDRGTITCRASQGIGNDLGWYQQKPGKAPKRLIYAASNLNSGVPSRFSGSGSG

TEFTLTISSLQPEDFATYYCLQHNTYPWTFGQGTKVEIK

365 134

QVQLEDLGAEVKKPGSSVKVSCTASGGTFDRSVIDWVRQAPGQGLEWVGRIIPLYGSANYAQKFHGRL

TI S AD E FTSTAYM E LSS LRS EDTAVYYC AGTT LVN PKAXDYWGQGT LVTVSS

366 134

DIQMTQSPSTLSASVGDTVSITCRASQSFSRWLAWYQQRPGKAPKLLIYQASSLQSGVPSRFSGSGSG

TEFTLTITSLQPDDFATYYCQQYNTYPYTFGQGTKVEIK

367 135

QVQLVQSGAEVKKPGSSVKVSCTASGGTFDRSVIDWVRQAPGQGLEWVGRIIPLYGSANYAQKFHGRL

TISADEFTSTAYMELSSLRSEDTAVYYCAGTTLVNPKAFDYWGQGTLVTVSS

368 135 EIVLTQSPGTLSLSPGERATLSCRASQSVSGNYLAWYQQKPGQAPRLLIYGISTRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYDTSQGTFGQGTKLEIK

369 136

QVQLEDLGAEVKKPGSSVKVSCTASGGTFDRSVIDWVRQAPGQGLEWVGRIIPLYGSANYAQKFHGRL

TI S AD E FTSTAYM E LSS LRS EDTAVYYC AGTT LVN PKAXDYWGQGT LVTVSS

370 136

DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQSGVPSRFSGSGSG

TEFTLTISSLQPEDFATYYCLQHNSYPHTFGQGTKLEIK

371 137

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEWMGRIIPI LGIVNYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARGFVGATTDAEMSNWGQGTLVTVSS

372 137

EVVLTQSPATLSSSPGERVTLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPASSVAVGLG

QTSLSPSAAWSLKI LQFITVCSVATGLRSLSAEGPRWRS

373 138

EVQLVESGGGWTGPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

374 138

DIQMTQSPSTLSASVGDRVTITCRASESISSWLAWYQQKPGEAPKLLMYKSSI LESGVPSTFSGTGSG

TEFTLTISRLQPDDFATYYCQQYNSYPHTFGQGTKLDIK

375 139

QVQLQESGPRLVKPSQTLSLICTVSGVSITSRGVYWNWIRHHPGKGLEWIGYVYYTGDTLYNPSLKSR

LTLSVDTSKNQLSLQLSSVTAADTAVYYCARVSNFARQSDYWGHGTLVTVSS

376 139

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRGTGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCHQYGTSPWTFGQGTKVEIK

377 140

QVQLQQWGAGLLKPSETLSLTCGVYGGSFSGYYWTWIRQSPGKGLEWIGEINHSGSTNYNPSLKSRVS

ISVDTSKKQFSLKLTSVTAADTAVFYCARGYGSGSYDSKSGFDIWGQGTMVTVSS

378 140

DIQLTQSPSFLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLVIYAASTLQSGVPSRFSGSGSG

TEFTLTISSLQSEDFATYYCQQVNDIPPYTFGQGTKLEIK

379 141

QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGGYYWSWIRQYPGKGLEWIGYIYSSGSTYYNPSLKSG

IIISVDTSKNQFSLKLTSVTAADTAVYYCARDPSSGSHGAAFDIWGQGTMVTVSS

380 141

DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGNNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKVEIK

381 142

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

382 142

SYELTQPPSVSVAPGQTARITCGGDNIGSRSVHWYQQQPGQAPVLVVYDDSARRSGIPERFSGSNSGN

TATLTISRVEAGDEADYYCQVWDSFSDHYVFGTGTTVTVL

383 143

QVQLQESGPRLVKPSQTLSLICTVSGVSITSRGVYWNWIRHHPGKGLEWIGYVYYTGDTLYNPSLKSR

LTLSVDTSKNQLSLQLSSVTAADTAVYYCARVSNFARQSDYWGHGTLVTVSS

384 143

SYELTQPPSVSVAPGQTARITCGGDNIGSRSVHWYQQQPGQAPVLVVYDDSARRSGIPERFSGSNSGN

TATLTISRVEAGDEADYYCQVWDSFSDHYVFGTGTTVTVL

385 144

QVQLMQSGAEVKKPGSSLKLSCNISGGTFSSYSVSWVRQAPGQGLEWVGGFITVSDTAHYSQKFQGRV

TITADESGSTVYMDLSGLKSEDTAIYYCAGRFCRSTSCYLQLSRSLSYMDVWGTGTTVTVSS

386 144 DIVLTQSPATLSLSPGERTTLSCRASQSVGTYLAWYQQRPGQTPRLLIYDTSNRATGIPARFSGSGSG

TDFTLTISSLEPEDVAIYYCQQRSSWPLTFGGGTKVEI E

387 145

EVQLVESGGGLIQPGGSLRLSCAPSGFTVSGSYMSWVRQAPGRGLEWVSVI FSGGATYYSDSVKGRFT

ISRDSSKNTLFLQMNNLRAEDTAIYYCARDGGFYGDYAAFDLWGLGTMVTVSS

388 145

EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASKRAAGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCHQRSNWLTFGGGTKVEIK

389 146

EVQLVESGGGLIQPGGSLRLSCAPSGFTVSGSYMSWVRQAPGRGLEWVSVI FSGGATYYSDSVKGRFT

ISRDSSKNTLFLQMNNLRAEDTAIYYCARDGGFYGDYAAFDLWGLGTMVTVSS

390 146

EIVLTQSPGTLSLSPGERATLSCRASQTISSTYLAWYQQRPGQALRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRVEPEDFAVYYCQQYDYSGSLWTFGQGTKVDVK

391 147

EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYWMSWVRQAPGKGLEWVANIKQDGSERYYVGSLKGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARDLEGKYSYFDCWGQGTLVTVSS

392 147

SYELTQTPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVLVVYDDTVRPSGIPERFSGSNSGS

TATLTISRVEAGDEADYYCQVWDSSTDHLMFGGGTKLTVL

393 148

QMQLVESGGGVVQPGRSLRLSCAASGFTFSNHGIHWVRQAPGKGLEWVAVISSDGSDKYYGDSVKGRF

TISRDNSQNI LYLQMNSLRSEDTAVYYCAKDGGEDLDFWGQGTLVTVSS

394 148

SYELTQPPSVSVAPGQTARITCGGDNIGSRSVHWYQQQPGQAPVLVVYDDSARRSGIPERFSGSNSGN

TATLTISRVEAGDEADYYCQVWDSFSDHYVFGTGTTVTVL

395 149

EVQLEKTGGGLVKPGGSLKLSCAASGFNLHSYTMNWVRQAPGKGLEWVSFITSDSRKTFYADSVRGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGVEWDTSTNWFASWGQGTLVTVSS

396 149

QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWFQQHPGKAPKLMIYEGSKRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSLHVVFGGGTKLTVL

397 150

QVQLVQSGAEVKKPGASVKISCKASGYI FTSYAVHWVRQAPGQRLEWMGWINAGNGETKYSQKFQGRV

TITRDTSASTAYMEMSSLRSEDTAVYYCAREPPYYDFDDYWGQGTLVTVSS

398 150

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAIYYCQQRSTWPRTFGQGTRLEIK

399 151

QVQLEDLGAEVKKPGASVKISCKASGYI FTSYAVHWVRQAPGQRLEWMGWINAGNGETKYSQKFQGRV

TITRDTSASTAYMEMSSLRSEDTAVYYCAREPPYYDFXDYWGQGTLVTVSS

400 151

DIQMTQSPSSLSASVGDRVTITCRASHTIRGFLNWYQQKPGKAPNLLIYAGSSLQSGVPPRFSGSASG

TDFTLTISSLQPEDFATYYCQQTYSAPRTFGQGTRVEVK

401 152

QVQLMQSGAEVKKPGSSLKLSCNISGGTFSSYSVSWVRQAPGQGLEWVGGFITVSDTAHYSQKFQGRV

TITADESGSTVYMDLSGLKSEDTAIYYCAGRFCRSTSCYLQLSRSLSYMDVWGTGTTVTVSS

402 152

QSALTQPASVSGSPGQSITISCTGTTSDIGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTISRTGVLFGGGTKLTVL

403 153

QVQLVESGGGVVQPGRSLRLSCQASGFTFNRYGMHWVRQAPGKGLEWLALIWYDGSEKYYADSVKDRF

TISRDNSKNMLFLQMNNLRAEDTAVYYCAKVTLTSYGDFGHEDYWGQGTLVTVSS

404 153 DLVLTQSPGTLSVFPGESATLSCRASQSLSSTYLAWYQQKPGQPPRLLIYGTSTRATGIPDRFSGSGF

GTDFTLTISGLEPEDFAVYHCQHYGPSHFTFGPGTRVDLK

405 154

EVQLLASRGGLVQPGGSLRLSCEASGFTFSRYPMRLVRQAPGQGLGWVSGISGSGGRTYHADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCAKAGTYYYDSSGYTHYWGQGTLVTVSS

406 154

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYPTFGQGTKLEIK

407 155

QVQLVESGGGLVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWFDGSNKFQADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARGTDDFDFWGQGTLVTVSS

408 155

SYELTQTPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVLVVYDDTVRPSGIPERFSGSNSGS

TATLTISRVEAGDEADYYCQVWDSSTDHLMFGGGTKLTVL

409 156

QVQLVESGGGLVQPGRSLRLSCAASGFPFSSYGMHWVRQAPGKGLEWVAVIVYDGKSEYYADSVKGRF

TITRDNSRNTVHLQMNSLRAEDTALYYCAKDRSSWYEGLYYYYYGMDVWGQGTAVTVSS

410 156

SYELTQTPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVLVVYDDTVRPSGIPERFSGSNSGS

TATLTISRVEAGDEADYYCQVWDSSTDHLMFGGGTKLTVL

411 157

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWFDGSNKFQADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARGTDDXDFWGQGTLVTVSS

412 157

SYELTQTPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVLVVYDDTVRPSGIPERFSGSNSGS

TATLTISRVEAGDEADYYCQVWDSSTDHLMFGGGTKLTVL

413 158

QVQFVQSGAEVKKPGASVKISCKASGYI FTSFGIHWVRQAPGQRLEWMGWINIGNGNTNYPQKFQGRV

TISRDTSASTAYMELSSLTFEDTAVYYCARDSDPTYGYFFPKYFYAMDVWGQGTTVTVSS

414 158

EIVLTQSPGTLSLSPGETATLSCRASQSVSSKYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSSSAS

RTDFTLTISGLEPEDFAVYYCQQYGSLPQTFGQGSKLEIR

415 159

QVRLVESGGGVVQPGRSLRLSCAASGFSFTSYSVHWVRQAPGKGLEWVAVISYDGTNKYYADSVKGRF

TISRDSSKNTLYVQMSSLRAEDTAVYYCARVAYYYGSGSYYSPHFYYYGMDVWGQGTTVTVSS

416 159

QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKFMIYDVSKRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSYTWVFGGGTKLTVL

417 160

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

418 160

EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSASGS

GTDFTLTISRLEPEDFAVYYCQQYGNSRFTFGPGTKVDIK

419 161

EVHLVESGGGLVQPGGSLRLSCAASGFTFSNYWMHWVRQTPGKGLEGVANIKQDGSEEYYVDSVRGRF

TISRDNPHNSLYLQMNSLRAEDTAVYYCARVGPTGWRAGPFDSWGQGTLVTVSS

420 161

EVVLTQSPATLSLSPGERATLSCGASQSISNYLAWYQQKPGQSPRLLIYDASNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSDWPPTFGGGTKVEIK

421 162

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

422 162 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYPLTFGGGTKVEIK

423 163

EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISGGSTYIYYADSLKGRF

TISRDNAKNSLYLQMNSLSAEDTAVYYCAKPLAAAGLLALDFWGQGTQVTVSS

424 163

AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKLEIK

425 164

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

426 164

EIVLTQSPGTLSLSPGERTTLSCRASQTVSNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDSAVYYCQQYAGSLPTFGGGTKVEIK

427 165

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

428 165

EIVMTQSPATLSVSPGERATLSCRASQSVGNSLAWYQQKPGQPPRLLIYDASTRATGIPASFSGIGSG

TEFTLTISSLQPEDFAAYHCQQYYNWPLTFGGGTKVEIK

429 166

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

430 166

QSALTQPASVSASPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKVMIYEVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEAHYYCSSYTSDYTWVFGGGTKLTVL

431 167

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

432 167

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

433 168

EVQLVDSGGGLIQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVSAISGSAGSTYYADSVKGRF

IISRDNSKNTLHLQMNSLRADDTAVYYCARSVGTTHYYMDVWGKGTTVTVSS

434 168

DIQMTQSPSSLSASVGDRVTITCRASQSITTYLNWYQHKPGKAPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSFITPAWTFGQGTKLEIK

435 169

EVQLVDSGGGLIQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVSAISGSAGSTYYADSVKGRF

IISRDNSKNTLHLQMNSLRADDTAVYYCARSVGTTHYYMDVWGKGTTVTVSS

436 169

SYELTQPPSVSVSPGQTARITCSGDALSKQYAYWYQKKPGQAPELVIYQDSERPSGIPERFSGSSSGT

TVTLTISGVQAEDEADYYCQSTDSSGTFGVFGGGTRLTVL

437 170

EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSSISGGSTYIYYADSLKGRF

TISRDNAKNSLYLQMNSLSAEDTAVYYCAKPLAAAGLLALDFWGQGTQVTVSS

438 170

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIAARFSGSGSG

TEFTLTISSLQSEDVAVYYCQQYNNWPVITFGPGTKVDIR

439 171

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

440 171 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFI LTISTLQPDDFATYYCQQYNSYYTFGQGTKLEIK

441 172

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

442 172

EIVLTQSPGTLSLSPGERAALSCRASQSLSSTYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTIRRLEPEDFAVYYCQHFGTFGQGTTVEIK

443 173

QVQLVESGGSVVQPGRSLRLSCVASGFTFSKYAMHWVRQAPGKGLEWVAVVTYDGGAKYYADSVKGRF

TISRDNSENTLYLQMNSLRPEDTAVYFCAREWNYDSSPTYDFWGQGTLVTVSS

444 173

DIQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGRVPKLLIHSASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK

445 174

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

446 174

ETVVTQSPATLSVPLGEGATLSCRVSQGVLTNVAWYQHRPGQAPRLLIYGASTRATGVPARFSGSGSG

TEFTLAISSLESEDVAVYYCHQYSKWPPGAFGQGTKVEIK

447 175

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

448 175

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

449 176

EVQLMQSGAQMKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

450 176

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPQFTFGGGTKVEIK

451 177

QVQLEDLGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

452 177

DIVMTQSPDSLAVSLGERATINCKSSQSI LYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRF

SGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGPGTKVDIK

453 178

QLQLQESGPGLVKPSETLSLTCTVSRGSISSSAYYWGWVRQPPGKGLEWIGSINYNGNTYYTSSLKSR

LTISVDTSRNQFSLKLSSVTAADTAVYYCARIIISGSNWFDPWGQGTLVTVSS

454 178

EIVLTQSPGTLSLSPGERAALSCRASQSLSSTYLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGS

GTDFTLTIRRLEPEDFAVYYCQHFGTFGQGTTVEIK

455 179

QLQLQESGPGLVKPSETLSLTCTVSRGSISSSAYYWGWVRQPPGKGLEWIGSINYNGNTYYTSSLKSR

LTISVDTSRNQFSLKLSSVTAADTAVYYCARIIISGSNWFDPWGQGTLVTVSS

456 179

DIVLTQSPGTLSLSPGESATLSCRASQSVNNDYIAWYQQKPGQAPRLLIYGASSRASGIPDRFDGSGS

GTDFTLTIRRLEPDDFAVYYCHQYITLPLTFGGGSKVEIR

457 180

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSSISGSGDRIYGVDSLKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARRPLGSRFDLWGRGTLVTVSS

458 180 EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGTFDQGTKVEIK

459 181

QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSR

LTITKDTSKNQVVLTLTNMDPVDTATYYCAHRGPVAGHFGFWGQGTLVTVSS

460 181

AIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQHKPGKAPKLLIYKASTLESGVPSRFSGSGSG

TEFTLTINSLQPDDFATYYCQQYNSPLTFGGGTKVEIK

461 182

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

462 182

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

463 183

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

464 183

DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPRYTFGQGTKLEIK

465 184

QVQLQESGPGLVRPSETLSLTCTLSGGFISGSSYFWGFIRQPPGKGLEWIGSI FHNGTTKFNPSLKSR

VTISVEKSKNQFSLMLKSVTAADTAVYYCARHSPSMLRGVTIVGPHMDVWGKGTTVTAS

466 184

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

467 185

QVQLVESGGGVVQPGRSLRLSCEGSGFI FSDYTMGWVRQAPGKGLEWVALISHDGSTKRSADSVEGRF

SISRDNSKNLVHLHMDSLRAEDTAVYFCVRDHFLRLIREIWDNWGQGTQVTVSS

468 185

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

469 186

QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIRQAPGKGLVWVSTISTSSSYTNSADSVKGRF

TMSRDDAENSLYLQMNNLRADDTAVYYCARAYTAMAPFDLWGQGTLVTVSS

470 186

EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG

TEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK

471 187

EVQLMQSGAQIKKPGESLKISCQGSGYNFPNSWIAWVRQMPGKGLEYMGIIYASNSDTRYSPSFQGQV

SISVDKSISTAYLQWSSLKASDTAMYYCARRADYAFDHWGQGTLVTVSS

472 187

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGGGTKVEIK

473 188

EVQLVESGGGLVKPGGSLKLSCAASGFNLHSYTMNWVRQAPGKGLEWVSFITSDSRKTFYADSVRGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGVEWDTSTNWFASWGQGTLVTVSS

474 188

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTLLITFGPGTKVDIK

475 189

EVQLVESGGGLVKPGGSLKLSCAASGFNLHSYTMNWVRQAPGKGLEWVSFITSDSRKTFYADSVRGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGVEWDTSTNWFASWGQGTLVTVSS

476 189 EIVLTQSPATLSLSPGERAALSCRASQSVVNYLAWYQQRPGQAPRLLIYDASKRASGIPPRFSGNGSG

TDFTLTISSLEPEDFAVYYCQQRINWPLTFGGGTKVEIK

477 190

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDKI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

478 190

DIQMTQSPSAMSASVGDRVTITCRATQGFSNYLAWFQQRPGKAPKRLIYATSTLHSGVPSRFSGSGSG

TEFNLTISSLQPEDFATYYCLQHGRYPATFGQGTKLEIK

479 191

QVQLVHGLDLEDLLLASVRVSCKASGYTFTNHPIDWVRQAPGQGLEWMGIINPSGGGVRFAQKFQGRV

TLTTDTSTSTVYMELSSLTSDDTAVYFCARGAGRDVYKSI LAWFDYWGQGTLVTVSS

480 191

QAALTQPASVSGSPGQSSAISCDVAGYSYVSWFQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNAA

SLTISGLQAEDEADYYCAAFTSRNTWVFGGGTRLTVL

481 192

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGPEWMGRIIPIRAIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDYCTNGVCYAGQVLSFDIWGQGTMVTVSS

482 192

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTLLITFGPGTKVDIK

483 193

QVQLVQSGAEVKRPGASVKISCKTSGYTFTNYAVHWLRQAPGQGLEWMGWINGGTGHTKYSRKFQGRV

TITRDTSASTAYMEVHSLRSEDTAVFYCAGSPTYYSWFDPWGQGTQVIVSS

484 193

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSG

TEFTLTISSLQPDDFATYYCQQYNSYSLTFGGGTKVEIK

485 194

CVQLVQSGGGLIQPGGSLRLSCAASGFSFSSYWMHWVRQAPGKGLVWVSRIYRDGSGPTYADSVKGRF

TI FRDSAKNTLYLQMNSLRAEDTAVYYCLRGNSGNGNFDLWGPGTLVTVSS

486 194

QAALTQPASVSGSPGQSSAISCDVAGYSYVSWFQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNAA

SLTISGLQAEDEADYYCAAFTSRNTWVFGGGTRLTVL

487 195

EVQLVESGGGLVQPGGSLRLSCAASGFSFNYDWMHWVRQAPGEGPVWVSCINGDGSTIRYGESVKGRF

TISRDNAKNTLYLQMNSLRLEDTAVYFCVRGTGYI LSYWGPGTVVTVSS

488 195

DIVLTQSPGTLSLSPGESATLSCRASQSVNNDYIAWYQQKPGQAPRLLIYGASSRASGIPDRFDGSGS

GTDFTLTIRRLEPDDFAVYYCHQYITLPLTFGGGSKVEIR

489 196

QVQLVQSGAEVMQVGASVKVSCKASAYKSTTYGIIWARQAPGQGLEFMGWVTPHNGVTKYEQKFQDRI

TITTDTSTGTAYMEMRSLRFDDTAIYYCARFVDSDDYRGWLDPWGRGTLVTVSS

490 196

DIQLTQSPSFLSASVGDRVTITCRASQGISNYLAWYQHRPGKAPKLLI FPASTLQSGVPSRFSGSGSG

TAFTLTISSLQPEDFATYYCQQLDTYSFGGGTKVEIK

491 197

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCAEGSGSSSLQSYYWGQGTLVTVSS

492 197

DIVLTQSPGTLSLSPGESATLSCRASQSVNNDYIAWYQQKPGQAPRLLIYGASSRASGIPDRFDGSGS

GTDFTLTIRRLEPDDFAVYYCHQYITLPLTFGGGSKVEIR

493 198

QVQLVQSGAEVREPGSSVKVSCKASGDTLSNSAISWVRQAPGQGLEWMGRIIPMFGMASYSQKFQGRI

TISADKSTRTVYMELSSLTSEDTAVYYCARGGGTWAPFDPWGQGTQLTVSS

494 198 DIQLTQSPSFLSASVGDRVTITCRASQGISNYLAWYQHRPGKAPKLLI FPASTLQSGVPSRFSGSGSG

TAFTLTISSLQPEDFATYYCQQLDTYSFGGGTKVEIK

495 199

QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

VTISVDTSKNQFSLKLSSVTAADTAVYYCARKPSIAVAVRWGRSKINNWFDPWGQGTLVTVSS

496 199

DIQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGRVPKLLIHSASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK

497 200

EVQLVESGGGLVQPGGSLRLSCAASGFSFNYDWMHWVRQAPGEGPVWVSCINGDGSTIRYGESVKGRF

TISRDNAKNTLYLQMNSLRLEDTAVYFCVRGAGYI LSYWGPGTVVTVSS

498 200

QAVLTQPASVSGSPGQSSAISCDVAGYSYVSWFQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNAA

SLTISGLQAEDEADYYCAAFTSRNTWVFGGGTRLTVL

499 201

EVQLVESGGGLVKPGGSLKLSCAASGFNLHSYTMNWVRQAPGKGLEWVSFITSDSRKTFYADSVRGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGVEWDTSTNWFASWGQGTLVTVSS

500 201

AIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQHKPGKAPKLLIYKASTLESGVPSRFSGSGSG

TEFTLTINSLQPDDFATYYCQQYNSPLTFGGGTKVEIK

501 202

EVQLVQSGAEVKKSGESLKISCKGSGYSFSSYWIAWVRHMPGKGLEWMGIIYPGNSETKYSPSFQGQI

TMSVDKSISIAYLQWSSLKASDTAIYYCARRGYSISWGRVWMDVWGQGTTVTVSS

502 202

SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYDDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADYYCQVWDSSSDHHAVFGGGTQLTVL

503 203

QVQLVQSGAEVKKPGSSVTVSCKASGGTFSSYGLSWVRQAPGQGPEWMGGIIPI LGKPTYAPKFQGRV

TITADESTSTAYLELSSLRSEDTATYYCARGGDYTGSYYDYYYYYMDAWGKGTTVTVSS

504 203

EIVLTQSPDTLSLSPGERATLSCRASQSVSNNRRLAWYQRKPGQAPRLLIYGASVRATGIPDRFSGSE

SGTDFTLTISRLEPEDFGVYYCQQYGNSPPTFGQGTKVELK

505 204

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

506 204

DIQMTQSPSSLSASVGDRVTITCRASRSISNYLNWYQQKPGKVPKLLIYTASSLQSGVPSRFSGGGSG

TDFTLTISNLQPEDFATYYCQQSYSTLTFGGGTKVEIK

507 205

QVQLQQKGAALLKPSETLSLTCGVSGGTFSDYHWTWVRQPPGKGLEWIGKINHGGSTNYNPTLKSRVS

ISIDTSKSQFSLKMTSLTAADAAVYFCARLREGRALRLTPQPRYSYYHMDVWGKGTTVTVSS

508 205

DIQMTQSPSSLSASVGDRVTITCRASRSISNYLNWYQQKPGKVPKLLIYTASSLQSGVPSRFSGGGSG

TDFTLTISNLQPEDFATYYCQQSYSTLTFGGGTKVEIK

509 206

EVQLLESGGGLGQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVSTIDTSGRRTYYADSVKSRF

AISRDNSKDTLYLQVNTLRAEDTAIYYCAKDLAEEESLGFCDGNNCPDAFDIWGQRTRVTVSS

510 206

EIVLTQSPDTLSLSPGERATLSCRASQSVSNNRRLAWYQRKPGQAPRLLIYGASVRATGIPDRFSGSE

SGTDFTLTISRLEPEDFGVYYCQQYGNSPPTFGQGTKVELK

511 207

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRLGELSFRNWGQGTLVTVSS

512 207 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

513 208

EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAIHWVRQASGKGLEWVGRIRSKANSYATAYAASVKD

RFTISRDDSKNTAYLQMNSLKSEDTAVYYCTRHNVDTALEWGQGTLVTVSS

514 208

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

515 209

QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRVRYSLFYYFDYWGQGTLVTVSS

516 209

SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYDDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADYYCQVWDSSSDHHAVFGGGTQLTVL

517 210

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

518 210

QSVLTQPRSVSGSPGQSVTISCSGTSSDVGGFDYVSWYQQHPGKAPKLIIYGVTERPSGVPDRFSGSK

SANTASLTISGLQADDEAAYYCCSYAGTYI LLFGGGTKLTVL

519 211

QLQLQESGPGLVKSSEPLFLTCTVSGASISSSNYYWGWIRQPPGKGLEWIGSIYYSETTYYNPSLESR

VTISVDTSKHQFSLIVTSMTAADTAVYYCAGLRRGGNWFDPWGQGNPSHRLL

520 211

GIVMTQSPATLSVSPGERATLSCRASQSVSSSYLAWYQQKPGQPPRLLIYGASTRATGIPARFSGSGS

GTEFTLTISSLQSEDFAVYYCQQYSNWPLTFGGGTKVEIK

521 212

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRLGELSFRNWGQGTLVTVSS

522 212

QSALTQPPSASGSPGQSVTISCTGTSRDVGGYDFVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSK

SGNRASLTVSGLQAEDEADYYCSSYAGNNI LFGGGTKLTVL

523 213

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARDRTPYSSGWYVGYWGQGTLVTVSS

524 213

QSALTQPPSASGSPGQSVTISCTGTSRDVGGYDFVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSK

SGNRASLTVSGLQAEDEADYYCSSYAGNNI LFGGGTKLTVL

525 214

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRLGEVSFRNWGQGTLVTVSS

526 214

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

527 215

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

528 215

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPPWTFGQGTKVEIK

529 216

EVQLVESGGDLVQPGGSLRLSCAASGFTFTTYWMSWVRQTPGKGLEWLANIKQDGSEKYYVDSVKGRF

TISRDNAKNSVYLQMSSLRDEDTAVYYCARQGVVISSATNWFDPWGQGTLVTVSS

530 216 QSALTQPASVSGSPGQSITISCAGTRNDVGAYNYVSWHQQHPGQTPKLLIYDVDDRPSGVSNRFSGSK

SGNTASLTISRLQAEDEADYYCSSYTTSGTYVFGTGTKVTVV

531 217

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARGQSIAARPSWSDYYYMDVWGKGTTVTVSS

532 217

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

533 218

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

534 218

EIVLTQSPDTLSLSPGERATLSCRASQSVSNNRRLAWYQRKPGQAPRLLIYGASVRATGIPDRFSGSE

SGTDFTLTISRLEPEDFGVYYCQQYGNSPPTFGQGTKVELK

535 219

EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYWMAWVRQAPGKGLEWVANIKEDGSTKQYVGSVKGRF

TISRDNGKNLVYLQMNSLRAEDTAVYYCAKESGFWSGHYSSDDKFQHWGQGTWVTVSS

536 219

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQAPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

537 220

QVQLVQSGAEVKKPGSSVTVSCKASGGTFSSYGLSWVRQAPGQGPEWMGGIIPI LGKPTYAPKFQGRV

TITADESTSTAYLELSSLRSEDTATYYCARGGDYTGSYYDYYYYYMDVWGKGTTVTVSS

538 220

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

539 221

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRLGELSFRNWGQGTLVTVSS

540 221

GIVMTQSPATLSVSPGERATLSCRASQSVSSSYLAWYQQKPGQPPRLLIYGASTRATGIPARFSGSGS

GTEFTLTISSLQSEDFAVYYCQQYSNWPLTFGGGTKVEIK

541 222

EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRLGELSFRNWGQGTLVTVSS

542 222

QSVLTQPRSVSGSPGQSVTISCSGTSSDVGGFDYVSWYQQHPGKAPKLIIYGVTERPSGVPDRFSGSK

SANTASLTISGLQADDEAAYYCCSYAGTYI LLFGGGTKLTVL

543 223

EEQLVESGGGLVQPGGSLRLSCAASGFNFSSFWMHWVRQAPGKGLVWVSRIDSAGATTTYADSVKGRF

TISRDNANNTLYLQMSSLRAEDTAVYYCARLSSAPWSGFYVWHANWFDPWGQGTLVTVSS

544 223

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

545 224

EVHLVESGGGLVKPGESLRLSCEASGFTFTNAWMSWVRQAPGKGLEWIGRIKGESEGGTADYAAPVKG

RFSMSRDNSKNIVYLQMNSLKTEDTATYYCVTELGTALWVIDYFDNWGQGTLVTVSS

546 224

QSVLTQPPSASGSPGQSVTISCTGTSRDVGGYDFVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSK

SGNRASLTVSGLQAEDEADYYCSSYAGNNI LFGGGTKLTVL

547 225

EVQLLESGGGVVQPGGSVRLSCAASGFTFISYAMSWVRQAPGKGLEWVSAVSVSGGTTYYADSVKGRF

TISRDNSKKTLYLQMNSLRAEDTAVYYCAKEGVEMTRSFGYYFDHWGRGTLVTVSS

548 225 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQAPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

549 226

EEQLVESGGGLVQPGGSLRLSCAASGFNFSSFWMHWVRQAPGKGLVWVSRIDSAGATTTYADSVKGRF

TISRDNANNTLYLQMSSLRAEDTAVYYCARLSSAPWSGFYVWHANWFDPWGQGTLVTVSS

550 226

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

551 227

EVQLVESGGALVQPGGSLRLSCAASGSIVNNNYMNWVRQAPGKGLEWVSVIYKGGNTYYADSVKGRFT

ISRDNSKNMVYLQMNRLRAEDTAVYYCARALLGGTPNGPTNAWYWFHPWGLGTLVTVSS

552 1T1

DTQMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASSVESGVPSRFSGSGSG

TEFTLTISSLQPDDLGTYYCQQYSTYSTFGQGTKVDIK

553 228

QVQLQQSGPGLVKPSQTLSLTCTISGDTVSSNSASWNWIRQSPSRGLEWLGRTKYRSKWYYDYAVSVK

SRISINPDTSKNQFSLQLNSVTPEDTAVYYCARGLDIPPDGIVGFDFWGQGTLVTVSS

554 228

DTQMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASSVESGVPSRFSGSGSG

TEFTLTISSLQPDDLGTYYCQQYSTYSTFGQGTKVDIK

555 229

QLQLQESGPGLVKSSEPLFLTCTVSGASISSSNYYWGWIRQPPGKGLEWIGSIYYSETTYYNPSLESR

VTISVDTSKHQFSLIVTSMTAADTAVYYCAGLRRGGNWFDPWGQGTLVTVSS

556 229

DIQMTQSPSTLSASVGDRVSITCRASQSISTWLAWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSG

TVFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIK

557 230

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

558 230

DIQMTQSPSSLSASVGDRVSLTCRSSQTIYNYLNWYQQQPGKAPKLLIYAASTLHRGVPSRFSGSGSG

THFTLSISSLQHEDFATYYCQQNYLTPPWTFGPGTRVEVN

559 231

EVQLVESGGGWTGPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

560 231

QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

561 232

QIQLQESGPGLVKPSQTLSLTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

562 232

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

563 233

EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

564 233

QSALTQPPSASGSPGQSVTISCTGSRSDIGGYNYVSWYQHHPGKGPKLMIYEVSRRPSGVPDRFSGSK

SGNTASLTVSGLQADDEANYYCSSYGGSTNVI FGGGTKLTVL

565 234

QVQLVESGGGLVKPGGSLRLPCAASGFTFSDYYMSWIRQAPGKGLEWFSYISSSGSTIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRVRYSLFYYFDYWGQGTLVTVSS

566 234 QSALTQPPSASGSPGQSVTISCTGTSRDVGGYDFVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSK

SGNRASLTVSGLQAEDEADYYCSSYAGNNI LFGGGTKLTVL

567 235

QLQLQESGPGLVKPSETLSLTCTVSGGSIRSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

VTISVDTSKNQFSLKLSSVTAADTAVYYCAYYDFWSGLVWGKGTTVTVSS

568 235

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPPWTFGQGTKVEIK

569 236

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMVWVRQSPGKGREWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

570 236

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

571 237

QIQLQESGPGLVKPSQTLSLTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

572 237

QSVVTQPPSASGTPGQSVTISCSGSTSNIASSDVYWYQHLPGAAPNLLIYKNNQRPSGVPDRFSGSKS

GTSASLAISGLRAEDEANYYCATWDDSLRGPI FGGGTKLSVI

573 238

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

574 238

QSVLTQPPSASGSPGQSVTISCTGSRSDIGGYNYVSWYQHHPGKGPKLMIYEVSRRPSGVPDRFSGSK

SGNTASLTVSGLQADDEANYYCSSYGGSTNVI FGGGTKLTVL

575 239

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS

576 239

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

577 240

EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

578 240

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

579 241

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

580 241

DTQMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASSVESGVPSRFSGSGSG

TEFTLTISSLQPDDLGTYYCQQYSTYSTFGQGTKVDIK

581 242

QIQLQESGPGLVKPSQTLSLTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

582 242

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

583 243

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

584 243 QSALTQPPSASGSPGQSVTISCTGTSRDVGGYDFVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSK

SGNRASLTVSGLQAEDEADYYCSSYAGNNI LFGGGTKLTVL

585 244

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

586 244

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

587 245

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWMRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCARGALTMVRAVEYFQHWGQGTLVTVSS

588 245

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLTVL

589 246

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

590 246

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYDVSNRPSGVSDRFSGSK

SDNTASLTISGLQAEDEADYYCNSYTSTSTLVFGGGTKLTVL

591 247

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

592 247

QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

593 248

QVQLVQSGAEVMQVGASVKLSCEASGYKFTSYTMHWVRQAPGQRVEWMGWISVGNGNTKYSQKFQGRV

TITRDTSANTAYMEVRSLRSEDTAVYYCAREGYGSGTYFDYWGQGTLVTVSS

594 248

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYDVSNRPSGVSDRFSGSK

SDNTASLTISGLQAEDEADYYCNSYTSTSTLVFGGGTKLTVL

595 249

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

596 249

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQAPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

597 250

QLQLHESGPRLLKPSETLSLTCTVSGGSISNSNFCWGWIRQPPGKGLEWIGSVFYGGTTYYNPSLKSR

VALSLDASENQFSLKVTSVTAADTAMYYCARTRGRLYDYVGWYYYMDVWGRGTTVTVSS

598 250

KIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQVPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

599 251

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

600 251

QSVLTQPRSASGTPGQRVTISCSGSRSNIGRNTVNWYQQLPGTAPKLLI FGNDQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDTLNGLYVFGTGTKVTVL

601 252

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTTDFDYWGQGALVTVSS

602 252 KIVLTQSPGTLSVSPGERVTLSCRTSQSVSNNYLAWYQHKPGQAPRLLIYGASSGASDIPDRFSGGGS

GTDFTLTISRLEPEDFAVYYCQQYGTSPWTFGQGTKVEIK

603 253

EVQLVQSGAEVKKPGESLRISCKASGYSFANYWINWVRQMPGEGLEWLGRIDPSDSYTNYSPSFQGHV

TISTDTSISTVYLQWRSLKASDTAMYYCARPAAEVVPDSLVEDPFNVWGQGTMVTVSS

604 253

QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL

605 254

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

606 254

QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

607 255

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

608 255

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

609 256

EVQLVESGGGLVQPGGSLRLSCVASGFPFDNSAMHWVRQAPGKGLEWVSGINWNSVTMDYGDSVKGRF

TISRDYAKNSVYLQMNNLRI EDTALYYCAKADCSSTSCFMDVWGRGTTVTVSS

610 256

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQAPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

611 257

QVQLVQSGAAVKKPGAAVKVSCKPSGYTFASHDINWVRQATGQGLEWMGWMNPKSGNTGYAQKFRGRL

TMTRNASTTTAYMEMTGLTSEDSAVYYCARGRVGKPQDYYYHLDVWGKGTTVTVSS

612 257

QSVLTQPPSVSGAPGQKVTISCTGGSSNIGADYDVHWYQHLPETAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEADYYCQSYDSSLGGSYVFGTGTKVTVL

613 258

QVQLVESGGGLVKPGGSLRLSCAASGFI FSDYYMSWIRQAPGKGLEWVSYISGSGGTIHYADSVRGRF

TISRDNAKNSLYLQVNSLRAEDTAVYYCARELVPVAMRHYYFYGMDVWGQGTTVTVSS

614 258

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEADYYCQSYDRSLSGPVVFGGGTKLTVL

615 259

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

616 259

QSALTQPRSVSGSPGQSVTISCTGTSSDVGSNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSK

SDNTASLTISGLQAEDEADYYCCSYTGSRVVFGGGTKLTAL

617 260

EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

618 260

QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

619 261

QIQLQESGPGLVKPSQTLSLTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

620 261 QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

621 262

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

622 262

DIQMTQSPSSVSASIGDRVTITCRASQGINRWLPWYQQKPGKAPRLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFCNLLLSTGSDFPPHFRRRDQGGDQ

623 263

EVQLVESGGGLVQPGGSLRLSCVASGFPFDNSAMHWVRQAPGKGLEWVSGINWNSVTMDYGDSVKGRF

TISRDYAKNSVYLQMNNLRI EDTALYYCAKADCSSTSCFMDVWGRGTTVTVSS

624 263

QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

625 264

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

626 264

EIVMTQSPATLSVSPGEKATLSCKASQSLSSDLAWYQQKRGQAPRLLIYGASTRASGIPARFSGSGSG

TEFTLTITSLQSEDFQVYYCQQYNNWPPTFGLGTKVEIN

627 265

EVQLVESGGGLVQPGGSLRLSCVASGFPFDNSAMHWVRQAPGKGLEWVSGINWNSVTMDYGDSVKGRF

TISRDYAKNSVYLQMNNLRI EDTALYYCAKADCSSTSCFMDVWGRGTTVTVSS

628 265

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYDVSNRPSGVSDRFSGSK

SDNTASLTISGLQAEDEADYYCNSYTSTSTLVFGGGTKLTVL

629 266

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

630 266

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYDVSNRPSGVSDRFSGSK

SDNTASLTISGLQAEDEADYYCNSYTSTSTLVFGGGTKLTVL

631 267

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

632 267

DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMQTIQLPPYTFGQGTKLEIK

633 268

EVQLLESGGGLVQPGGSLRLSCAASGFRFSSYAMSWVRQAPGKGLEWVSAISGSGGNTYYADSVKGRF

TISRDNSKNTLYLQMSSLRVGDTAIYYCAKRDSAPYPDSFDYWGQGTLVTVSS

634 268

EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSESG

TELTLTISSLQSEDFAVYYCQYRGTFGQGTKLEIK

635 269

QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRF

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVLRVRYSLFYYFDYWGQGTLVTVTS

636 269

QSALTQPASVSGSPGQSITISCTGTSSDIGGYDYVSWYQQHPDTAPKLIIYDVYNRPSGVPDRFTASK

SDNTASLTISGLQAEDEADYFCSSYANVNTI LFGGGTKVTVL

637 270

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

638 270 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRFLIYGASSRATGIPDRFSGSGS GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

639 271

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISYVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREYTVGGI FGFWGQGTLVTVSS

640 271 EVVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGFPARFSGSGSG

TEFTLTISSLQSEDFAIYHCQQYNNWPLTFGGGTKVEIK

641 272 QVQLVQSGAAVKKPGAAVKVSCKPSGYTFASHDINWVRQATGQGLEWMGWMNPKSGNTGYAQKFRGRL

TMTRNASTTTAYMEMTGLTSEDSAVYYCARGRVGKPQDYYYHLDVWGKGTTVTVSS

642 272 EIVMTQSPATLSVSPGERVTLSCRASQSVGSNLAWYQQKPGQAPRLLIYGASSRAAGIPDRFRGTGSG

TEFTLTISNLQSEDFAVYYCQQYENWPPWTFGQGTKVEIK

643 273 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPI LGIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDAIVVVNYYYGMDVWGQGTTVTVSS

644 273

DIQMTQSPLLLLWLPGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASSVESGVPSRFSGSGSG

TEFTLTISSLQPDDLGTYYCQQYSTYSTFGQGTKVDIK

645 274

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLKNWFDAWGQGTLVTVTS

646 274

QSVLTQPRSASGTPGQRVTISCSGSRSNIGRNTVNWYQQLPGTAPKLLI FGNDQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDTLNGLYVFGTGTKVTVL

647 275

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

648 275

EIVLTQSPGTLSLSPGERAI LSCRASQTVISGYLAWYQQKPGQTPRLLISGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

649 276

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQV

TISADKSISTAYLQWSSLKASDTAMYYCARKDIYYYYMDVWGKGTTVTVSS

650 276 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEADYYCQSYDSSLSGPVVFGGGTKLTVL

651 277 QVQLVQSGTEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPI LGIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDAIVVVNYYYGMDVWGQGTTVTVSS

652 277 QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

653 278

EVQLVESGGGLVKPGGSLRLSCAASGLTFSNAWMNWVRQAPGKGLEWVGRIKSKADGGTTDYAVPVKD

RFTISRDDSKNTLFLQMNSLKTEDTAVYYCTTITGSTYSFRFSTYYYYYYYLDVWGKGTTVTVTS

654 278

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

655 279

EVQLVESGGGLVQPGGSLRLSCVASGFPFDNSAMHWVRQAPGKGLEWVSGINWNSVTMDYGDSVKGRF

TISRDYAKNSVYLQMNNLRI EDTALYYCAKADCSSTSCFMDVWGRGTTVTVSS

656 279 EIVLTQSPGTLSLSPGERATLSCRASQSVSSIYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS GTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK

657 280

EEQLLESGGGLVKPGGSLSLSCTASGFVFRSYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVIGESLENWFDAWGKGTLVTVTS

658 280 QSVLTQPPSVSGALGQRVTISCTGTSSNIGARYDVYWYQQFSGRAPKLLIYGNMNRASGVPDRFSGSK

SGTSASLAITGVQPEDEADYFCQSFDTRLNMVLFGGGTKLTVL

659 281 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPI LGIANYAQKFQGRV

TITADKSTSTAYMELSSLRSEDTAVYYCARDAIVVVNYYYGMDVWGQGTTVTVSS

660 281 DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMQTIQLPPYTFGQGTKLEIK

661 282 EVQLVESGGGLVKPGGSLRLSCAASGLTFSNAWMNWVRQAPGKGLEWVGRIKSKADGGTTDYAVPVKD

RFTISRDDSKNTLFLQMNSLKTEDTAVYYCTTITGSTYSFRFSTYYYYYYLDAWGQGTLVTVTS

662 282

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPPWTFGQGTKVEIK

663 283 EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVLE

664 283 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGYTFGQGTKLEIK

665 284 EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

666 284 PSVLTQLRSASGPPGQRVTISWSGSRSHIGSNPVNWYQPLPGPAHKLLI FGNDQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDTLNGLYVFGTGI FFFKQ

667 285 QVQLVQSGAEVMQVGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGLINPNSGGTNYAQKFQGWV

TMTRDTSISTAYMELSRLRSDDTAVYYCARDGSGVVPAAISSYYYYGMDVWGQGTTVTVSS

668 285

EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

669 286 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPI FGTANYAQKFQGRV

TITADESTSTAYMELSSLRSEDTAVYYCALVTAIPPYYFDYWGQGTLVTVSS

670 286 QSVLTQPPSASGTPGQTVTISCSGSSSNIGSNYVYWYQQVPGTAPQLLIYRNNQRPSGVPDRFSGSKS

GTSASLAISGLRSGDEADYYCAAWDDSLSGHVVFGGGTKVTVL

671 287

QVQLQQWGAGLLKPSETLSLTCGVYGGSFTGYYWSWIRQAPGKGLEWIGEINHNGRSTNYNPSLKSRV

TISVDTSNNQFSLKVRSVTAADTAVYYCARERDYNHYYYWHMDVWGKGTTVTVSS

672 287 EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

673 288 QVQLVQSGAEVKKPGASVKLSCKASGYSFTTYTMSWVRQAPGRGLEWMGWINPANGHTEYMERFRGRV

TITRDTSASTAYMELSSLTSEDTTIYFCARIYCSGDHCYDYWGQGI LVTVSS

674 288 EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

675 289

QVQLVQSGAEVKKPGASVKVSCTTSGFI FISHYMHWVRQAPGQGLEWMGIITPANTTKYSQRFQGRVT

MTSDASTSTVYMELSSLRSEDTAVYYCAREWGELDSSVFDYWGQGTLVTVSA

676 289

QSVLTQSPSASASLGASVKLTCTLSSGHTNYAIAWHQQQPDKGPRFLMRLNSDGSHIKGDGIPDRFSG

SSSGPERYLTISSLQSEDEADYYCQTWGTGTQVFGTGTKVTVL

677 290

QVQLVQSGAEVMQVGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWV

TMTRDTSISTAYMELSRLRSDDTAVYYCARDGSGVVPAAISSYYYYGMDVWGQGTTVTVSS

678 290

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSNWVFGGGTKLTVL

679 291

QVQLVQSGAEVMQVGASVKVSCKASNYTFTSFGINWVRQAPGQGLEWMGWISPYNGNTNYAQDLQGRV

TMTTDTSTSTAYMELRSLRSDDTAVYYCARERDHNYSNFYYYYGMDVWGQGTTVTVSS

680 291

EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

681 292

QVQLVQSGAEVMQVGASVKVSCTTSGFI FISHYMHWVRQAPGQGLGWMGIITPANTTKYSQRFQGRVT

MTSDASTSTVYMELSSLRSEDTAVYYCAREWGELDSSVFDYWGQGTLVTVSA

682 292

EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

683 293

EVQLVESGGGLVKPGGSLRLSCAASI FTFSDYTMNWVRQAPGKGLEWVSSISSTGTYIYYAGSVRGRF

TISRDNAKKLLYLQMNGLRAEDTAVYYCTRELTTVTRFRYWFDPWGQGTQVTVSS

684 293

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGFDVHWYQQLPGTAPKLLIYDNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEAHYYCQSYDSTLIGSVFGGGTKLTVL

685 294

EVQLVQSGAEVKKPGESLKISCKVSGYNFASYCIGWVRQMPGKGLEWMGII FPGDSDTRYSPSFQGQV

TFSADKSISTAYLQWSSLKASDTAMYYCARGRVLVRGVISEDYFDYWGHGTLVTVSS

686 294

QSVLTQSPSASASLGASVKLTCTLSSGHTNYAIAWHQQQPDKGPRFLMRLNSDGSHIKGDGIPDRFSG

SSSGPERYLTISSLQSEDEADYYCQTWGTGTQVFGTGTKVTVL

687 295

EVQLVQSGAEVKKPGESLKISCKGSGYSFPNYWIGWVRQMSGQGLEWMAIIYPGNSDTRYSPSLQDQV

TISADKSISTAYLQWSSLKASDTAMYFCARLSYFGSGTYYPFDYWGQGTLVTVSS

688 295

EIVLTQSPGTLSLSPGERVTLSCRTSQSVSGDYLAWYRQKPGQPPRLLVYRTSSRATGIPDRFSGSGS

RTDFTLSISGLEPEDFAVYYCQHYGSSHYTFGQGTKLEIK

689 296

QVQLVQSGAEVMQVGASVKVSCKAYGYTFSTHGISWVRQAPGQGLEWMGWISAYNGDTKFAQKVQGRV

TMTTDTSTSTAYMELRSLRSDDTAMYFCAREGADYGDRESMDAFDIWGRGTMVTVSS

690 296

QSVLTQPPSVSGAPGQRVAFSCTGSSSNIGAGFDVHWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSK

SGTSASLAITGLQVEDEADYYCQSYDSSLSWVFGGGTKLTVL

691 297

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

692 297 EIVLTQSPGTLSLSPGERATLSCRASQSVRGTYLAWYQQKPGQAPRLVIYAASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKLEIK

693 298

QVQLVQSGAEVKKPRPSLKVSCKASGGTFTGYAISWVRHAPGQGLQWLGGIIPI FGTANYAQKFQGRV

TITADESTSTAYMELSSLRSEDTAVYYCALVTAIPPYYFDYWGQGTLVTVSS

694 298

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL

695 299

QVQLQESGPGLVKPSETLSLTCTVSGASVTSNNYYWSWVRQPPGKGLEWIGHISYRGITNYIPSLKSR

VTISADTSKNQFSLNLKSVIDADTAVYYCVREDLVSQSRYYYYYMDVWGKGTTVTVSS

696 299

EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGTPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

697 300

QVQLVQSGAEVMQVGASVKVSCKASGYTFTLYAMHWVRQAPGQRLEWLGWINAGNGDTKYSQKFQGRV

TITRDTPASTAYMELSSLRSEDTAIYYCARDKEGWNDPNYFDFWGQGTLVTVSS

698 300

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGVSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

699 301

QVQLVQSGAEVMQVGASVKVSCKASGYTFTLYAMHWVRQAPGQRLEWLGWINAGNGDTKYSQKFQGRV

TITRDTPASTAYMELSSLRSEDTAIYYCARDKEGWNDPNYFDFWGQGTLVTVSS

700 301

QSVLTQPPSLSAAPGQKVTISCSGSSKIDYVSWYQQFPGTAPKLLIYDNSHRPSGIPDRFSGSKSGTS

ATLGITGLQTGDEADYYCGTWDSRLNVYVFGPGTKVTVL

701 302

EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

702 302

DIQVTQSPSTLSASVGDRVTITCRGSQRLTNWLAWYQQKPGKAPKLLIYKASI LHSGVPSRFSGSESG

TEFTLTISSVQPDDFATYYCQHYDTYWTFGQGTKVEIK

703 303

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARDRTPYSSGWYVGYWGQGTLVTVSS

704 303

EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGTPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

705 304

QVQLVQSGAEVKKPGSSVTVSCKASGGTFSSYGLSWVRQAPGQGPEWMGGIIPI LGKPTYAPKFQGRV

TITADESTSTAYLELSSLRSEDTATYYCARGGDYTGSYYDYYYYYMDVWGKGTTVTVSS

706 304

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGFSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

707 305

QVQLVQSGAEVMQVGASVKVSCKASGYTFINYGISWVRQAPGQGLEWMGWISTYNGNTDFAQKLQGRF

TMTTDTSASTAYMEVRSLRSDDTAVYYCARDRRLGTPASGWTADYSYSYMDVWGTGTTVTVSS

708 305

EIVLTQSPATLSLSLGERATLSCRASQSVRRYLAWFQQRPGQSPRLLIYDASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAIYYCQQRSHWPKYTFGQGTKLEIK

709 306

EVQLVESGGDLVQPGGSLRLSCAASGFSFSSFSMTWVRQAPGKGLEWVAYISGNGYIIYYTDSVKGRF

TISRDNARNSLYLQLNSLRAEDTAVYFCASWVDSRGYYYVDYFDNWGQGTLVTVSS EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGTPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

711 307

EEKLLESGGGLVKPGGSLRLSCTASGFVFKNYVMSWVRRAPGRGLEWISGIRGGDQMTFYANSVKGRF

IISRDNVKNMVHLQMNDLRDDDTAIYYCTKVVVESLENWFDAWGQGTLVTVTS

712 307

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGRTKLTVL

713 308

QVQLVQSGAEVKKPGSSVTVSCKASGGTFSSYGLSWVRQAPGQGPEWMGGIIPI LGKPTYAPKFQGRV

TITADESTSTAYLELSSLRSEDTATYYCARGGDYTGSYYDYYYYYMDVWGKGTTVTVSS

714 308

EIVLTQSPDTLSLSPGERATLSCRASQSVSNNRRLAWYQRKPGQAPRLLIYGASVRATGIPDRFSGSE

SGTDFTLTISRLEPEDFGVYYCQQYGNSPPTFGQGTKVELK

715 309

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARDRTPYSSGWYVGYWGQGTLVTVSS

716 309

QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSYTFVVFGGGTKLTVL

717 310

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKWLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS

718 310

EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGTPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

719 311

EVHLVESGGGLVKPGESLRLSCEASGFTFTNAWMSWVRQAPGKGLEWIGRIKGESEGGTADYAAPVKG

RFSMSRDNSKNIVYLQMNSLKTEDTATYYCVTELGTALWVIDYFDNWGQGTLVTVSS

720 311

QSVLTQPPSLSAAPGQKVTISCSGSSKIDYVSWYQQFPGTAPKLLIYDNSHRPSGIPDRFSGSKSGTS

ATLGITGLQTGDEADYYCGTWDSRLNVYVFGPGTKVTVL

721 312

EVQLLESGGGLVQPGGSLRLSCAASGFTFNIYAINWVRQAPGKGLEWVSSISGSGDSAYYADSVKGRF

TISRDNSKNTVFLQMNSLTAEDTAVYYCAKQYCTNGVCYTDYYFYNHMDVWGKGTTVTVSS

722 312

QSALTQPASVSGSPGQSITISCTGTSSDVVTYNLVSWYQQHPGKAPKLIIYEATKRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGTSSVVFGGGTKLTVL

723 313

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

724 313

QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSYTFVVFGGGTKLTVL

725 314

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

726 314

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGVSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

727 315

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

728 315 DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLYPGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQTLTFGGGTKVEIK

729 316

EVHLVESGGGLVKPGESLRLSCEASGFTFTNAWMSWVRQAPGKGLEWIGRIKGESEGGTADYAAPVKG

RFSMSRDNSKNIVYLQMNSLKTEDTATYYCVTKLGTALWVIDYFDNWGQGTLVTVSS

730 316

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGVSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

731 317

EVQLVESGGDLVQPGGSLRLSCAASGFSFSSFSMTWVRQAPGKGLEWVAYISGNGYIIYYTDSVKGRF

TISRDNARNSLYLQLNSLRAEDTAVYFCASWVDSRGYYYVDYFDNWGQGTLVTVFL

732 317

QSVLTQPPSLSAAPGQKVTISCSGSSKIDYVSWYQQFPGTAPKLLIYDNSHRPSGIPDRFSGSKSGTS

ATLGITGLQTGDEADYYCGTWDSRLNVYVFGPGTKVTVL

733 318

QVQLQQKGAALLKPSETLSLTCGVSGGTFSDYHWTWVRQPPGKGLEWIGKINHGGSTNYNPTLKSRVS

ISIDTSKSQFSLKMTSLTAADAAVYFCARLREGRALRLTSQPRYSYYHMDVWGKGTTVTVSS

734 318

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGRTKLTVL

735 319

EVQLLESGGGSVQPGGSLRLSCAASGFSFSSYVMGWVRQAPGKGLEWVSAISGSGGSTYYANSVKGRF

TISRDNSKNTLSLQMNSLRVEDTAVFYCAKEATGDCGGDCVRWFDPWGQGTLVTVSS

736 319

DIQMTQSPSSVSASIGDRVTITCRASQGINRWLAWYQQKPGKAPRLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYSCQQAQTFPLTFGGGTKVEIK

737 320

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

738 320

QSVLTQPPSLSAAPGQKVTISCSGSSKIDYVSWYQQFPGTAPKLLIYDNSHRPSGIPDRFSGSKSGTS

ATLGITGLQTGDEADYYCGTWDSRLNVYVFGPGTKVTVL

739 321

EVHLVESGGGLVKPGESLRLSCEASGFTFTNAWMSWVRQAPGKGLEWIGRIKGESEGGTADYAAPVKG

RFSMSRDNSKNIVYLQMNSLKTEDTATYYCVTELGTALWVIDYFDNWGQGTLVTVSS

740 321

DIQMTQSPSPLSASVGDRVTIYCRASQSISNFLNWYQQRPGKAPKLLIYATSSLQSGVSSRFSGHGFG

TEFTLTISSLQPEDFATYYCQQSYTTSQLTFGPGTKVEIK

741 322

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYTDSVKGRF

TISRDNSINTLYLQMNSLRAEDSAVYYCAKDRDRSAYNYGPAMAREYFQHWGQGTLVTVSS

742 322

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGVSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

743 323

EVQLVESGGDLVQPGGSLRLSCAASGFSFSSFSMTWVRQAPGKGLEWVAYISGNGYIIYYTDSVKGRF

TISRDNARNSLYLQLNSLRAEDTAVYFCASWVDSRGYYYVDYFDNWGQGTLVTVSS

744 323

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSLYTFGQGTKLEIK

745 324

EVQLVESGGGSVQPGGSLRLSCTTSGFSFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVEGRF

TISRDNAKNSLYLQMNSLRAEDTAVYFCARDQLGGAVVPADYFDYWGQGTLVTVSS

746 324 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGN

TATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL

747 325

QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYTMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDVI EYSGSSEYYGMDVWGQGTTVTVSS

748 325

SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGN

TATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL

749 326

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARDRTPYSSGWYVGYWGQGTLVTVSS

750 326

DIQMTQSPSSLSAYVGDRVTITCRTSQSISSYLNWYKQKPGEAPKLLMYAASTLQSGVPSRFSGRGSG

TDFTLTISNLQADDSATYYCQQSYSTPPTFGQGTKVEIK

751 327

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARDRTPYSSGWYVGYWGQGTLVTVSS

752 327

QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLMIYDVSNRPSGVSNRFSASK

SGNTASLTISGLQAEDEGDYYCSSYTSRSTLVFGGGTKLTVL

753 328

QVQLVQSGAEVMQVGASVKVSCKASGYTFTLYAMHWVRQAPGQRLEWLGWINAGNGDTKYSQKFQGRV

TITRDTPASTAYMELSSLRSEDTAIYYCARDKEGWNDPNYFDFWGQGTLVTVSS

754 328

QSVLTQPPSVSAAPGQNVTISCSGSSSNIGNYLVSWYQHLPGTAPKLLIYDNNKRPSGIPDRFSGSKS

GTSATLGITGLQTGDEGDYFCGTWDNSLSGGVFGGGTKLTVL

755 329

EVQLVESGGGSVQPGGSLRLSCTTSGFSFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVEGRF

TISRDNAKNSLYLQMNSLRAEDTAVYFCARDQLGGAVVPADYFDYWGQGTLVTVSS

756 329

EIVLTQSPATLSLSPGERATLSCRASVNIAMSLAWFQQKPGQVPRLLIYDASHRATGIPARFSGSGSV

TDFTLTISSLEAEDFAVYYCQQRASWPKVTFGGGTKVEIT

757 330

QVQLQQKGAALLKPSETLSLTCGVSGGTFSDYHWTWVRQPPGKGLEWIGKINHGGSTNYNPTLKSRVS

ISIDTSKSQFSLKMTSLTAADAAVYFCARLREGRALRLTSQPRYSYYHMDVWGKGTTVTVSS

758 330

EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGTPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK

759 331

QVQLVESGGGVVQPGRSLRLSCAASGFTLRNYAMHWVRQAPGKGLEWVAVLSYDGNNKKYADSVKGRF

TISRDISNNTLYLHMDSLRAEDRAVYYCARYRTPYSSGWYVGYWGQGTLVTVSS

760 331

EIVLTQSPATLSLSPGERATLSCRASVNIAMSLAWFQQKPGQVPRLLIYDASHRATGIPARFSGSGSV

TDFTLTISSLEAEDFAVYYCQQRASWPKVTFGGGTKVEIT

761 332

AVQLLESGGGLIQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSAISHSSDSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSGSSWSLLYFDYWGQGTLVTVSS

762 332

QSVVTQPPSASGTPGQSVTISCSGSTSNIASSDVYWYQHLPGAAPNLLIYKNNQRPSGVPDRFSGSKS

GTSASLAISGLRAEDEANYYCATWDDSLRGPI FGGGTKLSVI

763 333

EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

764 333 DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWHQQKPGKAPNLLIYEASSLESGVPSRFSGSGSG

TEFTFTISSLQPDDFATYYCQHYKSYPLTFGGGTKVEIK

765 334

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

766 334

EIVLTQSPGTLSLSPGERATLSCRASQNVIRDYLAWYQQKPGQAPRLLI FGTSNRATGIPDRFSGSGS

GTDFTLTINRLAPDDFAVYYCQHYGSSLFTFGPGTKLDIK

767 335

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISHVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREHTVGGI FGFWGQGTLVTVSS

768 335

QSVLTQPPSASGTPGQRVTISCSGSSSNIGSYTVNWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDSLNGHVVFGGGTKLTVL

769 336

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

770 336

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

771 337

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISYVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREYTVGGI FGFWGQGTLVTVSS

772 337

QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSYTHVVFGGGTKLTVL

773 338

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCARGALTMVRAVEYFQHWGQGTLVTVSS

774 338

DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWHQQKPGKAPNLLIYEASSLESGVPSRFSGSGSG

TEFTFTISSLQPDDFATYYCQHYKSYPLTFGGGTKVEIK

775 339

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYSMDVWDQGTTVTVSS

776 339

DIQMTQSPSTLSASVGDRVSITCRASQSISTWLAWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSG

TVFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIK

777 340

EVQLLESGGGLVQPGGSLRLSCAASGFTFNIYAINWVRQAPGKGLEWVSSISGSGDSAYYADSVKGRF

TISRDNSKNTVFLQMNSLTAEDTAVYYCAKQYCTNGVCYTDYYFYNHMDVWGKGTTVTVSS

778 340

QSVLTQPPSASGTPGQRVTISCSGSSSNIGSYTVNWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKS

GTSASLAISGLQSEDEADYYCAAWDDSLNGHVVFGGGTKLTVL

779 341

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCARGALTMVRAVEYFQHWGQGTLVTVSS

780 341

QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSK

SGNTASLTISGLQAEDEADYYCCSYAGSYTHVVFGGGTKLTVL

781 342

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARAPRTTVTTGRWFDPWGQGTLVTVSS

782 342 EVVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGFPARFSGSGSG

TEFTLTISSLQSEDFAIYHCQQYNNWPLTFGGGTKVEIK

783 343 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

784 343

QSVVTQPPSASGTPGQSVTISCSGSTSNIASSDVYWYQHLPGAAPNLLIYKNNQRPSGVPDRFSGSKS

GTSASLAISGLRAEDEANYYCATWDDSLRGPI FGGGTKLSVI

785 344

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARLRRDIVVVPAANRGGGSSWQNYYYYYMDVWGKGTTVTVS S

786 344

AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISCLQSEDFATYYCQQYYSYPRTFGQGTKVEIK

787 345

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARMFSSSGHFDYWGQGTLVTVSS

788 345

QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTPVFGGGTKLTVL

789 346

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVTFDIWGQGTMVTVSS

790 346 EIVMTQSPATLSVSPGERATLSCRASQSISTNLAWYQQKPGQAPRVLIYGASTRATDVPDRFSGTGSG

TDFTLTISSLQSEDFAIYYCQQYHNWPPETFGQGTKVEIK

791 347

QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRV

TISVDKSKNQFSLKLSSVTAADTAVYYCARDEGGVGGWFDPWGQGTLVTVSS

792 347

EIVLTQSPGTLSLSPGERATLSCRASQNVIRDYLAWYQQKPGQAPRLLI FGTSNRATGIPDRFSGSGS

GTDFTLTINRLAPDDFAVYYCQHYGSSLFTFGPGTKLDIK

793 348

KIQLQESGPGLVKPSQTLSPTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

794 348 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

795 349

EVHLVESGGGLVKPGESLRLSCEASGFTFTNAWMSWVRQAPGKGLEWIGRIKGESEGGTADYAAPVKG

RFSMSRDNSKNIVYLQMNSLKTEDTATYYCVTELGTALWVIDYFDNWGQGTLVTVSS

796 349

DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPENFATYYCQQSYSAPHTFGPGTKVDIK

797 350

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

798 350

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

799 351

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS 800 351

EVVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGFPARFSGSGSG

TEFTLTISSLQSEDFAIYHCQQYNNWPLTFGGGTKVEIK

801 352

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARAPRTTVTTGRWFDPWGQGTLVTVSS

802 352

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

803 353

EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMHWVRPAPGKGLVVVARISGDGSDADYADSVRGRF

TISRDNAKNTLFLQMNSLRVEDTAVYYCVRDRDVRDCNNGVCHTAYFNYWGQGTLVTVSS

804 353

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

805 354

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

806 354

DIQMTQSPSSVSASIGDRVTITCRASQGINRWLAWYQQKPGKAPRLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYSCQQAQTFPLTFGGGTKVEIK

807 355

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARLRRDIVVVPAANRGGGSRWQNYYYYYMDVWGKGPIGL

808 355

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

809 356

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARLRRDIVVVPAANRGGGSSWQNYYYYMDVWGKGTTVTVSS

810 356

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

811 357

QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVI LDDGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCARASEMATI EDAFDIWGQGTMVTVSL

812 357

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK

813 358

QLQLQESGPGLVNPWETLTLTCSVSGASISSISYNWGWVRQPPGKGLEWIGNIYFTGTTHYNPSLNSR

VTISVDTSRNQFSLTLSSVTAADTAMYYCVREGQTVTTWFDPWGQGTLVTVSS

814 358

EIVLTQSPGTLSLSPGERATLSCRASQNVIRDYLAWYQQKPGQAPRLLI FGTSNRATGIPDRFSGSGS

GTDFTLTINRLAPDDFAVYYCQHYGSSLFTFGPGTKLDIK

815 359

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYATTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCATVKQWLALDYWGQGTLVTVSS

816 359

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

817 360

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS 818 360

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

819 361

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCARGALTMVRAVEYFQHWGQGTLVTVSS

820 361

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

821 362

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

822 362

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISSLQPEDVATYYCQKYNSAPPWTFGQGTKVEIK

823 363

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

824 363

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

825 364

QIQLQESGPGLVKPSQTLSLTCTVSGGSLSSGDYYWSWIRQPPGKGLEWIGYIYYSGSTSHNPSLKSR

VSISVDTSKNQFSLKLSSVSAADTAVYYCARYYYATSGFYERPPGPRFNWFDPWGQGTLVTVSS

826 364

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

827 365

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS

828 365 EVVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGFPARFSGSGSG

TEFTLTISSLQSEDFAIYHCQQYNNWPLTFGGGTKVEIK

829 366

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

830 366

AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISCLQSEDFATYYCQQYYSYPRTFGQGTKVEIK

831 367

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCARGALTMVRAVEYFQHWGQGTLVTVSS

832 367

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

833 368

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS

834 368

DIQMTQSPSTLSASVGDRVSITCRASQSISTWLAWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSG

TVFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIK

835 369

QVQLQESGPGLVKPSETLSLTCTVSTGTVRDNMFYWGWIRQSPGKGLEWIGSVFFLGTTYYNPSFKSR

ATI FVNLSKNQFSLELTSVTAADTAVYYCARENYGDSQRDYHYGMDVWGPGLRVTVSS 836 369

EIVMTQSPATLSVSPGEGVTLSCRASRTISNNVAWFQVKPGQGPRLLIYGASNRAAGIPLRFSGSGSG

TEFTLTISSVQSEDFAVYYCQHYNNWPGYTFGQGTKLDIK

837 370

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISYVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREYTVGGI FGFWGQGTLVTVSS

838 370

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGWKTEDEADYYCHSYDANKRGVFGGGTKLTVL

839 371

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYATTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAGTRPYITVQPSSSGWHLTIGAREPWSPSP

840 371

SYELTQPPSMSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDNKRPSGIPERFSGSNSGN

TATLTISGTQAMDEADYYCQAWDSGTVLFGGGTKLTVL

841 372

EVQLLESGGGLVQPGGSLRLSCAASGFTFNIYAINWVRQAPGKGLEWVSSISGSGDSAYYADSVKGRF

TISRDNSKNTVFLQMNSLTAEDTAVYYCAKQYCTNGVCYTDYYFYNHMDVWGKGTTVTVSS

842 372

EIVLTQSPATLSLSPGERTTLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

843 373

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

844 373

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLGWYQHKPGQAPRLLIYDTSNRATGIPARFSGSGSG

TDFI LTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

845 374

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYATTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCATVKQWLALDYWGQGTLVTVSS

846 374

QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSK

SGTSASLAITGLQAEDEDDYYCQSYDSRLSGWVFGGGTKLTVL

847 375

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSESVAWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVK

SRITINPDTSKNQFSLQVSSMTPEDTAVYYCARVFSSSGHFDYWGQGTLVTVSS

848 375

DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNSLDWYLQKPGQSPQLLIYLGSNRASGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMEALQTPYTFGQGTKLEIK

849 376

QVQLVESGGGVVQPGMSLRLSCAASGFTFNSYAIHWVRQAPGKGLEWVAVISYDETSNFYTDSVKGRF

TISRDNSKNTVYLQMNSLGVDDTAVYYCARDFYPGSGTNWATNRFDPWGQGTLVTVSS

850 376

DIQMTQSPSSLSASVGDRVTITCRASQSVSTYFNWYQHKPGKAPKLLIYAASSLQSGVPSRFTGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK

851 377

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARAPRTTVTTGRWFDPWGQGTLVTVSS

852 377

DIQMTQSPSSLSASVGDRVTITCRASQSVSTYFNWYQHKPGKAPKLLIYAASSLQSGVPSRFTGSGSG

TDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK

853 378

EVQLVESGGGLVQPGGSLRLPCAASGFTFRTYGMNWVRQAPGKGLEWISYISSSGSTIYYADSVKGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGFRRITIRPGNYYYYMDVWGKGTTVTVSS 854 378

SYELTQPPSVSVAPGKTARITCGGDNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGN

TATLTISRVEAGDEADFYCQVWDGSSDHVVFGGGTKLTVL

855 379

EVQLVESGGGLVQPGGSLRLPCAASGFTFRTYGMNWVRQAPGKGLEWISYISSSGSTIYYADSVKGRF

TISRDNAKNSLFLQMNSLRAEDTAVYYCARGFRRITIRPGNYYYYMDVWGKGTTVTVSS

856 379

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

857 380

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCARVLRLGELSFRNWGQGTLVTVSS

858 380

AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISCLQSEDFATYYCQQYYSYPRTFGQGTKVEIK

859 381

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAFISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

860 381

SYELTQPPSVSVSPGQTASITCSGDKLGDKYTSWYHQKPGQSPVLVIYQNTKRPSGIPERFSGSNSGN

TATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL

861 382

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYLSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRIT

ISVATSKNQFSLKLSSVTAADTAVYYCTRARPLGGSGTNYGMDVWGQGSTVTVSS

862 382

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSK

SGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL

863 383

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVT

ISVDTSKNQFSLKLSSVTAADTAVYYCAKADGTSTVTTFSDYWGQGTLVIVSS

864 383

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

865 384

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYATTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF

TISRDNSKNTLYLQMNSLRAEDTAVYYCATVKQWLALDYWGQGTLVTVSS

866 384

EIVMTQSPATLSVSPGEGVTLSCRASRTISNNVAWFQVKPGQGPRLLIYGASNRAAGIPLRFSGSGSG

TEFTLTISSVQSEDFAVYYCQHYNNWPGYTFGQGTKLDIK

867 385

QLQLQESDSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGFIYQSGTTSYNPSLKSR

VTISVDRSKNQFSLKLSSVTAADTAVYYCARELGRGTAFEIWGQGTMVTVSS

868 385

QSALTQPASVSGSPGQSITISCTGTSSDIGAYNYVSWFQQHPGKAPKLMIYDVNYRPSGVPNRFSGSK

SGNTASLTISGLQAEDEADYYCTSYTSSSTLVVFGGGTRLTVL

869 386

EVQLVESGGGLVQTGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVASVKGRF

TISRDNAKKSLYLQMNSLRAEDTAVYYCARDWEGDGSFWSGFFPTPAQKYGMDVWGQGTTVTVSS

870 386

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

871 387

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNRAKSYTTEYAASVKG

RFTISRDDSKNSLYLQMNSLKTEDTAVYYCARARPLGGSGTNYGMDVWGQGTTVTVSS 872 387

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

873 388

QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRFT

ISVATPKNHFSLKLSSVTAADTAVYYCARHFAARPGYFDYWGQGTLVTVSS

874 388

SYELTQPPSVSVSLGQMARITCSGEALPKKYAYWYQQKPGQFPVLVIYKDSERPSGIPERFSGSSSGT

IVTLTISGVQAEDEADYYCLSADSSGTYWVFGGGTKLTVL

875 389

QLQLQESGPGLVKPSETLSLPCTVFGVSISSNSYYWGWIRQPPGKGLEWIGSINYSGNTYYNPSLKSR

VTISVDTFKNQFSLKLSPVTAADTGMFYCARLPPPRGSAAGRYYFDSWGLGTLVTVSS

876 389

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

877 390

QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYHDYALSVK

SRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAAWEGGGYQLVLYYSYYYGMDVWGQGTTVTVSS

878 390

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

879 391

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

880 391

EIVMTQSPATLSVSPGEGVTLSCRASRTISNNVAWFQVKPGQGPRLLIYGASNRAAGIPLRFSGSGSG

TEFTLTISSVQSEDFAVYYCQHYNNWPGYTFGQGTKLDIK

881 392

QLQLVESGGGVVQTGRSLRLSCLASGFTLSGFAMHWVRQTPHKGLEWVAVISSDGGDIYYADSVKGRF

TISRDNFKNTI FLQMNNLRGDDTAVYFCVRPQSQLDRSGSSYFVAFDIWGQGTMVTVSS

882 392

QLVLTQPPSASGSPGQRVTLSCSGGSSNIGKNYVYWYQHVPGTAPRLLIYRDHQRPSGVPDRFSGSKS

GTSASLAISGLRSEDEADYYCAAWDGSLSGPYVFGTGTKVTVL

883 393

QVQLVQSGAEVMQVGASVKVSCKTSGYTFTSYYLHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRV

TMTRDTSTSTVYMELSSLRSEDTAVYYCAREALTMVRAVEYFQHWGQGTLVTVSS

884 393

DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG

TDFTLTISSLQPENFATYYCQQSYSAPHTFGPGTKVDIK

885 394

EEQLVESGGGLVQPGGSLRLSCAASGFNFSSFWMHWVRQAPGKGLVWVSRIDSAGATTTYADSVKGRF

TISRDNANNTLYLQMSSLRAEDTAVYYCARLSSAPWSGFYVWHANWFDPWGQGTLVTVSS

886 394 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSG

TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK

887 395

QVQLEESGAGLVQPGGSRCLSCAASGCTFSSYWMSWVRQAPGKGLEWVGNIKQGGSANYYVASVKGGF

TITRDNAKKSLYLQMNSLGAEDTAVYYCARDWEGDGSFWSGFFPTTAQKYDMDVWGKGTTVTVSS

888 395

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

889 396

QVQLQESGPGLVKPSETLSLTCTVYGGSISSFYWSWIRQPPGKGLEWIGYIYYSGNTNYNPSLKSRVT

ISIDTSKNQFSLKLSSVTAADTAVYYCANSYGTGSYYHWGQGTLVTVSS 890 396

SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGT

MATLTISGAQVEDEADYYCYSTDSSGNHWVFGGGTKLTVL

891 397

QLQLQESGPGLVKPSETLSLPCTVFGVSISSNSYYWGWIRQPPGKGLEWIGSINYSGNTYYNPSLKSR

VTISVDTFKTHFSLKLSPVTAADTGMFYCARLPPPRGSAAGRYYFDSWGLGTLVTVSS

892 397

EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS

GTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK

893 398

QVHLVESGGGVVQPGRSLRLSCAASGFSFSSYGLHWVRQAPGKGLEWVAFISYVGSNKYYADSVKGRF

TISRDNSKNTLYLQMNSLRTEDTAVYYCAREYTVGGI FGFWGQGTLVTVSS

894 398

DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNSLDWYLQKPGQSPQLLIYLGSNRASGVPDRFS

GSGSGTDFTLKISRVEAEDVGVYYCMEALQTPYTFGQGTKLEIK

895 399

QLQLQESDSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGFIYQSGTTSYNPSLKSR

VTISVDRSKNQFSLKLSSVTAADTAVYYCARELGRGTAFEIWGQGTMVTVSS

896 399

EIVLTQSPGTLSLSPGERATLSCRASQNVIRDYLAWYQQKPGQAPRLLI FGTSNRATGIPDRFSGSGS

GTDFTLTINRLAPDDFAVYYCQHYGSSLFTFGPGTKLDIK

897 400

QVQLLESGGGLVQPGGSLSLSCAASGFTFSTYSTTWVRQAPGKGLEWFSAISGSGGSTYYADSVKGRF

TISRDNSKNTVYLRVSSLRAEDTAVYYCAGARPLGGSGTNYGMDVWGQGTTVTVSS

898 400

SFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYENNQRPSGVPDRFSGSID

SSSNSASLTISGLKTEDEADYYCHSYDANKRGVFGGGTKLTVL

899 401

EVQLVESGGGLVQPGGSLRLSCAASGFI FSDHYMDWVRQAPGKGLEWVGRSWRKTESATPDYAASVRG

RFTISRDDSQNSLYLQMDSLKTEDTAVYYCATSVGDTADFDYWGQGALVTVSS

900 401

DIQMTQSPSTLSASVGDRVSITCRASQSISTWLAWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSG

TVFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIK

901 402

QLHLQESGPGLVKPAETLSLTCTVSGASIRSSDYYWVWIRQPPGKGLEWIGSIYHGGSTYYNSSLKSR

VTVSADASTNQFSLRLNSVNAADTAVYYCSSRGLRVPAIWGQGTLVTVPS

902 402

AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSG

TDFTLTISCLQSEDFATYYCQQYYSYPRTFGQGTKVEIK

Ab Ab Antigen Specificity

Index Var 1 1 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

Spike Trimer,

2 1 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2 Spike Trimer,

3 2 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

4 2 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

5 3 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

6 3 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

7 4 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

8 4 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

9 5 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

10 5 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

11 6 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

12 6 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

13 7 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 Spike Trimer,

14 7 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 Spike Trimer,

15 8 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

16 8 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

17 9 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

18 9 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD,

19 10 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

20 10 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

21 11 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

22 11 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

23 12 SARS-CoV-2 RBD,

24 12 SARS-CoV-2 RBD,

25 13 SARS-CoV-2 RBD,

26 13 SARS-CoV-2 RBD,

27 14 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

28 14 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

29 15 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

30 15 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer,

31 16 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2 RBD, SARS-CoV-2 Spike Trimer, 32 16 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

33 17 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

34 17 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

35 18 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

36 18 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

37 19 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

38 19 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

39 20 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

40 20 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

41 21 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

42 21 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

43 22 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

44 22 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

45 23 link CoV,

46 23 link CoV,

47 24 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

48 24 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

49 25 SARS-CoV-1 RBD,

50 25 SARS-CoV-1 RBD,

51 26 link CoV,

52 26 link CoV,

53 27 link CoV,

54 27 link CoV,

55 28 link CoV,

56 28 link CoV,

57 29 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

58 29 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

59 30 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

60 30 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

61 31 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

62 31 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike Trimer,

63 32 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

64 32 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

65 33 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, 66 33 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

67 34 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

68 34 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

69 35 link CoV,

70 35 link CoV,

71 36 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

72 36 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

73 37 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD, SARS-CoV- Spike Trimer,

74 37 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD, SARS-CoV- Spike Trimer,

75 38 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

76 38 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

77 39 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

78 39 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

79 40 link CoV,

80 40 link CoV,

81 41 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

82 41 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

83 42 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

84 42 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

85 43 SARS-CoV-1 RBD,

86 43 SARS-CoV-1 RBD,

87 44 link CoV,

88 44 link CoV,

89 45 link CoV,

90 45 link CoV,

91 46 link CoV,

92 46 link CoV,

93 47 link CoV,

94 47 link CoV,

95 48 link CoV,

96 48 link CoV,

97 49 link CoV,

98 49 link CoV,

99 50 link CoV,

100 50 link CoV,

101 51 link CoV,

102 51 link CoV,

103 52 link CoV,

104 52 link CoV,

105 53 link CoV,

106 53 link CoV, 54 link CoV,

54 link CoV,

55 link CoV,

56 link CoV,

57 link CoV,

58 link CoV,

59 link CoV,

60 link CoV,

61 link CoV,

62 link CoV,

63 link CoV,

64 link CoV,

65 link CoV,

66 link CoV,

67 link CoV,

68 link CoV,

69 link CoV,

70 link CoV,

71 link CoV,

72 link CoV,

73 link CoV,

74 link CoV,

75 link CoV,

76 link CoV,

77 link CoV,

78 link CoV,

79 link CoV,

80 link CoV,

80 link CoV, 81 link CoV,

81 link CoV,

82 link CoV,

83 link CoV,

84 link CoV,

85 link CoV,

86 link CoV,

87 link CoV,

88 link CoV,

89 link CoV,

90 link CoV,

91 link CoV,

92 link CoV,

93 link CoV,

94 link CoV,

95 link CoV,

96 link CoV,

97 link CoV,

98 link CoV,

99 link CoV,

100 link CoV,

101 link CoV,

102 link CoV,

103 link CoV,

104 link CoV,

105 link CoV,

106 link CoV,

107 link CoV,

107 link CoV, 108 Unk CoV,

108 Unk CoV,

109 Unk CoV,

110 Unk CoV,

111 Unk CoV,

112 Unk CoV,

113 Unk CoV,

114 Unk CoV,

115 Unk CoV,

116 Unk CoV,

117 Unk CoV,

118 Unk CoV,

119 Unk CoV,

120 Unk CoV,

121 Unk CoV,

122 Unk CoV,

123 Unk CoV,

124 Unk CoV,

125 Unk CoV,

126 Unk CoV,

127 Unk CoV,

128 Unk CoV,

129 Unk CoV,

130 Unk CoV,

131 Unk CoV,

132 Unk CoV,

133 Unk CoV,

134 Unk CoV,

134 Unk CoV, 135 link CoV,

135 Unk CoV,

136 Unk CoV,

137 Unk CoV,

138 Unk CoV,

139 Unk CoV,

140 Unk CoV,

141 Unk CoV,

142 Unk CoV,

143 Unk CoV,

144 Unk CoV,

145 Unk CoV,

146 Unk CoV,

147 Unk CoV,

148 Unk CoV,

149 Unk CoV,

150 Unk CoV,

151 Unk CoV,

152 Unk CoV,

153 Unk CoV,

154 Unk CoV,

155 Unk CoV,

156 Unk CoV,

157 Unk CoV,

158 Unk CoV,

159 Unk CoV,

160 Unk CoV,

161 Unk CoV,

161 Unk CoV, 323 162 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike T rimer,

324 162 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD, SARS-CoV-2 Spike T rimer,

325 163 Unk CoV,

326 163 Unk CoV,

327 164 Unk CoV,

328 164 Unk CoV,

329 165 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

330 165 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

331 166 Unk CoV,

332 166 Unk CoV,

333 167 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

334 167 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

335 168 Unk CoV,

336 168 Unk CoV,

337 169 Unk CoV,

338 169 Unk CoV,

339 170 Unk CoV,

340 170 Unk CoV,

341 171 SARS-CoV-2 Spike Trimer,

342 171 SARS-CoV-2 Spike Trimer,

343 172 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

344 172 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

345 173 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

346 173 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

347 174 Unk CoV,

348 174 Unk CoV,

349 175 Unk CoV,

350 175 Unk CoV,

351 176 Unk CoV,

352 176 Unk CoV,

353 177 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

354 177 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

355 178 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

356 178 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

357 179 SARS-CoV-1 RBD,

358 179 SARS-CoV-1 RBD,

359 180 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

360 180 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

361 181 Unk CoV,

362 181 Unk CoV,

363 182 Unk CoV,

364 182 Unk CoV,

365 183 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

366 183 SARS-CoV-1 RBD, SARS-CoV-1 Spike Trimer, SARS-CoV-2

RBD,

367 184 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

368 184 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

369 185 Unk CoV,

370 185 Unk CoV, 371 186 SARS-CoV-2 RBD, SARS-CoV-2 Spike T rimer,

372 186 SARS-CoV-2 RBD, SARS-CoV-2 Spike T rimer,

373 187 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

374 187 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

375 188 SARS-CoV-1 RBD,

376 188 SARS-CoV-1 RBD,

377 189 Unk CoV,

378 189 Unk CoV,

379 190 SARS-CoV-1 RBD,

380 190 SARS-CoV-1 RBD,

381 191 Unk CoV,

382 191 Unk CoV,

383 192 SARS-CoV-2 RBD,

384 192 SARS-CoV-2 RBD,

385 193 SARS-CoV-2 RBD,

386 193 SARS-CoV-2 RBD,

387 194 SARS-CoV-2 RBD,

388 194 SARS-CoV-2 RBD,

389 195 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

390 195 SARS-CoV-1 RBD, SARS-CoV-1 Spike T rimer, SARS-CoV-2

RBD,

391 196 Unk CoV,

392 196 Unk CoV,

393 197 Unk CoV,

394 197 Unk CoV,

395 198 Unk CoV,

396 198 Unk CoV,

397 199 Unk CoV,

398 199 Unk CoV,

399 200 SARS-CoV-1 RBD,

400 200 SARS-CoV-1 RBD,

401 201 SARS-CoV-1 RBD,

402 201 SARS-CoV-1 RBD,

403 202 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

404 202 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

405 203 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

406 203 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

407 204 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

408 204 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

409 205 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

410 205 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

411 206 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

412 206 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

413 207 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

414 207 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

415 208 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

416 208 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

417 209 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

418 209 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid,

419 210 Unk CoV,

420 210 Unk CoV, 211 link CoV,

211 Unk CoV,

212 Unk CoV,

213 Unk CoV,

214 SARS-CoV-2 Nucleocapsid ,

215 SARS-CoV-2 Nucleocapsid ,

216 Unk CoV,

217 Unk CoV,

218 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

219 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

220 Unk CoV,

221 SARS-CoV-2 Nucleocapsid ,

222 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

223 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

224 Unk CoV,

225 Unk CoV,

226 Unk CoV,

227 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

228 Unk CoV,

229 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

230 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

231 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

232 Unk CoV,

233 Unk CoV,

234 Unk CoV,

235 Unk CoV,

236 SARS-CoV-2 Nucleocapsid ,

237 Unk CoV,

237 Unk CoV, 238 link CoV,

238 Unk CoV,

239 Unk CoV,

240 Unk CoV,

241 Unk CoV,

242 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

243 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

244 SARS-CoV-2 Membrane,

245 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

246 Unk CoV,

247 Unk CoV,

248 Unk CoV,

249 Unk CoV,

250 Unk CoV,

251 Unk CoV,

252 Unk CoV,

253 Unk CoV,

254 Unk CoV,

255 Unk CoV,

256 Unk CoV,

257 Unk CoV,

258 Unk CoV,

259 Unk CoV,

260 Unk CoV,

261 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

262 Unk CoV,

263 Unk CoV,

264 Unk CoV,

264 Unk CoV, 265 link CoV,

265 Unk CoV,

266 Unk CoV,

267 Unk CoV,

268 Unk CoV,

269 Unk CoV,

270 Unk CoV,

271 SARS-CoV-2 Nucleocapsid ,

272 Unk CoV,

273 SARS-CoV-2 Virus ,

274 Unk CoV,

275 Unk CoV,

276 Unk CoV,

277 Unk CoV,

278 Unk CoV,

279 Unk CoV,

280 SARS-CoV-2 Membrane, SARS-CoV-2 Nucleocapsid ,

281 Unk CoV,

282 Unk CoV,

283 Unk CoV,

284 Unk CoV,

285 Unk CoV,

286 Unk CoV,

287 Unk CoV,

288 SARS-CoV-1 RBD , SARS-CoV-2 RBD ,

289 Unk CoV,

290 SARS-CoV-1 RBD ,

291 SARS-CoV-1 RBD ,

291 SARS-CoV-1 RBD , 292 SARS-CoV-1 RBD,

292 SARS-CoV-1 RBD,

293 SARS-CoV-1 RBD,

294 Unk CoV,

295 SARS-CoV-1 RBD,

296 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

297 SARS-CoV-1 RBD,

298 SARS-CoV-1 RBD, SARS-CoV-2 RBD,

299 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

300 Unk CoV,

301 Unk CoV,

302 Unk CoV,

303 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

304 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

305 Unk CoV,

306 Unk CoV,

307 Unk CoV,

308 Unk CoV,

309 HKUl-CoV S1+S2,

310 HKUl-CoV S1+S2,

311 Unk CoV,

312 Unk CoV,

313 SARS-CoV-2 RBD,

314 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

315 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

316 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

317 Unk CoV,

318 Unk CoV,

318 Unk CoV, 319 HKUl-CoV S1+S2,

319 HKUl-CoV S1+S2,

320 HKUl-CoV S1+S2,

321 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

322 SARS-CoV-2 RBD, SARS-CoV-1 SI,

323 SARS-CoV-2 RBD,

324 link CoV,

325 link CoV,

326 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

327 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

328 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

329 link CoV,

330 link CoV,

331 link CoV,

332 SARS-CoV-2 RBD,

333 link CoV,

334 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

335 link CoV,

336 link CoV,

337 SARS-CoV-2 RBD, SARS-CoV-1 SI,

338 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

339 HKUl-CoV S1+S2,

340 HKUl-CoV S1+S2,

341 link CoV,

342 link CoV,

343 link CoV,

344 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

345 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

345 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI, 691 346 link CoV,

692 346 Unk CoV,

693 347 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

694 347 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

695 348 Unk CoV,

696 348 Unk CoV,

697 349 Unk CoV,

698 349 Unk CoV,

699 350 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

700 350 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

701 351 Unk CoV,

702 351 Unk CoV,

703 352 Unk CoV,

704 352 Unk CoV,

705 353 Unk CoV,

706 353 Unk CoV,

707 354 Unk CoV,

708 354 Unk CoV,

709 355 SARS-CoV-2 RBD, SARS-CoV-2 Virus , HKUl-CoV S1+S2,SARS-

CoV-1 Sl,

710 355 SARS-CoV-2 RBD, SARS-CoV-2 Virus , HKUl-CoV S1+S2,SARS-

CoV-1 Sl,

711 356 SARS-CoV-2 RBD, SARS-CoV-2 Virus , HKUl-CoV S1+S2,SARS-

CoV-1 Sl,

712 356 SARS-CoV-2 RBD, SARS-CoV-2 Virus , HKUl-CoV S1+S2,SARS-

CoV-1 Sl,

713 357 HKUl-CoV S1+S2,

714 357 HKUl-CoV S1+S2,

715 358 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

716 358 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

717 359 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

718 359 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

719 360 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

720 360 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

721 361 Unk CoV,

722 361 Unk CoV,

723 362 Unk CoV,

724 362 Unk CoV,

725 363 Unk CoV,

726 363 Unk CoV,

727 364 Unk CoV,

728 364 Unk CoV,

729 365 Unk CoV,

730 365 Unk CoV,

731 366 Unk CoV,

732 366 Unk CoV,

733 367 Unk CoV,

734 367 Unk CoV,

735 368 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

736 368 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

737 369 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

738 369 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

739 370 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI,

740 370 SARS-CoV-2 RBD,HKUl-CoV S1+S2, SARS-CoV-1 SI, 371 link CoV,

371 Unk CoV,

372 Unk CoV,

373 Unk CoV,

374 Unk CoV,

375 HKUl-CoV S1+S2,

376 HKUl-CoV S1+S2,

377 HKUl-CoV S1+S2,

378 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

379 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

380 SARS-CoV-2 RBD,HKUl-CoV S1+S2,

381 Unk CoV,

382 Unk CoV,

383 Unk CoV,

384 Unk CoV,

385 Unk CoV,

386 Unk CoV,

387 Unk CoV,

388 Unk CoV,

389 Unk CoV,

390 Unk CoV,

391 HKUl-CoV S1+S2, SARS-CoV-1 SI,

392 HKUl-CoV S1+S2, SARS-CoV-1 SI,

393 HKUl-CoV S1+S2, SARS-CoV-1 SI,

394 Unk CoV,

395 Unk CoV,

396 Unk CoV,

397 Unk CoV,

397 Unk CoV, 398 Unk CoV, 398 link CoV, 399 Unk CoV, 399 Unk CoV, 400 Unk CoV, 400 Unk CoV, 401 Unk CoV, 401 Unk CoV, 402 Unk CoV, 402 Unk CoV,

Claims

CLAIMS We claim:

1. A method comprising the steps of: finding a subject needing treatment from a SARS-CoV - 2; and administering a therapeutically effective amount of an anti-SARS-CoV-2 antibody selected from Table I or Table 2 to the subject.

2. The method of claim I, wherein the anti-SARS-CoV-2 antibody is produced recombinantly.

3. The method of claim 1, wherein the anti-SARS-COV-2 antibody is an antibody fragment.

4. The method of claim 1 , wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 receptor binding domain.

5. The method of claim 1, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 receptor binding domain.

6. The method of claim 1, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2

51 protein.

7. The method of claim 1, wherein the wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 SI protein.

8. The method of claim 1, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2

52 protein.

9. The method of claim 1, wherein the subject is infected with the SARS-CoV-2.

10. The method of claim 1, wherein the anti-SARS-CoV-2 antibody is given to the subject prophylactically.

11. An anti-SARS-CoV-2 antibody, comprising an antibody selected from Table 1 or Table 2.

12. The anti-SzARS-CoV-2 antibody of claim 11, wherein the anti-SARS-CoV-2 antibody is produced recombinantly .

13. The anti-SARS-CoV-2 antibody of claim 11, wherein the anti-SARS-COV-2 antibody is an antibody fragment.

14. The anti-SARS-CoV-2 antibody of claim 11, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 receptor binding domain.

15. The anti-SARS-CoV-2 antibody of claim 11, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 receptor binding domain.

16. The anti-SARS-CoV-2 antibody of claim 1 1, wherein the anti-SARS-CoV-2 antibody binds to a S/\RS-CoV-2 SI protein.

17. The anti-SARS-CoV-2 antibody of claim 11, wherein the wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 SI protein.

18. The anti-SARS-CoV-2 antibody of claim 11, wherein the anti-SARS-CoV-2 antibody binds to a SARS-CoV-2 S2 protein.

19. A pharmaceutical composition, comprising an antibody of any one of claims 11-18 and an excipient.

20. The composition of claim 19, wherein the pharmaceutical composition is formulated for administration by inhalation.